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Summary
Ischaemia and reperfusion in the heart leads to necrotic cell death (infarction) and contractile 
dysfunction (stunning). Ischaemic preconditioning (non-lethal periods of ischaemia prior to a 
longer ischaemic episode) and postconditioning (modified reperfusion) both reduce infarct size 
and are thought to act via activation of reperfusion injury salvage kinase (RISK) pathways to 
prevent the opening of the mitochondrial permeability transition pore (MPTP) at reperfusion. 
Catecholamines are released centrally and locally during myocardial ischaemia and activate 
adrenoceptors. This investigation was concerned with the roles of 3-adrenoceptor activation in 
preconditioning and postconditioning.
Studies utilising isolated paced atrial and ventricular tissues demonstrated that preconditioning 
against stunning could be achieved by ischaemic preconditioning, or pre-treatment of tissues 
with isoprenaline, a 3-adrenoceptor agonist. Both forms of protection were blocked by 
propranolol, a 3-adrenoceptor antagonist. Postconditioning was not protective in this model.
A Langendorff model of regional ischaemia was used to determine effects of 3-adrenoceptor 
agonists and antagonists on infarct size. In this model, ischaemic postconditioning was blocked 
by timolol, a non-selective 3-adrenoceptor antagonist. Formoterol, a 32-adrenoceptor agonist, 
given at reperfusion, mimicked postconditioning. The non-selective adrenoceptor agonist, 
adrenaline, when applied at reperfusion, worsened reperfusion contracture but had no effect 
on infarct size. The application of a selective 3i-adrenoceptor antagonist (CGP-20712A) at 
reperfusion led to a reduction of infarct size whereas 32 (ICI-118,551) and 33 (SR-59230A) 
antagonists had the opposite effect.
If the results are replicable in man in vivo they would be of clinical relevance because a 
commonly used class of drugs (3-adrenoceptor antagonists) have the potential to abrogate the 
protection of postconditioning. Another widely available class of drugs (3-adrenoceptor 
agonists) can have cardioprotective effects at reperfusion.
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Chapter 1 -General introduction
1.1 Historical background
"Adrenalin is liberated normally in fear, rage, asphyxia and pain"
Walter B. Cannon (1914)
The late nineteenth and early twentieth century was a time of enormous discovery in the fields 
of physiology and pharmacology. Much of what was discovered at that time is directly relevant 
to the work presented in this thesis. Thirty years prior to Cannon's classic description of the 
physiological effects of adrenaline (Cannon, 1914), Cohnheim described the development of 
infarction in the heart following artery occlusion (Fye, 2002). At the turn of the last century, 
crude extracts of adrenaline were achieved independently by Abel and (the appropriately 
named) Takamine (Sears & Lotvall, 2005). Later, in what was arguably the first, albeit 
theoretical, description of a drug receptor, Dale discussed the possibility of a 'receptive 
substance' for adrenaline (Dale, 1906).
This work was continued throughout the twentieth century. Cannon went on to develop his 
own theory of sympathetic neurotransmission involving two sympathetic neurotransmitters, 
Sympathin E (mediating excitatory effects) and Sympathin I (mediating inhibitory effects). 
However, Von Euler showed that there was one sympathetic neurotransmitter, noradrenaline 
(Von Euler, 1951). Ahlquist invented the concept of a- and 3-adrenoceptors to account for the
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various effects of catecholamines in different tissues (Ahlquist, 1948). This neat explanation 
turned out to be a physiological reality.
Adrenaline has been thought of a 'stress hormone' ever since Cannon's famous description of 
its actions preparing the body for 'fight or flight' (Cannon, 1929; Cannon, 1914). This thesis 
examines the effects of adrenoceptors in one particular situation of extreme physiological 
stress -  myocardial ischaemia and reperfusion.
Ischaemia, from the Greek ischo meaning 'to hold back' and haima meaning 'blood' (Opie, 
1997) refers to a condition whereby a tissue is inadequately perfused with blood. Ischaemia 
ultimately leads to cell death and infarct formation. The process of infarct formation was 
extensively studied by Reimer and Jennings in the 1970s (Reimer & Jennings, 1979; Reimer et 
a i, 1977). Rapid restoration of blood flow (reperfusion) is necessary to salvage ischaemic 
myocardium. However, reperfusion is associated with damage over and above that sustained 
during ischaemia leading to the classic description of reperfusion as a 'double edged sword' 
(Braunwald 8c Kloner, 1985).
The first major advances in protecting the myocardium against the damage sustained during 
ischaemia and reperfusion came with the discovery that short periods of non-lethal ischaemia 
primed the myocardium such that, a later more severe ischaemic insult led to the development 
of a much smaller infarct than in untreated controls (Murry et al., 1986). This phenomenon, 
known as 'ischaemic preconditioning', has been widely studied ever since.
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More recently, it has been discovered that alternating short periods of ischaemia and 
reperfusion at the end of a period of ischaemia reduced infarct size to a similar extent to 
preconditioning. This phenomenon is known as postconditioning (Na et al., 1996; Zhao et al., 
2003). Early clinical data have demonstrated that postconditioning occurs in man and that it 
holds promise as a therapeutic strategy (Darling et al., 2007; Sivaraman et al., 2007; Staat et al., 
2005; Thibault et al., 2008)
Adrenoceptors and their ligands have important roles during ischaemia and reperfusion. 
Catecholamines are released from the adrenal medulla in response to stress (Cannon, 1929; 
Cannon, 1914) and are released locally in the myocardium in response to ischaemia (Kuroko et 
al., 2007; Lameris et al., 2000). Furthermore, since 1896, adrenaline has been administered to 
patients and experimental animals undergoing resuscitation from cardiac arrest in order to 
cause peripheral vasoconstriction, and to direct the blood-flow generated by cardiopulmonary 
resuscitation to the heart and brain (Penson et al., 2007).
Activation of adrenoceptors at reperfusion can worsen ischaemic damage, as demonstrated by 
the fact that P-adrenoceptor antagonists can be protective when administered at reperfusion 
(Feuerstein et al., 1998). Conversely, treatment of tissues with p-adrenoceptor agonists prior to 
ischaemia, can mimic the protection of ischaemic preconditioning (Frances et al., 2003). 
Nothing is yet known about the roles of p-adrenoceptors during postconditioning. These facts 
and questions have prompted this re-evaluation of the roles of p-adrenoceptor activation 
before and during ischaemia and at reperfusion.
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This introduction will begin with a discussion of ischaemia and reperfusion, followed by a 
section regarding adrenoceptors in the heart. The final section will discuss the roles of p- 
adrenoceptors in cardioprotection, the rationale, aims and hypotheses of the study.
1.2 Ischaemia and reperfusion
1.2.1 Definitions of ischemia and reperfusion 
Ischaemia has been defined as 'a reduction in local blood flow  such that the oxygen supply is 
less than the oxygen demand required for function' (Parums, 1999). Whilst correct, this 
definition is over-simplistic and overlooks some important points. Ischaemia occurs either as a 
result of occlusion of a blood vessel -  termed 'supply ischaemia' or by the increased metabolic 
demands of an organ or tissue above a level at which oxygen and nutrients can be supplied. 
This is called 'demand ischaemia' (Zucchi et al., 2007). Thus ischaemia can be relative; 'low-flow 
ischaemia' or absolute; 'no-flow ischaemia' (Pantos et al., 2006). Ischaemia should be 
differentiated from hypoxia. The latter refers only to a deficit in oxygen, whilst the former 
involves a deficit of blood-flow and therefore results in the accumulation of waste products of 
metabolism with consequent pathological effects (Allen & Orchard, 1987).
Prolonged no-flow ischaemia leads to well characterised consequences in the heart. Necrotic 
cell death occurs in the region distal to the occlusion forming an infarct. The infarct begins in 
the subendocardium and progresses in a 'wave-front' phenomenon towards the subepicardium 
until the entire area supplied by the blocked vessel is infarcted (Reimer et al., 1979; Reimer et 
al., 1977). Reperfusion, the restoration of blood flow to an ischemic region, is absolutely
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essential to salvage myocardium. The Gruppo Italiano per lo Studia Della Streptochinasi 
nell'lnfarcto Miocardio (GISSI) clinical trial in the 1980s demonstrated the survival benefit of 
revascularisation, now a mainstay of clinical therapy of myocardial ischaemia (GISSI 
Investigators, 1986). However, the rapid reintroduction of blood into ischemic tissue results in 
further damage known as reperfusion injury (Braunwald et al., 1985; Heyndrickx et al., 1975; 
Jennings et al., 1960). Reperfusion injury is an important consideration from a clinical 
perspective because whilst it is almost impossible to predict when myocardial infarction or 
cardiac arrest will occur, reperfusion usually occurs as a result of a medical intervention (e.g. 
defibrillation and thrombolysis) and is therefore more amenable to therapeutic interventions 
than the damage which occurs during ischaemia (Piper et al., 2004).
1.2.2 Pathophysiology of ischaemic damage and reperfusion injury 
All the studies in this thesis involve experimentally-induced acute ischaemia and reperfusion in 
tissues taken from healthy animals. However, in man, myocardial ischaemia occurs as the result 
of pathological processes which occur over long periods of time. Therefore, a discussion of 
these processes is relevant prior to a discussion of the cellular mechanisms of ischaemic 
damage and reperfusion injury.
1.2.2.1 Coronary heart disease and ischaemia 
Coronary heart disease kills 101,000 people in the United Kingdom every year, making it the 
most common cause of death. One in five men and one in six women die from the disease. It is 
also the biggest cause of premature mortality (death in people less than 75 years old) (Allender
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et al., 2007). Coronary heart disease is a chronic disorder, resulting from the deposition of 
atherosclerotic plaques in the coronary arteries. 'Athera' is the Greek for porridge (Aaronson et 
al., 2004) and in this context describes the consistency of the plaques. Early manifestations of 
atherosclerosis can be seen in children and adolescents, with lipoprotein accumulation in the 
arterial intima, forming fatty streaks. These develop to form atherosclerotic lesions by middle 
age. The lesions reduce the diameter of the artery lumen. The development of the plaque 
involves inflammation, increased endothelial permeability, the invasion of leucocytes and 
monocytes (which release cytokines and recruit macrophages) and smooth muscle 
proliferation. The smooth muscle cells produce collagen which contributes to the formation of 
the fibro-lipid plaque. This process has been extensively reviewed elsewhere (Camm, 2002; 
Hansson, 2005; Libby, 2001). Stable plaques reduce the luminal diameter of arteries and cause 
the symptoms of stable angina. Plaques are prone to rupture leading to acute myocardial 
infarction (see Section 1.2.2). Results from the Framingham Heart Study demonstrated that 
increasing age, hypertension, diabetes, smoking and plasma total and LDL cholesterol are 
important risk factors for the development of coronary artery disease (Wilson et al., 1998).
1.2.2.2 Pathophysiology o f acute m yocardial infarction  
Acute myocardial infarction occurs as a result of coronary thrombosis (DeWood et al., 1980). 
Atherosclerotic plaque rupture and damage to the vascular endothelium are important triggers 
for thrombus formation as both pathologies expose collagen in the arterial wall to which 
platelets can bind and become activated. Fibrin is formed at the site of the rupture and can 
occlude the vessel. The region of myocardium distal to the blockage is no longer adequately 
perfused with blood, thus does not receive oxygen or nutrients. Additionally, waste products of
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metabolism cannot be removed and accumulate locally. If unresolved, this leads to cell death in 
the ischaemic region; the area of dead tissue is called the infarct. As described above, the 
infarct begins in the subendocardium and progresses in a 'wave-front phenomenon' towards 
the subepicardium until the entire area supplied by the blocked vessel is infarcted (Reimer et 
al., 1979; Reimer et al., 1977). Coagulation necrosis occurs in the infarcted myocardium, and 
neutrophils enter the region after 18 hours. It was at one time argued that neutrophil entry was 
pathological; however, it is now understood to be a response to the damage. The most 
convincing evidence of this, being that all forms of ischaemic damage and reperfusion injury 
can be demonstrated in neutrophil-free systems such as the isolated perfused heart (Baxter, 
2002).
Over a period of several days, dead tissue is replaced by granulation tissue and scar formation 
takes place. The infarcted myocardium is liable to develop further pathologies. Mitral 
regurgitation can occur if the papillary muscles have been damaged. Injury to node or 
conducting tissue leads to arrhythmias and free wall and rupture of the inter-ventricular 
septum can also occur.
These pathologies have been reviewed elsewhere (Yang et al., 2006). Ventricular remodelling 
and progression to heart failure are also common complications of myocardial infarction 
(Hellermann et al., 2002; Sampson & Hutchinson, 1967). As a result of cell-death, the pump 
efficiency of the heart is reduced and ventricular emptying is impaired. Initially Starling's law 
provides a compensatory increase in cardiac contractility; however over a long period of time,
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pathological ventricular dilation occurs (Pfeffer & Braunwald, 1990; Sweetman, 2002). The 
failing heart is unable to pump sufficient blood to meet the metabolic demands of the tissues. 
The fall in cardiac output and reduced blood-flow to tissues leads to reflex sympathetic 
activation which increases P - a d r e n o c e p t o r  mediated tachycardia and increased force of 
contraction, p-adrenoceptors have been implicated in the pathophysiology of heart failure and 
studies indicate that chronic release of endogenous catecholamines stimulates p i- 
adrenoceptors to induce myocyte hypertrophy and apoptosis, whereas p2-adrenoceptors have 
an opposing protective action (Xiao et al., 2004).
Another compensatory mechanism which is activated in response to the fall in cardiac output 
after myocardial infarction is the renin-angiotensin-aldosterone system. Angiotensin II causes 
vasoconstriction, increased cardiac output and promotes sodium and water retention by 
activation of ATI receptors in vascular smooth muscle, the heart and kidneys and by causing 
the release of aldosterone from the kidneys. In the short term this restores blood pressure and 
organ perfusion. Long-term activation of the renin-angiotensin system is however detrimental 
and is an important element in the pathophysiology of the disease. Angiotensin II stimulates 
myocardial hypertrophy and interstitial fibrosis, and promotes noradrenaline release from 
nerve endings. Thus the renin-angiotensin-aldosterone cascade has important roles in 
pathological ventricular remodelling and angiotensin converting enzyme inhibitors, which 
prevent the production of angiotensin II, reduce mortality in heart failure (SOLVD Investigators, 
1992). The interested reader is directed to review articles on this topic (Ford, 2009; Opie & 
Pfeffer, 2009).
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1.2.3 Cellular mechanisms of ischaemic damage 
Blood-flow through the capillary beds in tissues serves to deliver oxygen and metabolic 
substrates and to remove the waste products of metabolism. The metabolic and functional 
changes which occur during ischaemia are a result of the cessation or impairment of these 
functions. Consequent biochemical and metabolic changes lead either to ischaemic cell death, 
or if reperfusion occurs, provide the milieu in which reperfusion pathologies occur.
Under normal physiological conditions the metabolic energy demands of the heart are met 
mainly by fatty acid catabolism. However glucose is also a substrate and plays an important role 
in supplying additional energy when myocardial workload is increased above basal levels 
(Chaitman et al., 2004; Depre et al., 1999; Kantor et al., 2000; Stanley et al., 1997). Both fatty 
acids and glucose feed into the Krebs' (citric acid) cycle and oxidative phosphorylation. 
Metabolism of glucose begins in the cytosol with the process of glycolysis which for each 
molecule of glucose, produces two molecules of pyruvate and converts two molecules of ADP 
to ATP. Oxygen is required for the next stage in metabolism, the production of acetyl coenzyme 
A from pyruvate which feeds into the Krebs' cycle and thereafter into oxidative 
phosphorylation, producing approximately 30 molecules of ATP from ADP, for each molecule of 
glucose metabolised. The oxygen-dependent reactions of the Krebs' cycle and oxidative 
phosphorylation cease soon after the onset of ischaemia. However, in the absence of oxygen, 
energy can be produced by the conversion of pyruvate to lactic acid. This is an inefficient 
process, producing a net of only 2 molecules of ATP from each molecule of glucose. For reviews 
see Stryer (1995) or Ingwall (2002). Upon the onset of ischaemia, glycolysis is initially 
stimulated to provide sufficient energy to sustain the metabolic processes of the cell. Under
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anoxia alone, the cell could continue to produce ATP in this manner, however during ischaemia 
there is an absence of blood-flow and anaerobic metabolites remain within the cytosol. The 
accumulating lactic acid decreases intracellular pH and suppresses glycolysis. Some ATP can be 
synthesised from creatine phosphate. This compound has a high energy phosphate bond which 
can be hydrolysed; the free energy liberated being used to produce ATP from ADP and Pi. The 
cellular content of creatine phosphate declines during ischaemia as a result of ATP production, 
eventually ATP levels fall Creatine kinase catalyses the transfer of a phosphoryl group from 
creatine phosphate to ADP (Ingwall, 2002).
ATP is required to sustain all metabolic processes within the cell. A high concentration of ATP in 
relation to its breakdown products (ADP and Pi) drives ATPase reactions. The reduction in the 
ATP/ADP ratio during ischaemia leads to the failing of the contractile machinery of the myocyte 
and disruption of active transport of ions and solutes across the plasma membrane (Bers, 2001; 
Kammermeier, 1987; Kammermeier et al., 1990).
1.2.3.1 Effects o f ischaemia on m em brane transport function  
Changes in ion-channel function as a result of ischaemia are shown below (Figure 1-1). Under 
normal physiological conditions, calcium is removed from the cell via a transporter protein in 
the plasma membrane which is dependent upon ATP for its activity (Figure 1-1 A), thus under 
ischaemic (low ATP) conditions, the transport is disrupted and the cytosolic calcium 
concentration increases. The smooth endoplasmic reticulum calcium ATPase is also inactivated. 
Additionally the sodium-potassium ATPase is inhibited leading to an increase in cellular sodium
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levels and a decrease in cytosolic potassium. The anaerobic metabolism of pyruvate into lactate 
causes a decrease in cytosolic pH (an increase in the concentration of hydrogen ions). These 
changes in cytoplasmic ion concentrations lead to a reversal of the sodium-hydrogen 
exchanger, which under ischaemic conditions removes hydrogen ions from the cytoplasm and 
allows sodium ions to enter the cells from the extracellular milieu. The increased osmotic load 
as a result of raised intracellular sodium draws water into the cell. (Figure 1-1 B) The calcium 
increase in the cytosol is also aided by entry via L-type channels (Smart et al., 1997). The 
intracellular ionic alterations during ischaemia have been reviewed extensively elsewhere 
(Ingwall, 2002; Moens et al., 2005; Murphy & Steenbergen, 2008a; Murphy & Steenbergen, 
2008b; Pantos et al., 2006; Solaini & Harris, 2005; Suleiman et al., 2001). Calcium is an 
important regulator in many cellular processes; therefore derangement of cellular calcium 
leads to many abnormalities. During ischaemia, calcium activates proteases and phospholipid- 
dependent protein kinases which can damage a wide variety of cellular structures including 
mitochondrial and sarcolemmal membranes. Damage to the sarcolemmal membrane causes 
more calcium to enter the cell. High cytosolic calcium concentrations favour the opening of the 
mitochondrial permeability pore at reperfusion (Crompton & Andreeva, 1994; Crompton et al., 
1988) (Figure 1 -1 C) resulting in cell death (See section 1.2.4.1 for further details).
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Figure 1-1: Disruption of ion channels during ischaemia and reperfusion. Modified from diagrams in numerous sources 
(Ingwall, 2002; Murphy et al., 2008b; Pantos et al., 2006)
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Metabolic processes in the myocyte during A, normoxia; B, ischaemia and C, reperfusion. (A) Under normal physiological 
conditions, calcium is removed from the cell via a transporter protein which is dependent upon adenosine triphosphate 
(ATP) for its activity, thus under ischaemic (low ATP) conditions (B), the transport is disrupted and the cytosolic calcium 
concentration increases. The smooth endoplasmic reticulum calcium ATPase is also inactivated. Additionally the sodium- 
potassium ATPase is inhibited leading to an increase in cellular sodium levels and a decrease in cytosolic potassium. The 
anaerobic metabolism of pyruvate into lactate causes a decrease in cytosolic pH (an increase in [H+]). These changes in 
cytoplasmic ion concentrations lead to a reversal of the sodium-hydrogen exchanger, which under ischaemic conditions 
removes hydrogen ions from the cytoplasm and allows sodium ions to enter the cells from the extracellular milieu. The 
increased osmotic load as a result of raised intracellular sodium draws water into the cell. The calcium increase in the cytosol 
is also aided by entry via l-type channels. The intracellular ionic alterations during ischaemia have been reviewed extensively 
elsewhere. Calcium is an important regulator in many cellular processes; therefore derangement of cellular calcium leads to 
many abnormalities. During ischaemia, calcium activates proteases which damage a wide variety of cellular structures 
including mitochondrial and plasma membranes causing more calcium to enter the cell. At reperfusion (C) High cytosolic 
calcium concentrations favour the opening of the mitochondrial permeability pore (MPTP) resulting in cell death. 
RR=ryanodine receptor, SERCA = Smooth endoplasmic reticulum calcium ATPase.
1.2.3.2 Effects o f ischaemia on contractile function  
Contractile dysfunction occurs rapidly after the onset of ischaemia, manifest by a reduction of 
contractility as a result of a decreased ratio of ATP/ADP and decreased intracellular pH. 
Contractile function is compromised when cellular ATP content is still relatively high (Stapleton 
& Allshire, 1998).
1.2.3.3 Ischaemic contracture 
Ischaemic contracture refers to the phenomenon whereby myocyte shortening occurs during 
ischaemia. In experimental models of myocardial ischaemia, this is seen as an increase in 
diastolic tension. Ischaemic contracture causes only a small amount of damage to the 
myocardial cytoskeleton. This is in contrast to hypercontracture which develops upon 
reperfusion (See Section 1.2.4.1). It has been suggested that the onset of contracture in the 
ischaemic period is concurrent with depletion of glycogen. This has been discussed by Pantos 
(2006) in an excellent review.
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1.2.3.4 Fate o f ischaemic cells 
The extent of the biochemical disturbance within the ischaemic cells will determine the fate of 
the cells upon reperfusion. However, if reperfusion does not occur, ischaemic cell death ensues 
by necrotic mechanisms. Necrosis under these conditions is also known as oncosis (Majno & 
Joris, 1995). The mechanism of cell death is probably sarcolemmal membrane rupture (Reimer 
& Ideker, 1987) as a result of osmotic increases of water in the cytosol and damage to the 
sarcolemmal membrane by calcium-activated enzymes (Buja, 2005; Buja et al., 1993; Buja & 
Entman, 1998). There is debate as to the extent of apoptotic cell death during ischaemia. 
Initially it was thought that the contribution of apoptosis to ischaemic cell death was minimal 
(Gottlieb et al., 1994), perhaps because of the ATP dependence of apoptosis. However a later 
study estimated to apoptosis to account for 86 % of ischaemic cell death after 2 hours 
ischaemia in the rat heart (Anversa et al., 1998). This question is likely to remain controversial. 
Since the first description of apoptosis (Kerr et al., 1972) evidence has emerged to suggest that 
different forms of cell death are not as distinct as was thought (Eefting et al., 2004; Leist & 
Jaattela, 2001). Furthermore, different methods of quantifying apoptosis give markedly varying 
results (Eefting et al., 2004). Of particular concern is the technique whereby broken strands of 
deoxyribose nucleic acid (DNA) are quantified as a measure of apoptosis. This technique is 
known as terminal deoxy-nucleotidyl transferase [TdT]-mediated deoxyuridine triphosphate 
[dUTP]-biotin nick end-labeling (TUNEL). However TUNEL has been shown to give a positive 
results in necrotic cells when minor damage to DNA has occurred (Jugdutt & Idikio, 2005).
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1.2.4 Reperfusion injury 
Reperfusion injury is best described by a series of seemingly paradoxical observations. The 
paradox that reperfusion is both necessary for survival and damaging has led to it being 
described as a 'double-edged sword' (Braunwald et al., 1985). Reperfusion injury is manifest in 
four distinct pathologies: i) Infarct development, known as lethal reperfusion injury, ii) 
Reversible contractile dysfunction known as stunning (Heyndrickx et al., 1975; Jennings et al., 
1960). iii) Reperfusion arrhythmias, such as ventricular tachycardia, premature ventricular beats 
and ventricular fibrillation (Manning & Hearse, 1984b) iv) The 'no-reflow phenomenon', 
whereby regions of ischaemic myocardium are not adequately reperfused when the blood 
supply is returned, due to endothelial dysfunction and capillary plugging with neutrophils 
(Kloner et al., 1974).
The concept of the 'oxygen paradox' was by first described by Latham (1951) and later 
developed by Hearse, who realised that whilst hypoxia was an important pathophysiological 
feature of ischaemia, the rapid reintroduction of oxygen to an ischaemic tissue resulted in 
further cell death (Hearse et al., 1973). It is thought that the combination of the partially 
damaged respiratory chain (Lesnefsky et al., 2004; Sack, 2006) and xanthine oxidase (Hearse et 
al., 1986; Manning et al., 1984a; Yellon et al., 1985) lead to pathologically high levels of reactive 
oxygen species within the cell. These cause DNA damage, lipid peroxidation of the sarcolemmal 
membrane and widespread damage to proteins and enzymes (Hausenloy & Yellon, 2008)
15
Chapter 1 -  General introduction 
The calcium paradox is another important concept involved in the pathology of ischaemic 
damage and reperfusion injury. It was first noted in the 1960s that if calcium was removed from 
the solution perfusing a heart, cell death accompanied by morphological changes appeared 
when calcium was returned (Zimmerman & Hulsmann, 1966; Zimmerman et al., 1967). An 
analogous situation occurs at reperfusion after ischaemia. Cytosolic concentrations of calcium 
are greatly increased during early reperfusion due to damage to the sarcoplasmic reticulum and 
sarcolemmal membrane (Figure 1-1 C).
Thus, the increase in intracellular calcium and reactive oxygen species are largely responsible 
for the reperfusion pathologies described below.
1.2.4.1 Lethal reperfusion in jury  
"Lethal Injury is defined as injury caused by restoration of blood flow  after an Ischemic episode 
leading to death of cells that were only reversibly injured during that preceding ischemic 
episode" (Piper et al., 1998).
Perhaps the most controversial aspect of the study of reperfusion injury has surrounded the 
existence of lethal reperfusion injury (Ambrosio & Tritto, 1997; Bauer & Deeg, 1997; Bolli, 1997; 
Cohen et al., 1997; Flaherty & Zweier, 1997; Reimer, 1997; Venturini & Schaer, 1997). 
Reperfusion was initially thought to simply hasten the death of cells which had been irreversibly 
injured during ischaemia (Jennings et al., 1960). However, because interventions at reperfusion
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can reduce necrosis, lethal reperfusion injury is likely to be an important pathophysiological 
entity (Piper et al., 1998).
Cell death at reperfusion occurs as a result of the opening of large non specific channels in the 
inner mitochondrial membrane. This 'mitochondrial permeability transition' was first described 
in the 1970s (Haworth & Hunter, 1979; Hunter 8t Haworth, 1979a; Hunter & Haworth, 1979b; 
Hunter et al., 1976) and it has long been known that the transition could be prevented by 
cyclosporine A (Crompton et al., 1988). However, the phenomenon has only recently been 
attributed to a specific channel, the mitochondrial permeability transition pore (MPTP). The 
molecular identity of the pore is uncertain (Halestrap et al., 2007) but may be formed of an 
aggregation of cyclophilin D (Urn et al., 2007b), the adenine nucleotide transporter and the 
voltage-dependent anion channel (Halestrap, 2006). It is thought that cyclosporine acts by 
preventing cyclophilin D interacting with other pore components (Javadov 8t Karmazyn, 2007; 
Woodfield et al., 1998).
When the MPTP is opened the mitochondrial potential gradient is lost, and thus ATP generation 
is halted. Pro-apoptotic mediators such as cytochrome C may also be released from the 
mitochondrial matrix into the cytoplasm (Halestrap, 2006), however, because the cell loses its 
capacity to generate ATP upon MPTP opening, it has been suggested that cell death following 
MPTP opening occurs predominantly due to necrosis rather than apoptosis, which is an energy- 
dependent process (Murphy et al., 2008b). Other studies however have demonstrated an
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important role for apoptosis in reperfusion injury (Gottlieb et al., 1994). For the reasons 
outlined above, this controversy is difficult to resolve.
During early reperfusion, intracellular pH returns to normal levels due to the removal of 
cytoplasmic lactic acid. This is paradoxically damaging because low pH prevents the formation 
of the MPTP (Halestrap, 2006). This phenomenon is known as the 'pH paradox' (Bond et al., 
1994; Lemasters et al., 1996). The high intracellular calcium concentrations which occur during 
early reperfusion also promote MPTP opening (Halestrap, 2006). The MPTP does not open 
during ischaemia (Levraut et al., 2003).
Another contributor to cell death at reperfusion is hypercontracture. Contracture can be 
enhanced during reperfusion to such an extent that mechanical damage to the myocyte occurs. 
This is called hypercontracture and is caused by calcium overload as a result of cytosolic calcium 
oscillations (Pantos et al., 2006). Hypercontracture can cause cell membrane rupture and lead 
to cell death. This form of myocardial damage is associated with specific morphological features 
referred to as contraction band necrosis (Duflou et al., 2006; Hutchins & Silverman, 1979; 
Rodriguez-Sinovas et al., 2007; Virmani et al., 1996).
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1.2.4.2 Stunning
"Postischemic dysfunction, or myocardial stunning, is the mechanical dysfunction that persists 
after reperfusion despite the absence of irreversible damage" (Bolli, 1990).
"(1) stunning is a transient, fully reversible abnormality, provided that sufficient time is allowed 
for recovery; (2) stunning is a mild, sublethal injury that must be kept apart from the irreversible 
damage occurring in myocardial infarction; and (3) stunned myocardium has a normal or near 
normal coronary flow" (Ferrari et al., 1999).
The term stunning was first used in 1982, to describe post ischaemic contractile dysfunction 
(Braunwald & Kloner, 1982). However, the phenomenon of post-ischaemic dysfunction had 
been recorded earlier (Heyndrickx et al., 1975) although not afforded much interest, because it 
was believed that, outside of the laboratory setting, reperfusion was a rare event (Bolli & 
Marban, 1999).
It has been demonstrated in a canine model that fifteen minutes of ischaemia can lead to 
subnormal myocardial function for twenty-four hours (Moens et al., 2005), This has potential 
clinical implications, although because stunning is reversible, it is probably more important as a 
cause of morbidity than mortality. However, in certain patients with low-cardiac output 
following ischaemia, stunning may be life threatening (Ferrari et al., 1999). Stunning may also 
occur repeatedly after episodes of angina and lead to ventricular failure (Bolli, 1990). Thus, the
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prevention of stunning is an important target in the treatment of ischemia and reperfusion and 
stunning is worthy of experimental and clinical study.
The mechanism of stunning has been attributed to two mechanisms which are not mutually 
exclusive. The oxyradical hypothesis and the calcium overload hypothesis. It is thought that 
high cytosolic levels of these two injurious mediators causes sarcoplasmic reticulum 
dysfunction and inhibits the contractile machinery of the cell, leading to excitation-contraction 
uncoupling (Bolli, 1990; Bolli etal., 1999).
1.2.4.3 No-reflow phenomenon 
"...under some circumstances, restoration of arterial flow into the previously ischemic tissue 
either does not occur or is greatly impeded. This so-called "no-reflow" phenomenon..." (Kloner 
et al., 1974)"
Reperfusion injury also occurs to the endothelium of the coronary blood vessels, resulting in 
increased cellular permeability and reduced ability of the endothelium to mediate vasodilator 
responses (Dauber et al., 1990). Damage to the microvasculature and neutrophil infiltration 
also occur causing plugging and preventing reperfusion of some areas of tissue on the 
restoration of blood-flow. This has been described as the 'no-reflow' phenomenon (Kloner et 
al., 1974). These factors have been extensively reviewed elsewhere (Carden & Granger, 2000; 
Honda et al., 2005; Jassem et al., 2002; Moens et al., 2005; Piper et al., 2003; Suleiman et al., 
2001).
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1.2.4.4 Reperfusion arrhythm ias  
"Dysrhythmia associated with reperfusion may ... play a critical role in sudden cardiac death" 
(Corr & Witkowski# 1983)
Arrhythmias such as ventricular tachycardia, premature ventricular beats and ventricular 
fibrillation often occur following reperfusion (Manning et al., 1984b) and are associated with 
sudden cardiac death (Corr et al., 1983). The arrhythmias are caused by ionic disturbances and 
the presence of reactive oxygen species at reperfusion (Pantos et al., 2006).
1.2.5 A m elio ra tion  of reperfusion  in ju ry  
Various pharmacological agents including adenosine and opioids have been demonstrated to 
attenuate reperfusion injury in animal models. This has been extensively reviewed by Gross and 
Gross (2006). Ischaemic postconditioning (Staat et al., 2005; Thibault et al., 2007a; Thibault et 
al., 2008) and its pharmacological mimic, cyclosporine (Piot et al., 2008) have additionally been 
demonstrated to be of benefit in man. Such strategies have the potential to be applied at the 
time of medical interventions which lead to reperfusion in order to minimise reperfusion injury. 
Possible uses would include thrombolysis and angioplasty after acute coronary thrombosis/ 
myocardial infarction and at defibrillation after cardiac arrest.
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1.3 Cardioprotection by pre-and post-conditioning 
In Reimer's first paper describing 'ischaemic preconditioning', it was demonstrated that short 
periods of non-lethal ischaemia primed the myocardium such that, a later more severe 
ischaemic insult (Figure 1-2) led to the development of a much smaller infarct than in untreated 
controls (Murry et al., 1986). This phenomenon has been widely studied ever since. In addition 
to reduction of infarct size, other benefits of preconditioning are seen, including improved post- 
ischaemic cardiac function (Urabe et al., 1993) and reduction in the frequency of reperfusion 
arrhythmias (Li et al., 1992). Reimers' study provided the first demonstration that the heart 
could be protected against the damage sustained during ischaemia-reperfusion and generated 
great excitement. However, the clinical utility of ischaemic preconditioning is limited by a 
number of factors: i) The onset of ischaemia in coronary heart disease cannot be reliably 
predicted, ii) The protective intervention must be administered prior to the ischaemic insult, iii) 
The protection of preconditioning is short-lived (although there is a later phase of protection, 
see 1.3.2.1). iv) The application of ischaemic preconditioning is invasive and potentially 
dangerous. However, preconditioning has been shown to be of benefit when administered 
prior to cardiac surgery (Yellon et al., 1993).
Recently, it has been discovered that alternating short periods of ischaemia and reperfusion at 
the end of a period of ischaemia (postconditioning) reduced the frequency of arrhythmias (Na 
et al., 1996) and reduced infarct size to a similar extent as preconditioning (Zhao et al., 2003) 
(Figure 1-2). This phenomenon is known as postconditioning. Early clinical data have 
demonstrated that postconditioning occurs in man and that it holds promise as a therapeutic 
strategy (Darling et al., 2007; Sivaraman et al., 2007; Staat et al., 2005; Thibault et al., 2008).
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It can be helpful to call the protective cycles of ischaemia 'conditioning ischaemia' and the long 
insult, against which protection is sought, the 'index ischaemia'. The optimal length of the 
'conditioning' cycles of ischaemia and reperfusion appear to be shorter for postconditioning 
than preconditioning. Postconditioning must be administered in the early minutes of 
reperfusion to be protective, whereas protection can be preserved even when the delay 
between preconditioning and the index ischaemia is up to two hours.
Control
Stabilisation Ischaemia Reperfusion
Ischaemic Precondition!
Ischaemic Postconditioni
Time
Figure 1-2. Typical experimental protocols used in the study of ischaemic pre- and post-conditioning. Time is shown along the 
abscissa. Red areas represent ischaemia, yellow areas represent normal perfusion. It should be noted that the cydes of 
ischaemia for postconditioning are generally shorter than those employed in preconditioning protocols. Postconditioning 
also requires to be employed in the first minutes of reperfusion whereas a longer delay is tolerated between the end of 
preconditioning and the beginning of the index ischaemia.
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1.3.1 Mechanisms of protection by preconditioning and postconditioning 
Since the discovery of pre- and post-conditioning, a great deal of effort has been invested in 
elucidating the mechanism by which these phenomena exert their protective effects and in 
attempts to replicate them pharmacologically. Although the mechanisms involved have not 
been fully elucidated, it is believed that both strategies confer protection by acting at 
reperfusion to prevent MPTP opening and consequent cell death (Garcia-Dorado et al., 2006; 
Hausenloy & Yellon, 2003; Hausenloy & Yellon, 2007b; Lim et al., 2007a).
Studies from Gross' laboratory demonstrated that the protection of preconditioning in dogs 
could be blocked by glibenclamide, and thus the importance of K Atp channels in preconditioning 
was realised (Gross & Auchampach, 1992). It was later realised that the channel involved was 
the mitochondrial K Atp  channel (mKATP) rather than its sarcolemmal equivalent (Garlid et al., 
1997; Liu et al., 1998; Sato et al., 2000). For some time it was thought that the mKATp was the 
end-effector of preconditioning, however this was later questioned (Oldenburg et al., 2002) and 
prevention of MPTP opening is now believed to hold that role (Garcia-Dorado et al., 2006; 
Hausenloy et al., 2003; Hausenloy et al., 2007b; Lim et al., 2007a). It is believed that mKATp 
opening causes the release of reactive oxygen species from the mitochondria into the 
cytoplasm (Andrukhiv et al., 2006) which activate Reperfusion Injury Salvage Kinase signalling 
pathways (see below) which exert their protective effects at reperfusion, although they also 
play a role in the conditioning (trigger) phase of preconditioning.
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Pre- and post-conditioning both prevent MPTP opening by the activation of RISK pathways at 
the time of reperfusion (Hausenloy & Yellon, 2004). These pathways consist of the Akt pathway 
and the Erk 1/2 pathways (Hausenloy et al., 2003; Lecour et al., 2005; Solenkova et al., 2006). 
RISK pathways are the mediators between the stimuli for preconditioning and postconditioning, 
and the end effector (currently thought to be prevention of MPTP opening). It would appear 
that evolution has furnished the cell with manifold ways of achieving protection such that there 
are a number of different mechanisms capable of activating the pathways and that 
redundancies exist such that cardioprotection may be achieved by numerous means.
Early studies demonstrated that autacoids such as adenosine (Liu et al., 1991), catecholamines 
(Banerjee et al., 1993) and bradykinin (Goto et al., 1995) are released from the cell during the 
preconditioning ischaemia and that these trigger protection. These activate signalling pathways 
which converge on the mKATp channel. Numerous G-protein coupled receptors can activate 
protective signalling pathways, however the important steps appear to be the activation of PI3- 
K/Akt which results in the production of nitric oxide from nitric oxide synthase which in turn 
activates protein kinase G (PKG) via guanylyl cyclase. PKG activates an isoforms of protein 
kinase C (PKCe) which is thought to activate the mKATP channel (Jaburek et al., 2006), and thus 
lead to cardioprotection. The mechanism by which activation of PKC before the index ischemia 
leads to protection at reperfusion is a matter of intense research. One well supported 
hypothesis is that upon reperfusion PKC interacts with the adenosine A2B signalling cascade, 
making it more sensitive to endogenous adenosine and leading to RISK pathway activation 
(Cohen & Downey, 2008) (Figure 1-3).
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ReperfusionPre-ischaemia
/ /  \
/  PI3k/Akt ER
P I3 K -^ . 
Akt
\  /
I GSK-3p/CGGTP cGMP I
/
Figure 1-3 Mechanisms of preconditioning. A) Autacoids released during ischaemia activate G-protein coupled receptors 
which activate PI3K-Akt and Mek-Erk signalling and eventual activation of protein kinase G (PKG). B) This results in the 
opening of the mitochondrial KATP channel and the release of reactive oxygen species (ROS). ROS activate protein kinase C 
(PKC). C) PKC activates Reperfusion Injury Salvage Kinase (RISK) pathways at reperfusion via the adenosine A2b receptor 
leading to the prevention of mitochondrial permeability transition pore (MPTP) opening (D). This diagram draws from ideas 
presented in numerous sources (see text) and in particular from Cohen and Downey (2008). NOS, nitric oxide synthase; GSK- 
3p glycogen synthase kinase 33-
Elucidating the mechanism by which postconditioning exerts protection is in some ways less 
problematic that preconditioning, because postconditioning does not require a 'memory'. In 
order to achieve protection, RISK pathways must be activated at reperfusion. It appears that
26
Chapter 1 -  General introduction 
adenosine may be responsible for this effect and that postconditioning delays washout of 
adenosine from the extracellular space (Kin et al., 2005; Philipp et al., 2006).
Adenosine is a purine nucleoside with widespread actions throughout the body (Drury & Szent- 
Gyorgyi, 1929). Perhaps more than any other endogenous mediator, adenosine has been 
implicated in the mechanism of preconditioning (Liu et al., 1991) and postconditioning (Kin et 
al., 2005). Adenosine is a vasodilator and is involved in the normal regulation of coronary 
vascular tone. It is released in response to increased myocardial oxygen requirements (Berne et 
al., 1983; Foley et al., 1978). Adenosine is formed in the heart from ATP during ischaemia 
(Meghji et al., 1988). Thus it can be seen that there are some parallels with adenosine and 
catecholamines during ischaemia.
1.3.2 Phenomena related to preconditioning and postconditioning
1.3.2.1 Second w indow  o f preconditioning  
The protective effects of preconditioning are transient and are lost in most studies within two 
hours after the preconditioning ischaemia. However protection against is seen once again at 
around 24 hours after reperfusion. This phenomenon is called the second window of 
preconditioning (Kuzuya et al., 1993; Marber et al., 1993) and involves de novo synthesis of 
cardioprotective proteins within the cardiomyocyte (Das & Maulik, 2006).
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1.3.2.2 Graded reperfusion
For some time it has been known that the consequences of reperfusion can be minimised by 
restoring blood-flow to ischaemic tissues in a graded manner (Okamoto et al., 1986). This 
phenomenon is known as graded reperfusion or stepped reperfusion and has been 
demonstrated to reduce infarct size in dogs (Sato et al., 1997). Whether the protective 
mechanisms involved in graded reperfusion are the same as those of postconditioning is not yet 
known.
1.3.2.3 Remote preconditioning and postconditioning
Remote preconditioning is the phenomenon whereby preconditioning of one organ or region of 
tissue can afford protection in another. The phenomenon was first described after it was 
discovered that preconditioning occlusions of dog circumflex artery protected the heart against 
ischaemia induced by occlusion of the left anterior descending artery (Przyklenk et al., 1993). 
Later it was discovered that ischaemic myocardial energy metabolism could be improved by 
prior renal ischaemia in rabbits (Takaoka et al., 1999) and that a similar technique in rats could 
reduce infarct size (Weinbrenner et al., 2002). Remote ischemic postconditioning has been 
achieved in pigs by inflation of a blood-pressure cuff over a limb at reperfusion. This led to a 
reduction in infarct size, assessed by creatinine kinase release (Andreka et al., 2007). This 
technique offers exciting possibilities for eliciting cardioprotection in a non-invasive manner. 
Remote ischaemic preconditioning has been demonstrated to be effective in humans, blood 
pressure cuff inflation over a limb, prior to coronary artery bypass graft, led to reduced 
troponin-T release in treated patients compared to controls (Hausenloy et al., 2007a). Recently,
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remote postconditioning against endothelial dysfunction in the forearm has also been 
demonstrated (Loukogeorgakis et al., 2007).
1.3.2.4 Effects o f disease states on preconditioning and postconditioning  
Most laboratory experiments are carried out in healthy animals, whereas preconditioning and 
postconditioning are likely to be used clinically in a population with pre-existing pathologies. 
Emerging evidence suggests that the protection afforded by preconditioning may be altered 
under these conditions. For example, three cycles of ischaemia and reperfusion are required to 
elicit protection in perfused hearts from diabetic hearts whereas two cycles are protective in 
hearts from healthy animals (Tsang et al., 2005). Other studies have demonstrated that the 
protective effects of preconditioning are lost in hearts taken from aged rats (18-20 months old) 
(Schulman et al., 2001) and hypertensive rats (Ebrahim et al., 2007b). However, in hearts taken 
from rats with DOCA-salt hypertensive left ventricular hypertrophy, infarct reduction by 
bradykinin was attenuated, however the protective effects of ischaemic preconditioning were 
unaffected (Ebrahim et al., 2007a). There have been few studies to date investigating the 
effects of disease states upon postconditioning, however the available evidence has been 
collated in a comprehensive review dealing with the interaction of cardiovascular risk factors 
with ischaemia-reperfusion injury, preconditioning and postconditioning (Ferdinandy et al., 
2007). An understanding of how disease processes affect pre-and postconditioning is essential 
to the successful translation of these strategies to the clinic.
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1.3.2.5 Pharm acological preconditioning and postconditioning  
Cardioprotection by preconditioning and postconditioning are both limited by the fact that 
induction of ischaemia is invasive and potentially dangerous. Thus many research groups have 
spent time searching for pharmacological mimetics of these phenomena. A number of 
pharmacological mimetics of preconditioning have been found, including adenosine (Downey et 
al., 1993), nitric oxide (Cohen et al., 2006) and anaesthetics (Cason et al., 1997). Clinically a 
pharmacological mimetic of postconditioning would be extremely useful and cyclosporine (Piot 
et al., 2008), adenosine A3 receptor agonists (Gardner et al., 2004) and recently B-type 
natriuretic peptide (Burley & Baxter, 2007) have shown promise in this regard.
Current understanding of the mechanisms of cardioprotection would predict a number of ways 
in which drugs could mimic pre- and post-conditioning. This could be achieved by activation of 
RISK pathways, opening of the mKATP channel, or direct inhibition of the MPTP
This thesis will investigate the possibility that agonists of 3-adrenoceptors may be able to mimic 
myocardial pre- and post-conditioning. Current evidence for pharmacological preconditioning 
by 3-adrenoceptors is described in Section 1.5 below.
1.3.2.6 Late pharm acological postconditioning
On the basis of studies investigating protocols and mechanisms of postconditioning, it has been 
suggested that protective strategies must be employed very early in reperfusion to be 
protective (Piper et al., 2004). However, there is also evidence that reperfusion injury develops
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in a wave-front phenomenon over a period of several hours, similar to ischaemic damage (Zhao 
et al., 2000). This progressive damage presents a therapeutic target. Administration of TG100- 
115, an inhibitor of pro-inflammatory PI3K isoforms (PI3K y and PI3K 6 ), reduced infarct size, 
even when administered 3 hours after reperfusion (Doukas et al., 2006).
1.4 Cardiac p-adrenoceptors 
Ahlquist first proposed the existence of a- and p-adrenoceptors in the 1940s to account for the 
various effects of adrenaline-related compounds in different tissues (Ahlquist, 1948). Lands and 
colleagues went on to suggest subpopulations of p-adrenoceptors. They described pr  
adrenoceptors as being responsible for lipolysis and cardiostimulation and p2-adrenoceptors as 
mediating bronchodilatation and vasodilatation (Lands et al., 1967). Today, the structures of 
nine adrenoceptors are known, the chromosomal locations of their genes have been mapped, 
and a great deal is known about their function. The predominant adrenoceptor found in the 
human heart is pi# although p2- adrenoceptors are present to a lesser extent and p3- 
adrenoceptors are found in very small numbers. Whilst the total density of p-adrenoceptors is 
homogenous throughout the organ, there exist regional differences in the ratio of pi- and p2- 
subtypes. In human atria, the p i/p2 ratio is 7:3 whereas in the ventricles it is 4:1 (Brodde et al., 
2006; Brodde & Michel, 1999).
Based on empirical observations which did not fit the accepted pattern of P 1 /P 2 /P 3  
pharmacology, the existence of a p4 adrenoceptor was proposed for some time. It was shown 
that CGP 12177, a p i/p2 non-selective antagonist, at high concentrations, caused positive
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inotropic effects in isolated left atria. This effect was not susceptible to propranolol and was not 
abolished in p3 knockout mice hence a new receptor subtype was proposed (Kaumann & 
Molenaar, 1997; Kaumann et al., 1998). However, this idea has lost favour since it was 
demonstrated that putative p4 responses were abolished in Pi knockout mice, suggesting that 
responses ascribed to ^-adrenoceptors occurred by ligands interacting with an alternative 
binding site on the pi-adrenoceptor (Kaumann et al., 2001; Konkar et al., 2000).
Because rats will be used for all the experiments in this study, it is important to understand the 
similarities and difference between 3-adrenoceptors in the model species, and in man. There is 
89% amino-acid sequence homology between the rat pi-adrenoceptor and the human pr  
adrenoceptor. The sequence identity is most similar for p2 at 93%. The p3 receptor is the most 
different between the species with only 88% homology (Hieble, 2000).
1.4.1 p-adrenoceptor signalling 
Adrenoceptors belong to the family of rhodopsin-like (Family A) seven transmembrane 
membrane domain receptors (Bylund et al., 1994). The p2-adrenoceptor was the first such 
receptor to be cloned after bacteriorhodopsin (Dixon et al., 1986). p-adrenoceptors have 
between 408 and 477 amino acids with an extracellular N-terminus and an intracellular C- 
terminus (Table 1-1) (Bylund et al., 1994; International Union of Basic and Clinical 
Pharmacology, 2008).
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Table 1-1 Characteristics of human 3-adrenoceptors (International Union of Basic and Clinical Pharmacology, 2008)
Number of amino 
acids
Chromosome
location
Gene name
3 i-adrenoceptor 477 10q24-q26 ADR B1
02-adrenoceptor 413 5q31-q32 ADR B2
03-adrenoceptor 408 8p l2- p l l .2 ADR B4
The transmembrane alpha helices group together and form a pocket into which ligands bind 
(Tota & Strader, 1990). The 7-transmembrane coupled receptors couple to heterotrimeric 
guanine nucleotides binding proteins (referred to as 'G-proteins) through which they activate 
intracellular signalling. Gilman and Rodbell were awarded the 1989 Nobel Prize in Physiology of 
Medicine "for their discovery of G-proteins and the role of these proteins in signal transduction 
in cells". When the receptor is inactive, the G-protein binds guanosine diphosphate (GDP). 
Upon agonist binding GDP is exchanged for GTP and the G-protein dissociates into a and (3y 
subunits which mediate cellular effects, particularly via modulation of adenylyl cyclase. 
Signalling is terminated by the intrinsic GTPase activity of the G-protein which converts GTP 
back to GDP. (Gilman, 1994; Rodbell, 1994).
Numerous varieties of G-protein exist and they are classified by their a  subunits (Table 1-2).
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Table 1-2 G protein families and their cellular effects (Goldsmith & Dhanasekaran, 2007; Rodbell, 1994).
G protein family Cellular effects
Gs Increased activity of adenylyl cyclase
Gj Decreased activity of adenylyl cyclase
Gq Increased activity of phospholipase C
g 12 Increased activity of mitogen activated protein (MAP) kinases
Classic 0-adrenoceptor signalling is via Gs. This was the first G-protein to be discovered and was 
designated 's' because the a-subunit stimulates adenylyl cyclase as opposed to Gt which inhibits 
adenylyl cyclase (Rodbell, 1994). Adenylyl cyclase functions to increase the production of cAMP 
which in turn activates the cAMP-dependent protein kinase, protein kinase A (PKA). This effect 
can be mimicked pharmacologically by forskolin, a direct activator of adenylyl cyclase (Figure 
1-4).
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Forskolin
cAMP ATP
Figure 1-4 0-adrenoceptor signalling via adenylyl cydase and protein kinase A. 1) In the absence of agonist, the Agonist 
binding to the 0]-adrenoceptor-G-protein complex causes a conformational change leading to the dissociation of the a  and 
the 0y subunits. The a-subunit activates the enzyme adenylyl cydase (AC) which catalyses the production of cydic adenosine 
monophosphate (cAMP) from adenosine triphosphate (ATP). Protein Kinase A is activated by cAMP and has numerous 
downstream cellular effects. Forskolin is an experimental compound which activates AC directly.
Activation of protein kinase A has widespread actions throughout the heart including positive 
inotropic (increased force of contraction), lusitropic (increased rate of relaxation), dromotropic 
(increased excitability) and bathmotropic (increased conductivity) actions (Brodde et al., 1999; 
Michel & Insel, 2006).
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Recently, it has been observed that 0-adrenoceptors do not signal exclusively via classic 
pathways. Indeed a wide variety of downstream targets of 0-adrenoceptor have been 
discovered. These have been discussed elsewhere (Finch et al., 2006; Minneman, 2006) and a 
full discussion is beyond the scope of this thesis. However, some of the recently discovered 
signal transduction mechanisms have the potential to activate cardioprotective mechanisms.
Whilst 0i-adrenoceptors appear to signal exclusively via Gs, it is now known that 02- 
adrenoceptors can also couple to Gi (Xiao et al., 1995). One study using isolated H9c2 
cardiomyocytes showed evidence that the pro-survival kinase, phosphoinositide 3-kinase (PI3K) 
could be activated by 02-adrenoceptors via G| (Yano et al., 2007). The signalling pathway 
downstream of PI3K is one of the most important reperfusion injury salvage kinase (RISK) 
pathways, which protect the myocardium at reperfusion (Hausenloy et al., 2005). Furthermore, 
0-adrenoceptor ligands have recently been demonstrated to modulate Erk 1/2 signalling, 
another important RISK pathway (Chesley et al., 2000; Galandrin & Bouvier, 2006; Tutor et al., 
2007). However, the picture is complicated by the fact that agonists for classic 0-adrenoceptor 
signalling do not necessarily act as activators of Erk 1/2 signalling, in fact they may possess 
properties of a neutral antagonist or an inverse agonist (Ciccarelli et al., 2007; Galandrin et al.,
2006). To date, only a very small number of 0-adrenoceptor agonists have been investigated for 
their effects on Erk 1/2 signalling so this represents an emerging field.
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1.4.2 p-adrenoceptor polymorphisms 
A number of genetic polymorphisms occur for each subtype of adrenoceptor, some have been 
suggested to be of potential functional importance. Much of this work in this field was carried 
out in the laboratory of the late Otto Brodde. Mutations with likely functional consequences 
are summarised below (Table 1-3).
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Table 1-3 Phenotypic effects of 0-adrenoceptor polymorphisms. Data is a summary of that presented by Brodde (Leineweber 
e ta l., 2004)
Receptor Mutation Comments
Pi Ser49Gly Gly49 leads to greater binding affinity of agonists, larger 
maximal increase in adenylyl cyclase by isoprenaline and 
greater agonist-induced receptor downregulation in 
HEK293 cells (Levin et al., 2002)
Pi Gly389Arg Arg389 results in greater hypotensive effect of P- 
adrenoceptor antagonists in vivo (Liu et al., 2003; Sofowora 
et al., 2003)
P2 A rg l6Gly G lyl6 results in lower responsiveness of cardiac muscle 
and vascular smooth muscle to salbutamol in vivo (Gratze 
et al., 1999)
p2 Gln27Glu Glu27 causes raised peripheral vasodilator responses to 
isoprenaline in vivo (Cockcroft et al., 2000; Dishy et al., 
2001).
P2 Thrl64lle Ile l64 leads to a blunted inotropic and chronotropic 
responses to terbutaline in vivo (Brodde et al., 2001).
Pa T rp l6Arg A rgl6 results in lower basal autonomic nervous system and 
increased autonomic response upon standing in vivo 
(Shihara etal., 1999; Shihara etal., 2001).
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Table 1-4 : Binding affinities and adenylyl cyclase responses (% isoprenaline response) for a range of ligands at human 0- 
adrenoceptors expressed in Chinese hamster ovary cells. All data are taken from Hoffmann (2004) except that marked with * 
which was taken from (Baker, 2005).
Compound 0 i-adrenoceptor
Ki (nM) Efficacy
02-adrenoceptor
Ki (nM) Efficacy
03-adrenoceptor
Ki (nM) Efficacy
Noradrenaline 3,570.0 123.0 26,400.0 103.0 4,300.0 122
Adrenaline 3,970.0 133.0 735.0 110.0 126,000.0 106
Isoprenaline 224.0 100.0 458.0 100.0 1,570.0 100
Fenoterol 13,600.0 66.0 719.0 76.0 55,700.0 110
Salbutamol 2,440.0 2.0 2,170.0 33.0 53,700.0 87
Salmeterol 1,600.0 -33.0 24.6 44.0 7,180.0 -13
Formoterol 1,710.0 58.0 2,570.0 ? 8,090.0 139
Terbutaline 31,300.0 6.0 15,400.0 41.0 79,800.0 45
BRL-37344 37,900.0 -5.0 9,170.0 -7.0 430.0 28
Alprenolol 5.8 -24.0 1.2 ? 35.0 11
Pindolol 2.6 -25.0 4.8 -34.0 44.1 13
Carvedilol 1.7 -28.0 1.1 -30.0 247.0 2
Atenolol 388.0 -23.0 8,140.0 -26.0 65,100.0 7
Bisoprolol 22.4 -33.0 1,150.0 -30.0 9,070.0 -1
Metoprolol 47.0 -24.0 2,960.0 -34.0 10,100.0 2
S-Propranolol 1.8 -35.0 0.8 -35.0 186.0 -4
CGP-20712A 4.7 -25.0 4,040.0 -30.0 2,360.0 -20
SR-59230A 16.4 -19.0 61.9 ? 122.0 5
CGP-12177 4.5 -19.0 4.3 -32.0 77.1 36
ICI-118,551 49.5 -22.0 0.7 -32.0 611.0 -30
Broxaterol 1,310.0 -11.0 1,290.0 20.0 3,990.0 42
Timolol* 5.4 ? 0.2 ? 158.4 ?
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1.4.3 Effects of ischaemia on cardiac p-adrenoceptors 
The effects of ischaemia on adrenoceptor density are complex. Widely varying results have 
been reported by different laboratories (albeit in different experimental systems). It is difficult 
to draw conclusions from such a wide variety of models, however there appears to be a trend 
towards reduction of 3 i adrenoceptor density during ischaemia in cell culture, and the opposite 
effect in isolated organs and in vivo, although this is not true for all studies.
Table 1-5 A summary of published studies investigating the effects of ischaemia on cardiac ^-ad^enoceptors.
Species Model Ischaemia/
hypoxia
length
(min)
Effects of Ischaemia on 0- 
adrenoceptors
Investigators
HEK293T Cell culture 
/simulated 
ischaemia
30 Reduction of surface 0i assessed 
by radioligand binding
(Iwatsubo et al., 
2003)
Dog Coronary 
ligation in vivo
60 Increased levels of 0- 
adrenoceptors assessed by 
radioligand binding
(Mukherjee et 
al., 1982)
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Species Model Ischaemia/
hypoxia
length
(min)
Effects of Ischaemia on 0- 
adrenoceptors
Investigators
Rat Langendorff 15 Increased levels of p- (Strasser et al.,
Global adrenoceptor in cell membrane 1990)
ischaemia (radioligand binding). Increased
sensitivity of adenylyl cyclase
system to forskolin
50 Further increase in p-
adrenoceptor levels but
decreased adenylyl cyclase
activity
Dog Coronary 60 Increased in P-adrenoceptor (Vatner et al.,
artery ligation density(radioligand binding) 1988)
in vivo decreased adenylyl cyclase
activity
Dog Coronary 60 No change in P-adrenoceptor (Karliner et al.,
artery ligation
120
density at either time-point. 1989)
in vivo Both led to decline in adenylyl
cyclase activity
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Species Model Ischaemia/
hypoxia
length
(min)
Effects of Ischaemia on 0- 
adrenoceptors
Investigators
Chick Embryonic 
ventricular 
cells exposed 
to hypoxia
120 Decreased surface 0- 
adrenoceptor density
(Marsh & 
Sweeney, 1989)
Rat Neonatal 
ventricular 
myocytes 
exposed to 
hypoxia
120 Decreased cytosolic 0- 
adrenoceptor levels. Increased 
cytosolic 0-adrenoceptor levels
(Rocha-Singh et 
a!., 1991)
Rabbit Coronary 
ligation in vivo
10,20,60 Reduction in surface 0- 
adrenoceptor levels at all time- 
points.
(Iwase et a i,  
1993)
1.4.4 Cardiovascular clinical uses of drugs acting upon p-adrenoceptors 
Adrenoceptors are present throughout the body and respond to circulating adrenaline and 
sympathetic nerve stimulation by noradrenaline. Because of their many functions in different 
organs, adrenoceptors have become a target for drug development in several conditions 
affecting diverse organs. These have been extensively reviewed elsewhere (Michel et ol., 2006).
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James Black (now Sir James) working at I.C.I. in the 1960s developed the first selective |3- 
adrenoceptor antagonists with the rationale that by reducing the workload of the heart, the 
severity of ischaemic attacks could be reduced in patients with angina pectoris (Black, 1988; 
Black et al., 1964). The antihypertensive effects of these agents were observed later (Black, 
1988; Black & Stephenson, 1962; Prichard, 1964; Prichard et al., 1963; Prichard & Gillam, 1969). 
Initially (3-adrenoceptor antagonists were thought to be contraindicated in heart failure 
because of their negative inotropic effects, and (3-adrenoceptor agonists were used acutely in 
the treatment of heart failure. However, it is now realised that heart failure is associated with 
adrenergic overload and (3-adrenoceptor desensitisation and is susceptible to treatment with (3- 
adrenoceptor antagonists (Bond, 2001; Bond etal., 2007; Waagstein etal., 1975).
Adrenaline and adrenoceptor agonists are used clinically to mimic the Tight or flight' (Cannon, 
1929; Cannon, 1914) actions of this hormone. Thus adrenaline is given by the intramuscular 
route to patients suffering acute anaphylactic shock. The rationale is to reverse the 
bronchospasm and hypotension associated with this condition (Mehta, 2006). In an example of 
adrenoceptor ligand use from outside the cardiovascular system, selective (32-adrenoceptor 
agonists are used for their bronchodilator effects in asthmatics (Mehta, 2006). Similarly, during 
cardiac arrest, intravenous adrenaline is administered in order to cause peripheral 
vasoconstriction (an a-adrenoceptor mediated effect) and direct any cardiac output generated 
by chest cardiopulmonary resuscitation to the heart and brain. There is very little evidence for 
the effectiveness of this approach, indeed no clinical trial has shown adrenaline to be more 
effective than placebo leading to the suggestion that a non-selective agent such as adrenaline 
exerts detrimental effects upon the heart at reperfusion which outweigh the benefits achieved 
by vasoconstriction (Penson et al., 2007). This issue is considered in greater detail in Chapter 4.
43
Chapter 1 -  General introduction
1.5 Adrenoceptors and cardioprotection 
Preconditioning has been demonstrated by short periods of ischaemia (Murry et al., 1986) 
alterations in temperature (Khaliulin et al., 2007), rapid pacing of the heart (Vegh et al., 1991) 
and stretching of myocardial fibres (Gysembergh et al., 1998). These stimuli have in common 
that they are all stressful to cardiac cells but do not result in irreversible damage when applied 
for short periods of time. It is likely that these stimuli result in the release of an endogenous 
mediator which activates a protective signalling cascade. Catecholamines are released from the 
adrenal medulla in response to stress (Cannon, 1929; Cannon, 1914) and are released locally in 
the myocardium in response to ischaemia (Kuroko et al., 2007; Lameris et al., 2000) and are 
therefore potential mediators of preconditioning (Broadley & Penson, 2004).
1.5.1 p-adrenoceptor mediated preconditioning 
Several groups have demonstrated that a preconditioning-like adapted state can be induced by 
transient treatment with an agonist of the P-adrenoceptor (Lange et al., 2006; Lochner et al., 
1999; Marais et al., 2001; Moolman et al., 2006b; Moolman et al., 2006c; Nasa et al., 1997; 
Robinet et al., 2005; Tong et al., 2005; Yabe et al., 1998; Yates et al., 2003) (Table 1-6).
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Table 1-6 Receptors and signalling pathways implicated in mediating preconditioning by 3-adrenoceptor agonists.
Species Model Endpoint Receptor Mediators Investigators
Mouse Langendorff LVDP t  
Infarct Size 4,
f*2 Switch from Gs to Gj 
signalling
(Tong et al., 2005)
Rat Langendorff MCF
LVEDP^
RPP t
CK release 4^
01 PI3-K, PKC, PKA, (Robinet et al., 
2005)
Rat Langendorff LVDP
CK release 4,
? ? (Nasa etal., 1997)
Rat Langendorff RPP ^
CK release 4/
01>02 ? (Frances et al., 
2003)
Rat Langendorff Apoptosis 4, 
Infarct Size 4^
? P38 MAPK (Moolman et al., 
2006a)
Rat Langendorff Infarct Size 4r ? Adenosine A3 
receptor
PI3-K
(Moolman et al., 
2006c)
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Species Model Endpoint Receptor Mediators Investigators
Rat Working Aortic output ? PKA (Lochner et al.,
Heart 1999)
Rat Working Cardiac ? P38 MAPK (Marais et al.,
Heart Output ^ 2001)
Guinea- Isolated ^Stunning ? ? (Yates et al., 2003)
Pig atria.
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Table 1-7 Evidence for p-adrenoceptor involvement in ischaemic preconditioning
Species Model Endpoint Conclusion Investigators
Rabbit In vivo 4, Infarct Size No 3-adrenoceptor 
involvement
(lliodromitis et al., 
2004)
Rabbit Langendorff 4 ,Infarct Size 3i-adrenoceptor required for 
preconditioning
(Spear et al., 2007)
Rat Langendorff RPP ^ Endogenous catecholamines 
not necessary for 
preconditioning
(Frances et al., 2003)
Mouse Langendorff 4 /Infarct Size 
RPP
Preconditioning abolished in 
32 knockouts.
(Tong et al., 2005)
Catecholamine release and subsequent activation of 3-adrenoceptor has also been implicated 
in the mechanism of cardioprotection achieved by administration of opioids (32) (Huang et al.,
2007) and anaesthetics (3i) (Lange et al., 2006).
Controversy remains as to whether activation of 3-adrenoceptors is an essential part of 
ischaemic preconditioning, or whether there are redundancies in the pathway which leads to 
protection -  that is to say that preconditioning could be activated by 3-adrenoceptors, but 
equally well by unrelated receptors (Table 1-7). This is an important question in the clinic, 
where 3-adrenoceptor antagonists are administered for the treatment of angina, hypertension
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and heart failure (Mehta, 2006). It is possible that minor 'silent' periods of ischaemia could 
induce preconditioning, and blockade of this protection could result in more serious 
consequences during longer ischaemic episodes such as occur during myocardial infarction.
In rabbits in vivo it has been demonstrated that blockade of pi-adrenoceptors by atenolol or 
esmolol had no effect on the infarct-size limitation afforded by ischaemic preconditioning 
(lliodromitis et al., 2004). However, a study in Langendorff perfused rabbit hearts showed 
protection of ischaemic preconditioning against necrosis was blocked by the Pi-adrenoceptor 
antagonist CGP-20712A (Spear et al., 2007). In a rat Langendorff model of ischaemic 
preconditioning, depletion of endogenous catecholamines by reserpine did not affect the 
improved functional recovery in hearts that had undergone ischaemic preconditioning (Frances 
et al., 2003). In a mouse Langendorff heart model, preconditioning protection (improved 
functional recovery and reduced infarct size) were abolished in knockout animals lacking the 32- 
adrenoceptor (Tong et al., 2005). It would seem likely that the reliance of ischaemic 
preconditioning on p-adrenoceptor activation varies between species and indeed different 
models, and the varying conditions and endpoints used in studies account for the apparently 
contradictory results observed.
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1.5.2 Mechanism of protection by p-adrenoceptors
1.5.2.1 Induction o f  dem and ischaemia
It is possible that positive inotropes such as isoprenaline could result in preconditioning by 
causing the energy demands of the tissue to exceed the capacity of diffusion to supply the 
substrates, and remove the waste products of metabolism. Indeed it has been noted that rapid 
pacing of the heart can mimic preconditioning by inducing ischaemia (Vegh et al., 1991).
1.5.2.2 Activation o f RISK pathw ays
There is a large body of evidence, from in-vivo and Langendorff isolated heart experiments, that 
activation of protein kinases cascades as a result of P-adrenoceptor activation results in the 
heart undergoing adaptive changes and becoming resistant to later ischaemic damage. Protein 
Kinase A (PKA) has been often implicated in the preconditioning achieved by P-adrenoceptor 
agonists (Table 1-6), this is to be expected, as PKA is also an essential mediator in classic p- 
adrenoceptor signalling leading to positive inotropic and chronotropic effects of p- 
adrenoceptor agonists. It has been suggested that P-adrenoceptor activation could lead to PKCe 
activation via the Py subunit of the G-protein directly activating PI3-K signalling. (Robinet et al., 
2005) thus activating RISK pathways. Other mechanisms by which p-adrenoceptors could lead 
to RISK activation have been discussed previously (Section 1.4.1)
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Reperfusion
L J
Adenosine 
L  JPre-ischaemia
Sarcolemmal membrane
I\I
/■ jPI3K/Akt
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PI3k/Akt ERK
\  /
i
CAMP
GSK-3P/cGMP
/inotropy
Figure 1-5 Possible mechanisms of preconditioning by 3-adrenoceptor agonists. A) (J2-adrenoceptor-mediated Protein Kinase 
A (PKA) production causes a switch from signalling via Gs to G,. B) Gs activates PI3K and subsequent downstream targets. C) 
Katp is opened causing the release of Reactive oxygen species (ROS). 0) ROS activate protein kinase C (PKC). E) PKC activates 
Reperfusion Injury Salvage Kinase (RISK) pathways at reperfusion via the adenosine A2b receptor leading to the prevention of 
mitochondrial permeability transition pore (MPTP) opening. This diagram draws from ideas presented in numerous sources 
(see text) and in particular from Cohen and Downey (2008)
It is well established that activation of Pi adrenoceptors (and therefore activation of adenylyl 
cyclase) at reperfusion is detrimental because selective Pi-adrenoceptor antagonists reduce 
infarct size (Feuerstein et al., 1998; Spear et al., 2007). Thus, p-adrenoceptor mediated 
cardioprotection is likely to be mediated by a non G s pathway, and possibly via Gj. These links 
between p-adrenoceptors and RISK pathways may predict protective effects of p2-adrenoceptor 
stimulation at reperfusion.
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1.5.3 A role for p-adrenoceptors in postconditioning?
Whilst a classical PKA mediated increase in cardiac workload resulting in demand ischaemia 
may lead to preconditioning (Section 1.5.1), mechanisms increasing myocardial workload at 
reperfusion are likely to be injurious. This has been demonstrated by the protective effects of 
Pi-adrenoceptor antagonists at reperfusion (Feuerstein et al., 1998).
Activation of RISK pathways at reperfusion leads to postconditioning (Sivaraman et al., 2007; 
Yang et al., 2005; Zhu et al., 2006) and evidence has been presented for the activation of Akt 
and Erk 1/2 by p2-adrenoceptor signalling (Section 1.4.1). Therefore, it is possible that 32- 
adrenoceptor agonists could mimic postconditioning, or even that activation of 32- 
adrenoceptor by endogenous catecholamines is responsible for the protective effect of 
ischaemic postconditioning. These hypotheses form the most important work in this thesis.
1.6 Aims of this thesis 
The overall aim of this thesis is to investigate the effects of 3-adrenoceptor activation, by 
endogenous and exogenous agonists, before myocardial ischaemia and at reperfusion. 
Administration of drugs at reperfusion (i.e. postconditioning) will be the main focus because of 
the clinical relevance and scientific novelty.
51
Chapter 1 -  General introduction
1.7 General Hypothesis 
Postconditioning, and to a lesser extent, preconditioning have remarkable potential to reduce 
the burden of mortality and morbidity which result from ischaemic heart disease. These 
phenomena exert their protective effects in the first moments of reperfusion when high 
concentrations of catecholamines are present in the ischaemic myocardium.
Catecholamines are able to mimic preconditioning. Nothing is known about their roles in 
postconditioning. By their actions on adrenoceptors, these compounds have the potential to 
alter the extent of reperfusion injury. Knowledge of signalling pathways downstream of 0- 
adrenoceptors allows predictions to be made about how different subtypes may act at 
reperfusion. It is expected that activation of adrenoceptor subtypes which increase myocardial 
workload at reperfusion O i) will have detrimental effects on infarct size when applied at 
reperfusion, whereas activation of 02 and 03 which have the potential to activate kinases 
involved in RISK pathways, may have protective effects.
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Chapter 2 General methods 
In order to facilitate ease of reading the text, the suppliers of all drugs and chemicals are given 
at the end of the chapter (Table 2-1). However, the suppliers of equipment are mentioned in 
the text.
2.1 Choice of species and strain
Rats were chosen for these experiments for a number of reasons. The rat has been extensively 
used as a model of ischaemic damage and reperfusion injury. Stunning, infarction, 
preconditioning and postconditioning can all be demonstrated in this species. There are 
commercially available antibodies to the mediators of cardioprotective transduction pathways. 
The rat is a small species which makes handling easy and keeps costs to a minimum. 
Importantly, the rat is deficient in coronary collateral blood vessels (Maxwell et al., 1987), 
making the reproducible induction of regional ischaemia possible. Furthermore, the Sprague- 
Dawley strain was readily available and has been extensively used by a number of research 
groups studying cardioprotection.
2.2 Choice of experimental techniques
The data described in this thesis have been obtained from two complementary experimental 
models: isolated paced cardiac tissues and isolated bicarbonate-buffer-perfused hearts 
prepared according to a modification of Langendorff's method (the 'Langendorff heart'). The 
Langendorff heart is an excellent model for studying ischaemic damage and reperfusion injury, 
as both functional data and infarct-size data can be obtained. However, the study of the effects
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of 3-adrenoceptor activation during ischaemia and reperfusion is likely to be complicated by 
the well documented positive inotropic and chronotropic effects of these agents and their 
vasodilator actions in the coronary circulation (Ahlquist, 1948). Therefore, electrically paced 
isolated cardiac tissues were additionally employed. This allowed the study of the direct effects 
of ischaemia, preconditioning, postconditioning and drug treatment on contractile function in 
different regions of the heart without interference from coronary vascular effects.
2.3 Animals and husbandry
These studies complied with the guidelines for the care and use of laboratory animals according 
to the Animals (Scientific Procedures) Act 1986. Male Sprague-Dawley rats were purchased 
from either Harlan (Bicester, UK) or B & K Universal (Bristol, U.K). See individual chapters for 
details of supplier and the weight ranges used. Rats were stored in cages containing between 
two and six animals. After arriving in the departmental animal facility, animals were allowed to 
acclimatise for at least one week before being used in experiments. Rats had ad libitum access 
to water and to food which was supplied in the form of Teklad Global 14% Protein Rodent 
Maintenance Diet supplied by Harlan. Temperature was maintained at 21 ± 2 °C and humidity 
at 55% ± 10%. Rats were exposed to 12 hour cycles of light and darkness.
2.4 Isolated atria and ventricular strips
2.4.1 O verview  o f technique  
Isolated paced atria and ventricular tissues have been used for many years in the study of
cardiac physiology and the pharmacological actions of drugs upon the heart (Blinks & Koch-
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Weser, 1961; Koch-Weser & Blinks, 1962; Koch-Weser & Blinks, 1963; Perry, 1970). Isolated 
right atria beat spontaneously providing the sino-atrial node has not been damaged during 
dissection. However, non-automatic tissue preparations such as the left atria and right 
ventricular strips used in this study require electrical pacing. Using low voltages and punctuate 
stimulation (as opposed to electrical stimulation field stimulation) contraction can be achieved 
without significant release of noradrenaline. This was an important consideration in this study 
in which the effects of adrenoceptor activation were studied. The tissues are tied at one end to 
a bipolar platinum electrode through which stimulation is achieved. The other end of the tissue 
is tied to an isometric force transducer. These preparations were chosen for this investigation 
because they allow the study of 3-adrenoceptor activation on the myocardium without the 
vascular effects of 3-adrenoceptor ligands.
2.4.2 Animal preparation
Rats were killed by a blow to the head followed by cervical dislocation. The abdominal cavity 
was opened using curved scissors and lateral incisions were made on each side of the rib cage 
to expose the heart. The pericardium was removed using a small pair of scissors and the heart 
was clamped at the apex using a pair of Spencer-Wells forceps.
2.4.3 Atrial and ventricular preparations
The left atrial appendage was lifted using a pair of curved forceps and a 5-0 suture was inserted 
through the tip and tied off for attachment to an isometric transducer (Pioden dynamometer 
UF1 range ± 55g). Another suture was inserted at the atrio-ventricular junction for securing the
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tissue to a bipolar platinum electrode. The atrial appendage was then cut free from the 
ventricle and immediately placed in ice-cold modified Krebs-Henseleit buffer (KHB) 
(composition (in mM): NaCI 118.4; MgS04 1.2; KCI 4.7; CaCI2.6H20  2.5; KH2P041.2; NaHC03 25.0 
and glucose 11.7) gassed with 95% 0 2 in C02. A suture was then inserted into the apical end of 
the right ventricular muscle and tied off for attachment to an isometric transducer. A strip was 
then cut by dissecting up to the top of the ventricle where another suture was put through the 
tissue for attaching the tissue to an electrode. Both tissues were submerged in ice-cold KHB 
whilst they were being tied on to the electrodes before being transferred to a 20 ml organ bath 
containing KHB at 37‘C gassed with 5% C02 in 0 2. Both tissues received punctuate electrical 
stimulation via a bipolar platinum electrode at 2Hz at 150% of the threshold voltage required to 
cause contraction. Square-wave pulses lasting 50 ms were given. Stimulation by this method 
does not cause significant release of neurotransmitters (Koch-Weser et al., 1963). The 
apparatus was adjusted so that there was an initial resting tension of lg  (±0 .1g) on atrial 
preparations and 1.5g (±0.lg) on ventricles. All preparations were left for one hour to stabilise, 
during which time they were frequently washed.
2.4.4 Induction of simulated ischaemia 
Ischaemia was simulated by replacing the 95% 0 2 /  5% C02 with 95% N2/C 0 2 and by bathing the 
tissues in a modified KHB without glucose, but containing 7.0 mM choline chloride in order to 
keep a constant osmolarity in the absence of glucose (Carr et al., 1997; Walker et al., 1994; 
Walker et al., 1995)
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2.4.5 Recording and calculation of data
Absolute tension was measured via transducers as described above, the signal was amplified 
using a Grass model 79D EEG polygraph data recording system (Grass instrument Co. Quincy, 
Mass., U.S.A.), converted from analogue to digital data using a Powerlab 200 (ADInstruments, 
and passed to a computer (Hardware: iMac, Apple Macintosh;. Software: AD instruments Chart 
v5.1 sampling frequency 200 Hz).
From the recorded tension values, the following parameters were calculated throughout the 
experiment using the Chart software 'cyclic variables' calculation facility which allows analysis 
of periodic waveforms (ADInstruments, 2008). Diastolic tension was defined as the minimum 
tension during each contraction cycle. Developed tension was calculated by subtracting the 
diastolic tension from the maximum contraction in each cycle.
2.5 Langendorff heart preparations
2.5.1 Overview o f technique 
The isolated perfused mammalian heart was first described by Langendorff following on from 
the work of Cyon, Ludwig and Martin (Zimmer, 1998). The Langendorff heart can be perfused 
with blood or with a crystalloid buffer (as is the case in this study). The aortic arch is perfused in 
a retrograde fashion, such that the aorta is cannulated and perfusate flows down the aorta until 
it reaches the aortic valve which remains closed under the pressure of the fluid which flows 
through the coronary ostia and into the coronary circulation in an anterograde fashion. A fluid- 
filled balloon can be inserted into the left ventricle to measure ventricular pressure and give an
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indication of cardiac contractile function. With careful technique, the heart can be kept viable 
for several hours after excision and commencement of perfusion. Drugs can be added to the 
perfusate to investigate their effects on the heart. Ischaemia can be induced globally, by 
stopping the flow of perfusate, or regionally, by occluding a coronary artery. Histological 
techniques can be applied to the heart after ischaemia to investigate the magnitude of infarct 
(Doring & Dehnert, 1987; Skrzypiec-Spring et al., 2007; Sutherland & Hearse, 2000).
2.5.2 Set-up
Male Sprague-Dawley rats 300-450g were anesthetised with an overdose of pentobarbitone 
sodium (54mg per rat) given via the intraperitoneal route. At the same time heparin (10 IU per 
rat) was given by the same route. Lack of consciousness and pain sensitivity was confirmed by 
the absence of pedal withdrawal reflex. Rats were laid in a supine position. Using a large pair of 
scissors and a large pair of rat-tooth forceps, a central lateral incision was made from below the 
rib-cage to the neck, removing skin and fur. The abdominal cavity was opened just below the 
diaphragm using scissors, and the diaphragm was carefully cut away. The ribcage was loosened 
by bilateral incisions and then folded back to reveal the thoracic cavity. The heart was gently 
lifted, and connective tissue and blood vessels gently cut away exposing the thoracic aorta 
which was cut approximately 1/3 of the way down the cavity, and then gently dissected away 
from the cavity wall. The heart was then removed with lungs attached and immediately placed 
in ice-cold KHB prior to mounting of the aorta on a cannula through which pre-warmed (37*C) 
KHB (containing NaCI 118mM, KCI 4.7mM, KH2PO4 1.2mM, MgS04 1.2mM, CaCh 2.5mM, 
glucose l lm M  and insulin lOOmU.I'1 and continuously bubbled with 95% O2/CO2) was initially 
pumped at 10 ml.min'1. The heart was held in place temporarily by a small artery clip. The lungs
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and connective tissue were carefully dissected away. A small slit was made in the pulmonary 
artery to allow egress and collection of perfusate. The heart was then tied firmly on to the 
cannula with suture and the artery clip removed. The left atrial appendage was removed and a 
fluid-filled latex balloon inserted into the left ventricle for the measurement of intra-ventricular 
pressure. A 5-0 suture was placed around the left main coronary artery, the ends of which were 
threaded through a small piece of tubing which could be pulled tight against the heart and 
clamped to occlude the vessel in a reversible manner.
Cannula
LVP probe
Right atrium
Pulmonary conus* Suture
Left main 
coronary artery
Area at risk
Right ventricle1
Cardiac apex
Figure 2-1 A drawing of the ventral view of the heart during regional ischaemia. A 5-0 suture was passed around the left 
main coronary artery. The ends of the suture were passed through a short piece of tubing and were held in place by a clamp 
made from two p200 pipette tips placed one inside the other with the sharp end cut away (not shown). The area at risk is 
shaded.
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The heart was then jacketed in a small water bath containing KHB to maintain normothermic 
conditions throughout the experiment. Coronary perfusion pressure was measured by means of 
a pressure transducer attached to a side arm located directly above the cannula. The flow-rate 
was then adjusted to give a constant coronary perfusion pressure of 60 (±2) mmHg which was 
maintained throughout the experiment. This was achieved by means of the peristaltic pump 
(Gilson Minipuls 3)) which was driving the KHB through the system. The pump was regulated by 
a pump controller (ADI STH Pump controller) which received the pressure signal from the CPP 
transducer and relayed a negative feedback signal to the pump in response to changes in 
pressure (Figure 2-2) Functional data were converted to digital signal using Powerlab/8SP (ADI 
instruments) and displayed and recorded using a personal computer (iMac, Apple Macintosh, 
software Chart 5, ADI instruments). Left ventricular pressure, coronary perfusion pressure and 
coronary flow were monitored continuously. The latter measurement was achieved by 
recording the voltage signal from the pump controller which determined the speed of the 
pump rotation. This was calibrated daily to give a reading in ml.minute'1. Left ventricular 
developed pressure, diastolic tension and rate were monitored from the left ventricular 
pressure signal. Rate pressure product (RPP) was obtained by multiplying the rate at any given 
point by the developed tension.
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*■ CPP 
Transducer
iv i LVP  
TransducerThermostatic
Grculator
Figure 2-2: A schematic diagram of the Langendorff apparatus used in these experiments. The system is designed to enable 
rapid switching between standard Krebs-Henseleit buffer (KHB) (A) and KHB containing the experimental drug which is 
drawn from a separate reservoir (B). KHB in both reservoirs is bubbled with 95% 02  /  5% C02 through a sintered glass 
gassing ro d .. A peristaltic pump (C,D) is used to pump KHB from each reservoir to a separate warming coil (E,F). The warming 
coils also serve as bubble traps. Three-way taps (G) allow warmed KHB to be recirculated to the reservoir (H) or directed to 
the heart via a stainless-steel cannula (I). The heart is immersed in KHB in a heart chamber (J), which in common with the 
warming coils, is maintained at 37°C by a thermostatic circulator (K). Coronary perfusion pressure (CPP) is continually 
monitored by a pressure transducer attached by a fluid-filled tube attached to a sidearm directly above the cannula (L). The 
voltage signal is used to control the peristaltic pump and keep average pressure constant. A fluid-filled balloon is inserted 
into the left ventricle and is attached to a pressure transducer used to monitor left ventricular pressure (LVP).
2.5.3 Inclusion criteria 
Hearts which had a left ventricular developed pressure of >60 mmHg and a rate of >200 
beats.min1 at the end of the stabilisation period were included in the study and were 
randomised to a treatment group. Hearts which underwent prolonged ventricular fibrillation 
during reperfusion were excluded from analysis. Induction of ischaemia was confirmed by at 
least a 30% drop in coronary flow after coronary ligation. Hearts which did not achieve this 
reduction in flow were excluded.
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2.5.4 Stabilisation and induction of regional ischaemia
Hearts were allowed to stabilise for 20 minutes prior to ischaemia which was induced by 
tightening the coronary snare (see above). Reperfusion was achieved by loosening the snare.
2.5.5 Recording and calculation of data
A pressure transducer (ADInstruments model MLT844, range -20 to 300 mmHg) was used to 
monitor coronary perfusion pressure and to control pump flow-rate to achieve constant 
pressure. The pressure in the ventricular balloon was measured using a pressure transducer 
(DTX Plus, Becton Dickinson, range -30 to 300 mmHg). Pressure signals were amplified using an 
ADInstruments Bridgeamp, converted from analogue to digital data using a Powerlab 8/SP 
(ADInstruments, and passed to a computer (Hardware: iMac, Apple Macintosh;. Software: AD 
instruments Chart v.5.1 sampling frequency 1 KHz).
From the recorded pressure values, the following parameters were calculated throughout the 
experiment using the Chart software 'cyclic variables' calculation facility. Diastolic pressure was 
defined as the minimum pressure during each contraction cycle. Developed pressure was 
calculated by subtracting the diastolic pressure from the maximum pressure in each cycle. Rate 
was calculated as the number of contractions per minute.
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2.5.6 Double staining to determine infarct size 
At the end of the reperfusion period, the left main coronary artery was re-occluded and the 
heart was perfused with a 1% solution of Evans blue dye, to enable differentiation of the 
ischaemic area at risk from the normally perfused myocardium. Thus the area at risk is the non­
blue region (Figure 2-3). Hearts were then frozen overnight before being sliced into six sections 
and placed into a 1% solution of 2,3,5-triphenyltetrazolium chloride at 37*C for 30 minutes and 
then placed in 10% formalin (phosphate buffered formaldehyde solution, pH 7.3) at 4°C 
overnight. This procedure resulted in infarcted areas of tissue appearing white, whilst non­
damaged tissue was seen as brick-red (Figure 2-3). This is because dehydrogenase enzymes in 
viable tissues react with tetrazolium to form a bright red formazan pigment (Nachlas & Shnitka, 
1963).The sections were placed between two glass plates, separated by a 2.5mm gap.
Figure 2-3: A photograph of heart sections after dual staining with Evans' blue dye and 2,3,5-triphenyltetrazolium chloride. 
Blue areas are regions which were normally perfused throughout the experiment (Evans Blue Positive). Red (Tetrazolium 
Positive )areas show viable tissue within the area which was made ischaemic. White areas (Tetrazolium negative) are regions 
of infarct.
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The area of the sections and the infarcted and non-damaged regions was traced onto a clear 
piece of film and the areas were measured using computer aided planimetry (ImageJ 1.38x , 
NIH) allowing the volume at risk and the infarct volume to be calculated from the known area 
and depth of the sections. Infarct size was measured blinded to the treatment group.
2.5.7 Stability of Langendorff preparations 
In order to test the viability of Langendorff preparations over the time periods used in these 
experiments, time controls were carried out whereby preparations were left for the duration of 
ischaemia. After stabilisation, time control hearts were left for two hours and 35 minutes, 
equivalent to the length of time spent in ischaemia and reperfusion in experimental hearts. At a 
time point equivalent to 35 minutes ischaemia and one hour reperfusion, there had been a 
modest decrease in coronary flow to 74±12 % of baseline and a similar fall in LVDP to 77±8 % 
(n=4). After the equivalent of two hours reperfusion, coronary flow had fallen to 66±9 % and 
LVDP to 61± 10% of baseline (Figure 2-4). These hearts were therefore considered suitably 
robust and stable for studies involving ischaemia and reperfusion.
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Figure 2-4. The deterioration in A) coronary flow and B) rate pressure product over time in Langendorff heart preparations 
not exposed to ischaemia and reperfusion. n=4, Initial RPP = 18730 ± 3476 mmHg.min'1, Initial flow = 16.59±2.02 ml.min 1 0 
is the time at which ischaemia was induced in experimental groups.
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2.6 Colourimetric assay for lactate dehydrogenase
2.6.1 Overview o f technique 
The detection and quantification of LDH in solution can be achieved by a spectrophotometric 
method which relies on the catalytic conversion of lactate to pyruvate, by LDH and the 
consequent reduction of NAD+ to NADH/H+. Diaphorase then catalyses the transfer of H/H+ 
from NADH/H+ to 2-p-iodophenyl-3-p-nitrophenyl-5-phenyl tetrazolium chloride (INT), a pale 
yellow tetrazolium salt, causing its reduction to formazan, which is red.
The degree of colour change can be measured by a spectrophotometer which shines light 
through the solution and measures light absorbance. Using samples of LDH of known 
concentration, a standard curve can be drawn. Interpolation of the absorbance values of 
unknown samples onto standard curve allows the quantification of LDH concentration.
The extent of cell death in isolated paced ventricles was estimated by taking samples of KHB 
from the organ bath (see Chapter 3 for details of sampling) and measuring the concentration of 
lactate dehydrogenase. A pipette was used to remove 0.5 ml of KHB which was sealed in a 
microcentrifuge tube and frozen at -20°C until analysis. Enzymes such as lactate dehydrogenase 
cannot cross the sarcolemma and their detection implies that membrane breakdown and cell 
death have occurred. A commercially available assay kit was used (Cytotoxicity detection kitplus 
(LDH)*, Roche Applied Science, Mannheim, Germany) according to the manufacturer's 
instructions (Roche Applied Science, 2006). Reaction mixture was made up immediately prior to 
the experiment. Samples of Krebs (100 pL), and standard solutions were added to a 96-well
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plate after which reaction mixture (100 pL) was added to each well. The plate was covered in 
aluminium-foil to exclude light and was gently rotated on a plate shaker for 30 minutes prior to 
spectrophotometric analysis. Absorbance was read at X49onm by a MRX TC Spectrophotometer 
using Revelation V 4.22 software (Dynex Technologies Limited, Worthing, UK). Samples were 
compared to a standard curve made up of concentration of l-lactate dehydrogenase from rabbit 
muscle lactate dehydrogenase (0.5,1, 5, 25, 50, and 100 units.ml-1) in KHB.
2.7 High performance liquid chromatography with electrochemical 
detection for measurement of catecholamines in coronary 
perfusate
2.7.1 O verview  o f technique  
Reversed-phase high performance liquid chromatography (HPLC) with electrochemical 
detection is a method which enables the separation and quantification of the components of a 
mixture in solution. Separation occurs prior to detection and is achieved by adding samples to a 
polar solvent, the 'mobile phase' which is pumped through a non polar, solid, porous 
'stationary phase' (the chromatographic column). The physiochemical interactions between the 
compounds of interest, the stationary phase and the mobile phase determine how long they 
are retained on the column. The retention time for a particular molecule is a constant 
(assuming constant experimental conditions). Thus unknown compounds can be identified by 
comparing their retention times with standard samples of known identity.
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Detection is achieved by an electrode at the end of the chromatographic column which is 
charged and (in the experiments described in this study) leads to the oxidation of the catechol 
ring of catecholamines. The resultant electrical signal is used to detect the presence of 
catecholamines. As larger concentrations of catecholamines give a larger electrical signal, a 
standard curve can be constructed using standard samples. Interpolation onto this curve can be 
used to estimate the concentration of unknown samples.
2.7.2 Sample collection and storage
Samples of coronary perfusate were collected using a 200 pi pipette at various time points from 
the pulmonary artery of hearts undergoing ischaemia and reperfusion (See Chapter 6 for 
details). The samples were immediately decanted into micro-centrifuge tubes and snap-frozen 
by immersion in liquid nitrogen. The samples were then stored at -80°C until analysis.
2.7.3 Analysis
The catecholamines, noradrenaline and adrenaline, were separated by their differential rates of 
elution through a reversed-phase chromatographic column (Genesis Ci8; 4pm particle 
diameter; 120 A pore size) which was held at 20°C . The mobile phase used was a modification 
of that described by Wester (1987a; 1987b) and consisted of an aqueous solution of lOOmM 
sodium citrate, 0.3 mM disodium ethylenediaminetetraacetic acid (EDTA), 0.43 mM octane 
sulphonic acid and 5.5% v/v acetonitrile, adjusted to pH 2.45 using o-phosphoric acid. The 
mobile phase was filtered via a Whatman 5 pm filter and was sonicated for 30 minutes prior to 
use in order to degas the solution. The mobile phase was pumped through the column at a rate
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of 1.2 m l.m in1, using a SpectraSYSTEM P1000 HPLC pump. Samples of noradrenaline and 
adrenaline (0.01, 0.1, 1, 10, 100, 1000 nM) were prepared In KHB and a standard curve was 
plotted in order to calculate the concentration of samples. Standards and samples were 
injected in 20pl boluses. A signal/noise ratio of 3 gave a detection limit of 0.1 nM for adrenaline 
and noradrenaline.
2.8 Western blotting for components of cellular signalling 
pathways
2.8.1 Overview of technique 
Western blotting (immuno-blotting) involves the separation of proteins in a biological sample 
by gel electrophoresis. Proteins are applied to a gel across which a potential difference is 
applied. They move at a rate determined by their mass and charge and thus separation of 
different proteins is achieved. Proteins are transferred onto a nitrocellulose membrane and 
identified by interaction of proteins of interest and specific antibodies. The strength of the 
antibody signal can be used as a semi-quantitative measure of the amount of protein present. 
Where proteins are modified by phosphorylation and specific antibodies have been raised 
against the phosphorylated and dephosphorylated forms of the protein then the proportion of 
the total protein which is in the phosphorylated state can be estimated.
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2.8.2 Sample collection
Hearts were prepared according to Langendorff as described above and exposed to various 
treatments (See Chapter 6 for details) They were then removed from the Langendorff 
apparatus, arrested in cold KHB and sliced into sections using a scalpel. The apex was removed 
first and divided into left and right sections. Two samples each of left and right ventricular 
tissue were also taken. Samples were placed into micro-centrifuge tubes (Eppendorf Ltd, 
Cambridge, UK) and were snap-frozen in liquid nitrogen and stored at -80°C until analysis. It 
was not possible to perform infarct-size measurements in the same hearts which were used for 
Western blotting experiments, thus experiments were repeated. Functional data were collected 
for all hearts used for Western blotting to ensure that these hearts conformed to the inclusion 
criteria.
2.8.3 Analysis
Tissue samples (from the left side of the apex) were pulverised in liquid nitrogen using a pestle 
and mortar and homogenised using lysis buffer, designed to encourage the solubilisation of the 
proteins. The buffer contained a commercially available protease inhibitor cocktail in order to 
prevent protein digestion by proteases present in the sample. Homogenates underwent 
sonication for 3 seconds and centrifugation at 13,000 g for 15 minutes after which the 
supernatant was removed.
A commercial assay kit, Bicinchonic acid (BCA)™ Protein Assay Kit (Pierce, UK) was used to 
determine the total protein concentration in each sample. Absorbance was read at X54onm by
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MRX TC Spectrophotometer using Revelation V 4.22 software (Dynex Technologies Limited, 
Worthing, UK). Samples were compared to a standard curve made up of concentrations (0, 25, 
250, 500,1000, 2000, 4000,10000 pg.ml'1) of bovine serum albumin in lysis buffer.
The supernatant was divided into 20pl aliquots. To each aliquot, 20pl of Laemmli sample buffer 
was added and the samples were stored at -20°C until further analysis. The composition of 
Laemmli sample buffer was (4% sodium dodecyl sulphate, 20% glycerol, 10% 2- 
mercaptoethanol, 0.0004% bromophenol blue, 0.215 M Tris HCI).
Protein separation was achieved by sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis (SDS-PAGE) using a mini-PROTEAN 3* cell and tank system (Bio-Rad 
Laboratories Inc., Hemel Hempstead, UK). 10 pg of each protein sample was loaded. Separated 
proteins were then transferred to a polyvinylidine difluoride (PVDF) membrane (Amersham 
Biosciences Ltd.). The membrane was agitated in a 5% solution of milk powder in Tris buffered 
saline-tween (TBS-Tween) for 3 hours to prevent non-specific binding of proteins. The PVDF 
membranes were initially probed with a rabbit anti-phospho-(ser473)-Akt primary antibody 
(1:500 dilution) at 4°C overnight. They were then washed in TBS-Tween (three 15 minute 
washes) after which the membranes were probed with a goat anti-rabbit-horseradish 
peroxidase conjugate secondary antibody (1:10000 dilution), followed by a further three 15 
minute washes. The membrane was then coated with Western Blotting Luminol Reagent (Santa 
Cruz Biotechnology Inc., USA), and then exposed to photographic film (Hyperfilm™, Amersham 
Biosciences Ltd., Amersham, UK) for 15 minutes. The films were developed, fixed and dried and
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then converted to digital images using an Epson perfection 2480 photo scanner (Epson Ltd. 
Hemel Hempstead, UK).
Membranes were then stripped of antibody using Restore™ Western blotting stripping reagent 
and then re-probed using a total Akt antibody (1:500 dilution). The procedure was exactly as 
described in the previous paragraph, except that the time for which the membrane was 
exposed to the photographic film was ten seconds.
Images were analysed using the software ImageJ vl.38x (National Institute of Health, USA). 
Mean grey values were obtained for bands. These were converted into optical density 
measurements using a calibrated step tablet (Kodak). Protein loading was controlled for by 
comparing total and phosphorylated Akt on the same blot (See chapter 6 for details)
2.9 Solutions and chemicals
2.9.1 Water
Water used throughout this experiment was double distilled (analytical grade) obtained from a 
Millipore Elix 10 still (Millipore Billerica, MA)
2.9.2 Krebs Henseleit buffer (KHB)
A buffer based on that first described by Krebs (Krebs & Henseleit, 1932), was used in 
Langendorff heart preparations and in experiments utilising isolated atria and ventricles. A
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tenfold stock solution was made weekly containing NaCI (1.184 pM); MgS04 (12 mM); KCI (47 
mM) and KH2P04(12 mM) in water. This was stored in a refrigerator at 4°C.
KHB was made up freshly before each experiment. To an appropriate volume of stock solution 
was added a freshly made solution of NaHC03 and glucose. The volume was then adjusted to 
approximately 90% of the final required volume using distilled water. CaCI2 was dissolved 
separately and added last to the mixture, before a final adjustment of the volume achieved by 
the addition of water. Final concentrations of reagents in the KHB were as follows: NaCI 
118mM, KCI 4.7mM, KH2P04 1.2mM, MgS04 1.2mM, CaCI2 2.5mM, glucose l lm M .
To the KHB used in Langendorff perfused heart experiments only was added insulin lOOmUl'1 
because of the problems of delivering sufficient energy substrate to the heart by glucose alone 
(Sutherland et al., 2000).
KHB was filtered through a Whatman 5 pm filter to remove particulate impurities prior to use in 
Langendorff preparations (Sutherland et al., 2000).
KHB was gassed with 95% 0 2 /  5% C02 for approximately 20 minutes prior to the 
commencement of the experiment. In bicarbonate buffers, C02is required to maintain the pH 
of the buffer at 7.4 (Sutherland et al., 2000).
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2.9.3 Pentobarbitone solution and preparation of injections 
Pentobarbitone solution was made up weekly to a final concentration of 60 mg.ml'1. This was 
achieved by first dissolving 600 mg in 2ml of pure ethanol. This was made up to 10 ml with 0.9% 
sodium chloride solution which had been warmed to approximately 30°C. This solution was 
stored in a refrigerator at 4°C.
Injections were prepared freshly, shortly before use. Into a 1ml syringe with needle attached 
0.1 ml of a lOOU.ml'1 solution of heparin was drawn up followed by 0.9 ml of the 
pentobarbitone solution. Injections were given via the intraperitoneal route close to the right 
hind limb.
2.9.4 2,3,5-triphenyltetrazolium chloride
A 1% solution of 2,3,5-triphenyltetrazolium chloride in KHB was prepared immediately prior to 
use. The solution was warmed to 37°C prior to addition of the heart slices.
2.9.5 Evans blue
Evans blue dye was prepared as a 10 % solution in water and was stored in the refrigerator (2-8 
°C) until immediately before use when an appropriate volume was diluted with KHB to form a 
1% solution.
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2.9.6 Insulin
Insulin was supplied as a lOOUml1 solution and was diluted to lU .m l'1 with water. This stock 
solution was kept in a refrigerator at 4°C and 0.1 ml was added to every litre of KHB to give a 
final concentration of 100 m il.I'1.
2.9.7 Lysis buffer
Lysis buffer contained Tris-HCI (pH 7.6),20 mM; EDTA (pH 8.0), 10 mM; Triton X-100, 0.25 %, 
NaCI, 100 mM; KCI, lOmM and MgCI2.6H20 , 3mM.
2.9.8 Running buffer (xlO concentrated)
Running buffer consisted of an aqueous solution of trizma base, 10.25M; glycine, 1.92 M and 
SDS, 1% (w/v).
2.9.9 Transfer buffer
Transfer buffer consisted of an aqueous solution of tris(hydroxymethyl)aminomethane (TRIS), 
25mM; glycine, 192mM and methanol 20% (v/v). pH was adjusted to 8.3.
2.9.10 Tris buffered saline (TBS) (concentrated) 1 L
TBS (concentrated) consisted of an aqueous solution of TRIS, 0.2 M and NaCI, 1.37 M. pH was 
adjusted to 7.6.
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2.9.11 TBS-tween 1L
TBS-tween consisted of an aqueous solution of TBS (concentrated), 10% and Tween-20, 0.1%.
2.9.12 Running gel
Running gel was freshly prepared with the following components: water (46.0%); 30% 
conjugated acrylamide, (26.7%); 15M Tris (pH 8.8), (25.3%); 10% SDS, (1.0%); 10% ammonium 
persulphate (O.lg/ml), (1%) and Tetramethylethylenediamine (TEMED), (0.06%).
2.9.13 Stacking gel
Each stacking gel was freshly prepared with the following components: water, (68.3%); 30% 
conjugated acrylamide, (17.9 %); 15M Tris (pH 8.8), (12.7 %); 10% SDS, (1%); 10% ammonium 
persulphate, (1.0%) and TEMED, (0.1%).
2.10 Cleaning of glassware and equipment 
At the end of each experiment (Langendorff or isolated tissue), glassware was washed firstly 
with very hot tap water. This was followed by soaking in a dilute solution of hydrochloric acid 
followed by thorough rinsing with distilled water. The organ baths which had contained the 
isolated atria and ventricles were washed in a similar manner. The Langendorff apparatus was 
cleaned by running very hot water through the tubing, followed by distilled water and lastly 
hydrochloric acid (approx 1 M) which was left in the apparatus until shortly before the next use, 
when it was thoroughly washed out with distilled water.
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2.11 Sources of drugs and chemicals
Table 2-1 A list of drugs and chemicals used in this thesis and the suppliers
Drug/Chemical Manufacturer
95% N2 /  5% C02 
95% 0 2 /  5% C02 
Acetonitrile
Acrylamide (30% conjugated) 
(-)-Adrenaline (+)- bitartrate
Akt antibody (Phospho-Ser473)
Akt antibody (Total)
Ammonium persulphate
Bovine Serum Albumin
BRL-37344 sodium 
Calcium chloride dihydrate 
CGP-20712A dihydrochloride 
Choline chloride
British Oxygen Company, Guildford, Surrey, GU2 
7XY
British Oxygen Company, Guildford, Surrey, GU2 
7XY
Fisher Scientific, Loughborough, LE115RG 
Fisher Scientific, Loughborough, LE115RG 
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Cell Signalling Technology Inc, 3 Trask Lane, 
Danvers, MA 01923
Cell Signalling Technology Inc, 3 Trask Lane, 
Danvers, MA 01923, USA 
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Tocris Bioscience, Avonmouth, Bristol, BS11OQL 
Fisher Scientific, Loughborough, LE115RG 
Tocris Bioscience, Avonmouth, Bristol, BS11 OQL 
Acros Organics, Geel, Belgium.
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Drug/Chemical Manufacturer
CL-316243
R(-)-Denopamine
EDTA (disodium salt)
Ethanol 
Evans Blue
Forskolin
Formoterol
Glucose
Glycine
Goat-anti Rabbit antibody HRP conjugate 
Heparin
Hydrochloric acid 
Hypurin porcine insulin 
ICI-118551 hydrochloride
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Fisher Scientific, Loughborough, LE115RG 
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Tocris Bioscience, Avonmouth, Bristol, BS11 OQL 
Fisher Scientific, Loughborough, LE115RG 
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Upstate (Millipore) 290 Concord Road, Billerica, 
MA 01821, USA
CP Pharmaceuticals, Wrexham, Clwyd, U.K. 
Fisher Scientific, Loughborough, LE115RG 
AAH hospital supplies, Coventry, UK.
Tocris Bioscience, Avonmouth, Bristol, BS11 OQL
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Drug/Chemical Manufacturer
(-)-isoprenaline (+)-bitartrate 
Laemmli buffer
l-lactate dehydrogenase from rabbit 
muscle
Magnesium sulphate (analytical grade) 
Marvel™(original) Dried Skimmed Milk 
Methanol 
N2 (liquid)
L-H-Noradrenaline (+)-bitartrate salt 
monohydrate
Octane sulphonic acid sodium 
Pentobarbitone sodium
Phentolamine mesylate 
Potassium chloride (analytical grade) 
Potassium dihydrogen orthophosphate 
(analytical grade)
Procaterol hydrochloride
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Fisher Scientific, Loughborough, LE115RG 
Premier International Foods, Spalding, UK 
Fisher Scientific, Loughborough, LE115RG 
British Oxygen Company, Guildford, Surrey, GU2 
7XY
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Fisher Scientific, Loughborough, LE115RG 
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Alliance Pharmaceuticals, Chippenham, Wiltsire. 
Fisher Scientific, Loughborough, LE115RG 
Fisher Scientific, Loughborough, LE115RG
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
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Drug/Chemical Manufacturer
(±)-propranolol
Protease inhibitor cocktail
Restore™ -  Western blotting stripping 
reagent
Salbutamol hemisulphate
Sodium chloride
Sodium chloride solution 0.9%
Sodium citrate 
Sodium dodecyl sulphate
Sodium hydrogen carbonate
SR-59230A hydrochloride 
TEMED
Timolol maleate
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Pierce (Thermo-Fisher) PO Box 117, Rockford, IL 
61105, USA)
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Pierce (Thermo-Fisher) PO Box 117, Rockford, IL 
61105, USA)
Fisher Scientific, Loughborough, LE115RG 
Baxter Healthcare, Newbury, Berkshire, RG20 
7QW
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Tocris Bioscience, Avonmouth, Bristol, BS11 OQL 
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
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Drug/Chemical Manufacturer
2,3,5-triphenyltetrazolium chloride 
TRIS
Triton X-100 
Trizma base 
Tween-20
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
Sigma-Aldrich Company Ltd, Poole, Dorset, BH12 
4QH
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2.12 Statistics and treatment of data 
When two groups of data were compared a t-test was used (paired or unpaired as appropriate, 
see individual chapters for details. Three or more groups were compared by 1-Way Analysis of 
Variance (ANOVA) followed by the Student Newman-Keuls post-hoc test. This test assumes 
equal variance between experimental groups. This was confirmed using Bartlett's Test of Equal 
Variance. ANOVA also assumes a near-Gaussian distribution of data. Each data set was thus 
subjected to D'Agostino & Pearson's Omnibus Normality Test. Coronary flow, LVDP and RPP 
were compared using repeated-measures ANOVA. All analyses were performed using GraphPad 
Prism* Version 4.02, GraphPad software, Inc.
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Chapter 3 - Can ischaemic preconditioning, postconditioning
and p-adrenoceptor-m ediated preconditioning protect 
against stunning in ra t isolated atria and ventricles?
3.1 Introduction
Ischaemic preconditioning is an extremely powerful cardioprotective phenomenon whereby 
transient periods of ischaemia protect the heart against later more severe ischaemic insult. The 
phenomenon, first discovered by Reimer's group (Murry et al., 1986) protects the heart against 
arrhythmias (Ravingerov£ et al., 2002) and importantly prevents lethal cell injury and reduces 
infarct size (Murry et al., 1986). However, controversy exists as to whether preconditioning 
reduces stunning (a component of reperfusion injury consisting of reversible contractile 
dysfunction). Whilst protection against stunning has been demonstrated in vitro by classic 
ischaemic preconditioning (Fralix et al., 1993) and pharmacological preconditioning (Gardner et 
al., 2004; Yates et al., 2003), this has been difficult to replicate in vivo (Jennings, 1996; Kloner & 
Jennings, 2001a; Kloner & Jennings, 2001b; Ovize et al., 1992). Conversely, the protection of 
late preconditioning (second window of preconditioning) against stunning is much more robust 
(Przyklenk & Heusch, 2003; Sun et al., 1995; Tang et al., 1996). Using in vivo experimental 
models with recovery of animals, stunning can easily be distinguished from lethal reperfusion 
injury, because of its reversal over time. However, using in vitro preparations which are stable 
only for several hours, it can be difficult to distinguish whether post-ischaemic contractile 
dysfunction is caused by stunning or cell death. Furthermore, any intervention which improves 
post-ischemic contractile function may do so by ameliorating either stunning or cell death (or
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both). For the same reasons it has been difficult to determine whether postconditioning 
improves contractile function after reperfusion as a result of reducing cell death or whether it 
truly improves stunning (Penna et al., 2008). Although a reduction of infarct size is the most 
important outcome in improving life expectancy after ischaemia in the clinic, reduction of 
stunning may also be important in reducing morbidity (See Section 1.2.4.2).
Several groups of investigators have demonstrated that a preconditioning-like adapted state 
can be induced by transient pre-treatment of hearts or other tissues with a (3-adrenoceptor 
agonist (Frances et al., 2003; lliodromitis et al., 2004; Spear et al., 2007; Tong et al., 2005). 
However, it is unclear whether or not ischaemic preconditioning is dependent on p- 
adrenoceptor activation (Tune et al., 2004). Studies investigating P-adrenoceptor-mediated 
preconditioning have demonstrated functional improvements (improved left ventricular 
developed pressure) in P-adrenoceptor-preconditioned hearts over controls, possibly 
representing a reduction in stunning (Frances et al., 2003; lliodromitis et al., 2004; Spear et al., 
2007; Tong et al., 2005). These studies have been carried out in Langendorff or working hearts 
which are excellent models for studying ischaemic damage and reperfusion injury, as both 
functional data and infarct-size data can be obtained. However, in these experiments, improved 
functional recovery was associated with reduced cell death as assessed by visualisation of 
infarct size or measurement of cardiac enzyme release which may also be responsible for the 
improved contractile function.
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A further limitation of experiments investigating p-adrenoceptor preconditioning in isolated 
hearts and indeed in vivo procedures is that these experiments may be complicated by the fact 
that activation of p2-adrenoceptors in the coronary vasculature, leads to coronary 
vasodilatation potentially increasing contractile force via the Gregg effect (Gregg, 1963). 
Furthermore, activation of pr adrenoceptor in the heart causes a positive chronotropic effect 
(Ahlquist, 1948).
One study, has demonstrated protection against post ischaemic dysfunction in isolated paced 
guinea-pig atria exposed to 30 minutes simulated ischaemia (Yates et al., 2003). This provides 
evidence that p-adrenoceptor-mediated preconditioning can protect against stunning. 
Electrically paced isolated cardiac tissues allow the study of the direct effects of ischaemic 
preconditioning and drug treatment on contractile function in different regions of the heart. As 
the tissues are not supplied by coronary flow but by diffusion, true ischaemia cannot be 
induced. Ischaemia is simulated by using a hypoxic buffer containing no glucose. Reperfusion is 
simulated by replacing normal buffer and reoxygenating the tissues (Carr et al., 1997; Gardner 
et al., 2004; Sivaraman et al., 2007; Walker et al., 1994; Walker et al., 1995). It has been 
suggested that when tissues are exposed to short periods of simulated ischaemia (such as 30 
minutes used in this study) contractile dysfunction is predominantly due to stunning, whereas 
with longer periods, cell death becomes more important (Walker et al., 1994).
Thus by using a short (30 minute) period of ischaemia in isolated paced tissues, it is anticipated 
that the effects interventions on stunning can be investigated without the confounding factors
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associated with cell death and without complications caused by vascular properties of P- 
adrenoceptor ligands.
The aim of this study was to use this model to test the hypothesis that ischaemic 
preconditioning and P-adrenoceptor-mediated preconditioning could be demonstrated in 
isolated paced cardiac tissues which provide a coronary vascular-independent model of 
myocardial ischaemia. One would expect p-adrenoceptor-mediated preconditioning to be 
susceptible to a P-adrenoceptor antagonist, a hypothesis which was tested. However, it was 
also an aim of this study to test the hypothesis that ischaemic preconditioning is dependent on 
P-adrenoceptor activation in this model. Furthermore, investigations were carried out to 
determine whether ischaemic postconditioning could protect against stunning.
3.2 Hypotheses
•  Ischaemic preconditioning will lead to improved post-ischaemic contractile function in 
isolated cardiac tissues
•  Activation by p-adrenoceptor agonists prior to ischaemia will mimic this protection
•  The protection elicited by ischaemic preconditioning will be blocked by a non-selective 
P-adrenoceptor antagonist.
•  Ischaemic postconditioning will improve post-ischaemic contractile function in isolated 
cardiac tissues
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3.3 Methods
3.3.1 Atrial and ventricular preparations
Male Sprague-Dawley rats (Harlan, Bicester, U.K.) were used throughout and weighed 250-350g 
at the time of killing. Atrial and ventricular preparations were set up as described in section 2.4. 
All preparations were left for one hour to stabilise, during which time they were frequently 
washed. Initial diastolic tension was lg  for atrial tissues and 1.5g for ventricular tissues.
3.3.2 Experimental protocols
After the stabilisation period, the tissues were randomised to one of the following treatment 
groups (Figure 3-1). Control; tissues underwent a further thirty minutes normoxia, followed by 
30 minutes simulated ischaemia (the index ischaemia), achieved as described in Section 2.5.4. 
Normoxic glucose-containing KHB was then restored and the contractile function of the tissues 
was monitored for one hour, during which time the KHB was replaced every fifteen minutes. 
Ischaemic preconditioning (IPC); tissues underwent ten minutes simulated ischaemia and ten 
minutes normal oxygenation prior to the index ischaemia. ischaemic preconditioning in the 
presence of propranolol (IPC + Pro). Ischaemic preconditioning was performed as described as 
above, in the presence of lO-6 M propranolol which was added twenty-five minutes prior to the 
preconditioning ischaemia and maintained throughout simulated ischaemia and throughout the 
experiment after reoxygenation and glucose replacement. 0-adrenoceptor mediated 
preconditioning (0P). Tissues were exposed to isoprenaline (10'6M) under normoxic conditions 
for 10 minutes, followed by washout. Simulated ischaemia begun twenty minutes later. 
Propranolol (Pro) Tissues were treated as controls, apart from the presence of 10-6 M 
propranolol which was present in the bath throughout the experiment. 0-adrenoceptor
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mediated preconditioning in the presence of propranolol (pP + Pro). Tissues were exposed to 
propranolol (10-6 M) for fifteen minutes prior to isoprenaline treatment as described above. 
Propranolol was maintained throughout the experiment. Ischaemic postconditioning (Postcon) 
-  Tissues were treated as for controls, except at reoxygenation, tissues were exposed to 3 
cycles of 1 minute normoxia followed by 1 minute simulated ischaemia. The protocols for 
ischaemic and pharmacological preconditioning were chosen based on preliminary data to find 
the optimum protocols for protection in this model (Table 3-1).
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Control
30' Ischaemia 30'
y  \
Reoxygenation 60'
Ischaemic Preconditioning (IPC)
Ischaemic Preconditioning + Propranolol (IPC + Pro)
Propranolol 10-6 M  
P-adrenoceptor preconditioning (0 -p re )
0-adrenoceptor preconditioning + Propranolol (0-pre + pro)m
Propranolol lO ^ M  
Propranolol only (Pro only)
Propranolol lO ^ M
Ischaemic Postconditioning (Postcon)
■ i i i i i__ i i i i i 1 1
30 -20 -10 0 10 20 30 40 50 60 70 80 90
Figure 3-1 Experimental Protocols. Time (minutes) is shown along the abscissa with the onset of simulated ischaemia 
designated 0. Yellow regions correspond to normoxic conditions, red: simulated ischaemia and grey, drug treatment. Vertical 
arrows indicate washes during reperfusion.
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The tissues were washed by replacing the KHB with fresh warmed oxygenated KHB three times. 
Tissues were paced throughout the experiment using a Grass S48 stimulator (Grass instrument 
Co. Quincy, Mass., U.S.A.) with threshold voltage + 50% (typically 1-5 V) at 2 Hz.
Analysis of the results of these experiments demonstrated a significant improvement of 
contractile function 60 minutes after reoxygenation in atria in tissues treated with isoprenaline 
prior to ischaemia (See Section 3.4.6). In order to discover the receptor subtype responsible for 
this effect, three further experimental groups were included in the study. These experiments 
involved applying the selective 3-adrenoceptor agonists, denopamine (10 pM, 3 r  
adrenoceptor), procaterol (10 pM, 32-adrenoceptor) and CL-316243 (100 nM, 33-adrenoceptor) 
to the tissues according to the same protocol as used for isoprenaline. Denopamine was initially 
dissolved in DMSO and thereafter in KHB. The vehicle control for DMSO is also shown.
3.3.3 Cell death/LDH assay 
Analysis of the concentration of LDH in the KHB was used as a measure of cell death in the 
tissues. This analysis was performed for the following experimental groups: Control, Ischaemic 
preconditioning, 3-adrenoceptor preconditioning. In addition a time control was carried out in 
which cell death was monitored in naive tissues which were paced but not exposed to 
ischaemia. Samples of Krebs (0.5 ml) were removed from the organ bath immediately prior to 
simulated ischaemia, 15 minutes into ischaemia, at the end of ischaemia and every 15 minutes 
during recovery. Samples were stored and analysed as described in Section 2.6. Data are
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presented as units of LDH per ml of KHB. Statistical analysis was carried out by ANOVA followed 
by Student-Newman-Keuls post-hoc test
3.3.4 Data analysis
Prism version 4.02 for windows (GraphPad Software, Inc) was used for production of graphs 
and statistical analyses. Tension was monitored continuously, enabling calculation of diastolic 
(baseline) and developed tension. The degree of ischaemic contracture was quantified by 
measuring the increase in diastolic tension during simulated ischaemia at its maximum point. 
The time taken to reach maximal contracture was also recorded. Cardiac function was assessed 
at fifteen and sixty minutes post reoxygenation. Developed tension at these time points was 
calculated as a percentage of developed tension at the end of the stabilization period for each 
preparation. Groups of data were compared by one-way ANOVA followed by Student-Newman- 
Keuls post hoc test.
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3.4 Results
3.4.1 Preliminary data
Table 3-1 A summary of preconditioning protocols used in preliminary studies to obtain optimal conditions for ischaemic and 
pharmacological preconditioning. Time proceeds along the abscissa. White regions correspond to normoxic conditions; black 
indicates simulated ischaemia and grey indicates exposure to isoprenaline (10-6 M). The magnitude of the developed tension 
of the tissues (± SEM) is given for 15 and 60 minutes after reoxygenation and is expressed as a % of the baseline (prior to 
preconditioning). The length of time in minutes of each stage of the protocol is shown. * Indicates significant (p<0.05) 
difference from respective controls, as determined by one-way ANOVA with Student-Newman-Keuls post hoc test.
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3.4.2 Baseline cardiodynamics
Table 3-2 M ean baseline values of developed tension for experimental groups in this study.
Atria Ventricles
n Baseline (g) n Baseline (g)
Control 11 0.32 1 0.05 12 1 .2710 .15
Ischaemic preconditioning (IPC) 6 0.34 ± 0.04 6 1 .5510 .13
IPC + Propranolol (IPC+ Pro) 6 0 .3 4 10 .1 1 6 1.45 10.08
Propranolol only (Pro) 6 0.40 ± 0.04 5 1 .1810.25
3-adrenoceptor preconditioning (pP) 6 0.43 ± 0.07 7 1 .4110.18
PP + propranolol (pP + Pro) 6 0 .4 2 10 .1 3 5 1.2710.35
Postconditioning (Postcon) 5 0 .5 0 1 0 .0 6 5 1.5410 .99
Denopamine 3 0 .511  0.12 N/A N/A
Procaterol 4 0.47 10 .07 N/A N/A
CL-316243 5 0.47 10 .08 N/A N/A
DMSO 4 0.39 10.03 N/A N/A
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3.4.3 General observations 
In control preparations in both atria and ventricles, simulated ischaemia led to a rapid 
reduction in developed tension, which fell to near-zero levels after five minutes. Diastolic 
tension rose during simulated ischaemia (indicative of contracture) reaching a maximum 
between 20 and 25 minutes and fell thereafter. Peak contracture was 0.65 ± O.lg in atria and 
1.95 ± 0.18 g in ventricles. Upon reoxygenation, recovery of developed tension occurred rapidly 
during the first 15 minutes, and more slowly thereafter (Figure 3-2). Therefore contractile 
function was compared at 15 and 60 minutes post-reoxygenation. Preconditioning protocols 
were optimised by carrying out preliminary studies (Table 3-1).
Reoxygenation
Figure 3-2 A representative trace from a ventricular preparation exposed to simulated ischaemia and reoxygenation. S 
represents the final minutes of the stabilisation period. Time (minutes) from reoxygenation are shown along the abscissa. 
Note the rapid fall in developed tension during simulated ischaemia and the increased diastolic tension indicating ischaemic 
contracture. Diastolic and developed tension both recover rapidly over the first 15 minutes of reoxygenation and more 
slowly thereafter.
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3.4.4 Effects of ischaemic and p-adrenoceptor-mediated preconditioning 
on ischaemic contracture
Ischaemic preconditioning in ventricular tissues led to a significant (p<0.05) reduction in 
maximal ischaemic contracture from 1.95 ± 0.18g in controls to 0.92 ± 0.28g. A similar trend 
was evident in atrial tissues although this did not reach significance, p-adrenoceptor-mediated 
preconditioning did not alter the maximal contracture compared to controls (Figure 3-3).
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Figure 3-3 Magnitude of ischaemic contracture (maximum increase in baseline/diastolic tension (g) during simulated 
ischaemia) in a) atria and b) ventricular strips. * indicates p<0.05, **indicates p<0.01; * * *  indicates pcQ.001.
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Ischaemic preconditioning led to a significant (p<0.01) reduction in the time taken to achieve 
maximal contracture in ventricular tissue from 22.45 ± 3.5 minutes in controls to 16.33 ± 1.5 
minutes. 0-adrenoceptor-mediated preconditioning did not alter the time taken to reach 
maximal contracture (Figure 3-4).
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* *
Figure 3-4 Time (minutes) into simulated ischaemia at which maximum contracture was reached in a) atria and b) ventricular 
strips. * indicates p<0.05, * *  indicates p<0.01, * * *  indicates p<0.001.
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Propranolol alone had no significant effect on either the magnitude of the maximal contracture, 
or the time taken to achieve this contracture. When ischaemic preconditioning was carried out 
in the presence of propranolol, the magnitude of ischaemic contracture was not significantly 
different from either control or preconditioned ventricular tissues. In atria however, the 
combination of ischaemic preconditioning and propranolol led to an ischaemic contracture of 
1.58 ± 0.36g which was significantly (p<0.001) greater than either control atria or those which 
had undergone ischaemic preconditioning.
3.4.5 Effects of ischaemic preconditioning and postconditioning on 
contractile recovery
Ischaemic preconditioning led to an improved recovery of developed tension in both atrial and 
ventricular preparations compared to controls when compared fifteen minutes after 
reoxygenation. By this time point, developed tension in control (untreated) atrial tissues had 
recovered to 29.3 ± 1.7 % of the developed tension measured at the end of the stabilization 
period. Recovery of function was significantly (p<0.05) improved to 47 ± 4.0 % in tissues that 
had undergone ischaemic preconditioning. When ischaemic preconditioning was carried out in 
the presence of propranolol, the protective effect was lost. Tissues thus treated recovered to
26.4 ± 5.1 % which was not significantly different to control, however was significantly (p<0 .01 ) 
smaller than recovery of atria which had undergone ischaemic preconditioning without 
propranolol. Propranolol alone had no significant effect on the recovery of tissues. 
Postconditioning did not significantly affect the recovery of atria (Figure 3-5 A).
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A similar picture was observed in ventricular tissues. Untreated tissues recovered to 22.4 ± 2.8 
% of pre-ischaemic values in the first fifteen minutes of reoxygenation. Ischaemic 
preconditioning significantly (p<0.05) increased this value to 39.0 ± 5.2 %. Propranolol had no 
significant effect on recovery when given alone, however when combined with ischaemic 
preconditioning, recovery at this time point was significantly (p<0 .01) less than ischaemic 
preconditioning alone, and not significantly different to control. Postconditioning did not affect 
the recovery of ventricular tissues (Figure 3-5 B).
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Figure 3-5: Developed tension after 15 minutes reoxygenation in a) atria and b) ventricular strips. Developed tension is 
expressed as a percentage of the developed tension achieved at the end of the stabilisation period. * indicates p<0.05 **  
indicates p<0.01.
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No significant effect of ischaemic preconditioning or postconditioning upon recovery was seen 
in either tissues 60 minutes after reoxygenation (Figure 3-6).
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Figure 3-6: Developed tension after 60 minutes reoxygenation in a) atria and b) ventricular strips. Developed tension is 
expressed as a percentage of the developed tension achieved at the end of the stabilisation period. * indicates p<0.05.
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3.4.6 p-adrenoceptor-mediated preconditioning: effects after
reoxygenation
Recovery of developed tension in tissues which had received a preconditioning exposure of 
isoprenaline was not different to control in either tissue 15 minutes after reoxygenation (Figure 
3-5). However, after 60 minutes reoxygenation in atria, the tissues treated with isoprenaline 
had recovered to 75.8 ± 16.6, significantly (p<0.05) greater than controls which recovered to 
47.9 ± 2.3. This increase was blocked in propranolol treated tissues to 44.0 ± 3.0 % which was 
significantly (p<0.05) smaller than isoprenaline preconditioned tissues, and not significantly 
different to controls. Propranolol alone had no significant effect on recovery at this time period 
(Figure 3-6 A). Isoprenaline treatment did not improve recovery of function in ventricular tissue 
(Figure 3-6 B).
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Figure 3-7 A) M axim al change in developed tension (as a % of baseline) caused by 0-adrenoceptor agonist preconditioning in 
isolated atria and B) Recovery of developed tension at 60 m inutes after reoxygenation in atria exposed to  preconditioning by 
0-adrenoceptor agonists. * indicates a significant difference p<0.05.
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None of the selective 0-adrenoceptor agonists led to improved post-ischaemic contractile 
recovery in the same way as isoprenaline (Figure 3-7 B). Successful application of denopamine 
and procaterol was confirmed by the positive inotropic effects of these agents during 
preconditioning (Figure 3-7 A).
3.4 .8  Cell d ea th /L D H  assay 
LDH in KHB taken from the organ bath was measured during ischaemia and during reperfusion 
for control, ischaemic preconditioning and 0-adrenoceptor preconditioning groups. There was 
no significant difference in LDH release between groups either during ischaemia or at 
reperfusion. There was a trend in all experimental groups towards larger LDH release during 
reperfusion than during ischaemia (Figure 3-8).
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Figure 3-8 LDH release from ventricles during A) ischaemia and B) reperfusion
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3.5 Discussion
This study has demonstrated cardioprotection by ischaemic preconditioning in both atria and 
ventricles. This was manifest by improved functional recovery at 15 minutes after 
reoxygenation in preconditioned tissues compared to controls. Pre-treatment of tissues with 
the non-selective 3-adrenoceptor agonist, isoprenaline, also resulted in improved functional 
recovery, although this was manifest later (60 minutes after reoxygenation). The failure of 3- 
adrenoceptor-mediated preconditioning to protect ventricular tissue in this model is unlikely to 
reflect the fact that ventricular tissue cannot be preconditioned by 3 -adrenoceptor activation, 
because isolated heart models have demonstrated that post ischaemic cardiac function can be 
improved by 3-adrenoceptor preconditioning (Frances et al., 2003; Lochner et al., 1999; Marais 
et al., 2001; Moolman et al., 2006b; Moolman et al., 2006c; Nasa et al., 1997; Robinet et al., 
2005; Tong et al., 2005; Yabe et al., 1998), a fact which would necessitate a protective effect on 
the left ventricle. However, as discussed above, improved functional recovery may be a result 
of reduced cell death rather than reduced stunning. Furthermore, the mechanisms of reduced 
stunning by preconditioning may be different to those which reduce cell death. Thus the failure 
to demonstrate protection in this study either reveals a peculiarity of this model of stunning or 
of the right ventricle.
In this series of experiments, LDH data support the hypothesis that this model is a model of 
stunning rather than a cell death model because improvements in cardiac function in 
preconditioned groups were not accompanied by a reduction in cell death assessed by LDH 
measurements. Despite an improvement in post-ischaemic function in ischaemic 
preconditioned and 3-adrenoceptor preconditioned tissues, there was no difference in LDH
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release between groups, either during ischaemia or at reperfusion. As LDH is only released from 
cells when the sarcolemma is damaged, LDH release is a good surrogate marker for cell death. 
The similar amount of cell death in all groups supports the hypothesis that any improvement in 
function was due to an anti-stunning effect.
However, because LDH could be measured in the KHB, cell death was evidently occurring to 
some extent in all experimental groups, indeed cell death could be observed in time controls 
which were not made ischaemic. The cell death may well have been most prevalent in the core 
of the tissue which is likely to be hypoxic because it relies on diffusion for the delivery of 
oxygen. Continuous cell death is a limitation of the model used. The cell death data were 
collected for the ventricular preparations only, because the mass of atrial preparations was 
extremely small in comparison to the size of the organ bath and therefore any LDH release was 
diluted to very low concentrations which could not be reliably measured using the assay 
employed in this study.
It has been suggested that ischaemia-induced release of catecholamines in the heart is a 
mechanism by which ischaemic preconditioning induces a protective state (Huang et al., 2007). 
Catecholamine release and subsequent activation of 3-adrenoceptor has also been implicated 
in the mechanism of cardioprotection achieved by administration of opioids (p2) (Lange et al., 
2006) and anaesthetics (3i) (Carr et al., 1997). However, controversy remains as to whether 
activation of 3-adrenoceptors is an essential part of ischaemic preconditioning, or whether 
there are redundancies in the pathway which lead to protection by alternative pathways (see
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Section 1.5.1). This is an important question in the clinic, where (3-adrenoceptor antagonists are 
administered for the treatment of angina, hypertension and heart failure (Kloner & Rezkalla, 
2006). Ischaemic preconditioning can be used as a protective strategy prior to cardiac surgery. 
It is thought that angina attacks may also induce preconditioning that can be protective against 
the damage sustained during a later myocardial infarction (lliodromitis et al., 2004). Therefore, 
it is important to understand how these protective phenomena may be modified by commonly 
used ^-blocking medication.
In this study, the beneficial effects of ischaemic preconditioning on post-ischaemic recovery 
were blocked by the non-selective 3-adrenoceptor antagonist, propranolol, suggesting an 
important role for 3-adrenoceptors in ischaemic preconditioning in this model. However, the 
timecourse of 3-adrenoceptor mediated and ischaemic preconditioning was different, 
ischaemic preconditioning led to improved contractile function early after reoxygenation (15 
minutes) but not after 60 minutes. At this later time point, however 3-adrenoceptor -agonist 
pre-treatment led to improved function. Furthermore, tissues preconditioned by ischaemia and 
by 3-adrenoceptor stimulation behaved differently from one another during ischaemia. 
Ischaemic preconditioning led to a reduction in the magnitude of ischaemic contracture which 
is consistent with a protective effect. Ischaemic contracture is of the rigor type, and develops 
under conditions where ATP concentrations are insufficiently high to break actin-myosin cross­
links (Kolocassides et al., 1995). Rigor contracture can lead to damage to the cytoskeleton and 
thus any reduction in the magnitude of contracture is likely to be protective. In contrast, 3- 
adrenoceptor stimulation by isoprenaline did not reduce the magnitude of contracture in either 
atria or ventricles even in tissues where there was improved recovery at 60 minutes. Thus,
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ischaemic preconditioning may involve wider ranging beneficial effects than those seen with 3- 
adrenoceptor-mediated preconditioning.
In agreement with studies in whole hearts (Kolocassides et al., 1995; Spear et al., 2007; Tong et 
al., 2005), ischaemic preconditioning in ventricular preparations reduced the time taken to 
achieve maximum contracture. It is difficult to predict how ischaemic tissues will recover based 
on the profile of ischaemic contracture (Pantos et al., 2006). However, the difference seen in 
these experiments between ischaemic and 3-adrenoceptor-mediated preconditioning suggests 
that different mechanisms may be involved in each.
It is possible that positive inotropes such as isoprenaline could result in preconditioning by 
causing the energy demands of the tissue to exceed the capacity of diffusion to supply the 
substrates, and remove the waste products of metabolism. Indeed it has been noted that rapid 
pacing of the heart can mimic preconditioning by inducing ischaemia (Lochner et al., 1999; 
Robinet et al., 2005). Such an effect might be exaggerated in an a model such as that used in 
this study, in which there is no flow of buffer through blood vessels in the tissue and the core of 
the preparation is entirely dependent on diffusion to receive oxygen and nutrients. In this study 
none of the subtype-selective 3-adrenoceptor agonists mimicked preconditioning in the same 
way as isoprenaline, but these agents also failed to induce positive inotropy to the same extent 
as isoprenaline. However, there is a large body of evidence, from in vivo and Langendorff 
experiments, in which the myocardium is inevitably better supplied with perfusate via the 
coronary vasculature and therefore do not depend on the diffusion of metabolic substrates
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over large distances, that activation of protein kinases cascades as a result of 3-adrenoceptor 
activation results in the heart undergoing adaptive changes and becoming resistant to later 
ischaemic damage.
No beneficial effects of postconditioning against stunning were seen in either tissue. The 
protocol ( 3 x 1  minute normoxia followed by 1 minute simulated ischaemia) was chosen largely 
due to methodological constraints, because the process of inducing simulated ischaemia was 
complicated using the available apparatus and 1 minute was the shortest period for which this 
could be feasibly achieved. However other groups have demonstrated improved functional 
recovery by postconditioning with a similar protocol ( 4 x 1  minute normoxia followed by 1 
minute simulated ischaemia) in paced human atrial trabeculae (Sivaraman et al., 2007). 
However that study utilised a longer period of ischaemia (90 minutes) and therefore improved 
recovery was probably due to reduced cell death whereas this study was designed as a stunning 
model (Walker et al., 1994). Thus the failure to see postconditioning protection in this study 
may have been a result of: i) The inability of postconditioning to protect against stunning in the 
rat (postconditioning has already been shown to be ineffective against stunning in the rabbit 
and dog) (Couvreur et al., 2006). ii) The use of insufficient cycles of postconditioning (3 v. 4). iii) 
Species differences in the algorithm required to elicit postconditioning.
The present study is limited by the fact that the model uses atrial appendage tissue and right 
ventricular strips rather than left ventricle which is of more functional importance. However
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these tissues were chosen, because of their thin walls, in order to minimise the limitations to 
the tissue caused by reliance on diffusion for the delivery of oxygen and nutrients.
In terms of physiological relevance, this model falls between isolated whole hearts and cell 
culture, but is not subject to the problems of cell differentiation seen in culture and is not 
complicated by the effects upon coronary flow which would be expected when 3-adrenoceptor 
agonists are administered in a Langendorff preparation. Indeed, the effects seen in this model 
must occur at the level of the myocardium. The most clinically relevant finding of this study was 
that the functional improvements of ischaemic preconditioning were blocked by propranolol. 
This finding mirrors the result of other studies (Laskey, 2005) in which 3-adrenoceptor 
activation has been shown necessary for the protection of ischaemic preconditioning. This 
study has proved inconclusive in determining the receptor subtype involved in these effects, 
and this issue requires further investigation.
In conclusion, it has been demonstrated that isolated left atria and right ventricles can be used 
as a convenient model of ischaemic and pharmacological preconditioning against stunning. 
Ischaemic- and 3-adrenoceptor-mediated preconditioning both led to an improvement in post 
ischaemic contractile function. The protective effects in both cases were abrogated by 
propranolol. However, the timecourse of protection during ischaemia and reoxygenation was 
different in each case suggesting that ischaemic preconditioning involved more complex 
mechanisms than the simple release of catecholamines and subsequent signalling activation of 
3-adrenoceptors.
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3.5.1 Clinical relevance  
Because many patients with cardiovascular diseases take 3-adrenoceptor antagonists, these 
drugs may have the potential to abrogate the effects of ischaemic preconditioning induced 
prior to cardiac surgery (Kloner et al., 2006) or as a result of angina attacks (Hieble, 2000). This 
may therefore be an undesirable consequence of 3-adrenoceptor antagonist therapy
3.6 Conclusions
•  Ischaemic preconditioning can protect against stunning in isolated rat atria and 
ventricles. This protection is dependent on 3-adrenoceptor activation.
•  3-adrenoceptor preconditioning can protect against stunning in isolated rat atria.
•  The protocol of ischaemic postconditioning employed in this study does not protect 
against stunning.
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Chapter 4 W hat effects do endogenous and exogenous 
adrenaline have upon the heart at reperfusion?
4.1 Introduction
The activation of adrenoceptors by catecholamines has important physiological and therapeutic 
roles in myocardial ischaemia and at reperfusion. The onset of myocardial ischaemia triggers 
the release of adrenaline from the adrenal medulla, as a result of fear and anxiety. An increase 
in sympathetic discharge also results in the release of noradrenaline from sympathetic 
neurones within the heart (Foley et al., 1987; Kern et al., 1989; Lindner et al., 1996a). In 
ischaemic regions, metabolic alterations during prolonged ischaemia lead to the emptying of 
neuronal noradrenaline vesicles into the sarcoplasm. A reversal of the noradrenaline uptakei 
transporter releases the neurotransmitter into the synaptic cleft where it is accumulates. This 
noradrenaline release is independent of neuronal activity. Some synaptic noradrenaline spills 
over into the circulation and can be measured (Schoemig & Richard, 1991).
One consequence of severe myocardial ischaemia is cardiac arrest. This occurs when
myocardial damage is so severe that the rhythmic control of the heart is lost and the heart
enters a non-pumping state, either ventricular fibrillation, pulseless electrical activity, asystole
or pulseless ventricular tachycardia (International Liaison Committee on Resuscitation, 2005).
The massive fall in blood pressure accompanying cardiac arrest leads to further catecholamine
release (Schoemig et al., 1991). Thus, cardiac arrest results in a raised plasma catecholamine
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state. Raised catecholamine concentrations are maintained long after cardiopulmonary 
resuscitation (Niemann & Garner, 2005). The treatment of cardiac arrest includes intravenous 
injections of adrenaline, designed to cause peripheral vasoconstriction. The administration of 
adrenaline during cardiac arrest is therefore a mimic of the natural response and both 
endogenous and exogenous adrenaline can be present in the heart during ischaemia and 
reperfusion and thus have the potential to modify the process of ischaemic damage and 
reperfusion injury. High endogenous levels of catecholamines during cardiopulmonary 
resuscitation are correlated with poor survival (Lindner et al., 1996a). This raises the possibility 
that increasing catecholamine levels further through exogenous administration is detrimental.
In Britain, it is recommended that 1 mg of adrenaline should be given intravenously every three 
minutes during cardiac arrest (Mehta, 2006) although international guidelines suggest dosing 
every three to five minutes (International Liaison Committee on Resuscitation, 2005). This 
disparity probably reflects the fact that the guidelines are based on best practice and collective 
wisdom rather than evidence-based medicine.
4.1.1 Rationale for the use of adrenaline in cardiopulmonary 
resuscitation
During a cardiac arrest, patients are treated using cardiopulmonary resuscitation. This includes 
chest compressions and artificial ventilation. Adrenaline is administered intravenously 
(International Liaison Committee on Resuscitation, 2005). The rationale for the use of this agent 
is that it causes an increase in blood pressure by increasing peripheral resistance. Crile and
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Dolley (1906) Stated "The value o f adrenalin in raising the blood pressure, by its action upon the vascular 
walls in the state of suspended animation*.
Vasopressors also prevent arterial collapse under the increased intrathoracic pressure caused 
by chest compressions (Michael et al., 1984). Aortic diastolic pressure, the main determinant of 
coronary blood-flow is increased (Brown & Werman, 1990; Michael et al., 1984). Maintenance 
of coronary blood-flow is the most important factor in enabling return of spontaneous 
circulation (ROSC) or successful defibrillation (Babbs et al., 2001; Kern et al., 1988; Paradis et 
al., 1990; Paradis et al., 1991; Zhong & Dorian, 2005)
The peripheral vasoconstrictor effects of adrenaline are as a result of the activation of a- 
adrenoceptors, particularly in arterioles in the kidney, mucosa and skin and also in many veins 
(Hoffman, 2001; Hoffman & Taylor, 2001). Catecholamines such as adrenaline do not penetrate 
the blood-brain-barrier (Dahlgren et al., 1980) and cannot act on central adrenoceptors when 
given systemically. Changes in systemic blood pressure, therefore, largely dictate alterations in 
cerebral blood flow (Dahlgren et al., 1980; Hoffman, 2001). Thus, the increased blood pressure 
achieved by peripheral vasoconstriction improves blood-flow in the coronary and cerebral 
circulation, protecting the most vital organs from ischaemic damage and improving the chances 
of achieving ROSC.
However, in addition to its vascular effects, adrenaline also acts upon adrenoceptors in the
heart where it has the potential to cause harmful effects which may account for the poor
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results with this agent in the clinic. In particular adrenaline increases the energy demand of the 
fibrillating heart (Ditchey & Lindenfeld, 1988; Ditchey et al., 1994a; Ditchey &. Slinker, 1994b; 
Monroe & French, 1960; Monroe & French, 1961) thus worsening ischaemia and its positive 
inotropic and chronotropic actions (Ahlquist, 1948) will increase the energy demands of the 
heart if normal cardiac rhythm is restored.
4.1.2 Clinical evidence for the (in)efTectiveness of adrenaline 
Despite its widespread use, a large body of experimental evidence from animal studies suggests 
that adrenaline may have no effect, or even a detrimental effect on various measures of well­
being and survival during resuscitation (Brown et al., 1988; Klouche et al., 2003; Niemann et al., 
2005; Schwartz & Lagranha, 2006; Wenzel et al., 1999). High doses do not improve survival and 
may increase adverse effects (Ditchey et al., 1988; Hilwig et al., 2000; Hornchen et al., 1993; 
Lindner et al., 1991a; Voelckel eta!., 2000). Poor survival after resuscitation with adrenaline has 
also been seen in several clinical trials (Barton & Callaham, 1991; Behringer et al., 1998; Brown 
et al., 1992; Callaham et al., 1991; Callaham et al., 1992; Gonzalez et al., 1989; Gueugniaud et 
al., 1998; Herlitz et al., 1995; Holmberg et al., 2002; Lindner et al., 1991b; Lipman et al., 1993; 
Marwick et al., 1988; Michael et al., 1984; Olson et al., 1989; Paradis et al., 1990; Paradis et al., 
1991; Sherman et al., 1997; Woodhouse et al., 1995). Trials have been designed to answer one 
or more of the following questions:
•  Is adrenaline more effective than placebo control in cardiopulmonary resuscitation?
•  Does high dose adrenaline produce better results than the standard dose?
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•  Are subtype-specific adrenoceptor agonists superior to adrenaline?
•  Is the response to adrenaline improved when specific antagonists are given 
concurrently?
•  Do non-adrenergic vasopressors produce better results than adrenaline?
Although a large number of studies have been carried out, interpretation of the results is 
difficult because of the variety of endpoints used in studies. These have ranged from the most 
basic studies which used the restoration of spontaneous circulation as the endpoint (taking no 
account of the fate of the patient thereafter) to complex studies which have monitored survival 
over a number of months and have included measures of patients neurological function. Most 
studies have been conducted on a small scale, presumably due to limited funding and facilities. 
These studies therefore have had limited power to detect differences between treatment 
groups. Many studies have included inherent scientific weaknesses, such as not being blinded 
to the physician or not including a placebo control. Several studies that were blinded included a 
direction that adrenaline be administered to the patient if the trial drug failed. These directions 
have been included on the basis of sound ethical reasoning; however, they make it difficult to 
draw definitive conclusions.
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Numerous studies have examined the effects of high and standard doses of adrenaline. The 
current guidelines for the administration of adrenaline allow for the repeated administration of 
the drug, and this too was the case for experimental agents. Where doses of drug are cited in 
the text below, they refer to the dose given in each individual bolus rather than the total dose 
administered except where stated otherwise.
4.1.2.1 Comparison o f standard-dose adrenaline and placebo  
For ethical reasons, no blinded randomised trials of adrenaline in the resuscitation setting have 
included a placebo control group (American Heart Association, 2005). Several investigators 
have compared the outcome of groups of patients treated with adrenaline with those not 
treated with adrenaline. This comparison is inherently biased, however, because patients 
treated with adrenaline are more likely to be complicated cases that do not respond to initial 
defibrillation. This makes interpretation of the data very difficult.
A retrospective study was carried out in Sweden, examining the role of adrenaline in treating 
out-of-hospital cardiac arrest over a 12-yr period. The records of 1360 patients were examined. 
Adrenaline was given to 35% of patients and did not result in any change in the survival of 
patients to hospital discharge compared to untreated patients. However, as the authors 
conceded the trial was not randomised, and a major confounding factor was that the patients 
treated with adrenaline were generally those who presented with more complicated clinical 
conditions (Herlitz et al., 1995) Later, a larger (10,966 patients) prospective evaluation of 
adrenaline in cardiopulmonary resuscitation was carried out by the same group of researchers.
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A more clinically useful endpoint, survival to one month after cardiac arrest, was employed. 
Using multivariate analysis, the use of adrenaline was found to be independently correlated 
with poor survival, especially in patients presenting with non-shockable cardiac rhythms 
(Holmberg et al., 2002). This study was also limited by the lack of randomisation and 
differences in baseline variables between patient groups. An Australian group compared both 
high and standard-dose adrenaline with placebo in cardiac arrest. They found no difference in 
survival to hospital discharge between the groups, and the overall hospital discharge rate was 
0.9%. This trial in 339 patients probably represents the best attempt at conducting a placebo- 
controlled clinical trial of adrenaline in cardiopulmonary resuscitation to date. However, the 
results must be taken with caution, as the trial was not well randomised and nearly half the 
patients were treated with un-blinded standard-dose adrenaline (Woodhouse et al., 1995).
One study recruited 199 patients in ventricular fibrillation who had failed to respond to 1 
defibrillation attempt. The patients were randomised to receive endotracheal adrenaline or 
lidocaine to compare the effectiveness of these drugs in resuscitation. These patients were 
compared to a group of 630 historical controls, treated with only sodium bicarbonate. The 
results of this study are hard to determine, as the number of patients available for analysis was 
reduced by poor compliance with study protocol. Survival to hospital discharge was significantly 
smaller (16%) in patients treated with adrenaline than in patients treated with sodium 
bicarbonate or no drug (38%) (Olson et al., 1989).
121
Chapter 4
In conclusion, no trial has identified a benefit of adrenaline over placebo in cardiopulmonary 
resuscitation, although it should be borne in mind that the quality of the investigations carried 
out to date is rather poor.
4.1.2.1 High-dose ad ren a lin e  
The standard dose of 1 mg adrenaline was taken directly from early studies in dogs conducted 
by Redding and Pearson (Pearson & Redding, 1964a; Pearson & Redding, 1963; Pearson & 
Redding, 1964b; Ralston & Babbs, 1985). More recently, concern was raised that due to the 
difference in mass between the dogs used in the study and an adult human, the dose of 
adrenaline used in the study was too small. Additionally, it was shown that at doses above 1 
mg, a dose-dependent vasopressor relationship existed for adrenaline in human beings during 
cardiopulmonary resuscitation (Gonzalez et al., 1989). In other words, 1 mg is a sub-maximal 
vasopressor dose. In dogs, it was shown that the peripheral vasoconstrictor effects of 
adrenaline were responsible for the beneficial effects (Michael et al., 1984). Thus, numerous 
trials have been carried out to compare the effects of high-dose adrenaline (up to 10 mg) with 
standard protocol. Some of these trials are of a high standard, being both randomised and 
blinded.
In the 1990s Barton and Callaham published a series of papers investigating treatment of 
cardiac arrest with standard-dose and high-dose adrenaline. They initially carried out a small 
trial on 49 patients. Apart from its small size, the trial suffered considerable weaknesses, in that 
it was not blinded and not randomised and the data were gathered retrospectively. However, a
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trend towards a higher rate of restoration of spontaneous circulation was seen in high-dose- 
treated patients (Barton et al., 1991).
These investigators set out to determine whether high-dose adrenaline was associated with a 
higher incidence of complications than normal dose. Sixty-eight patients with non-traumatic 
cardiac arrest were recruited into the study. The study was not randomised, and physicians 
treated as they saw fit. Patients were retrospectively allocated to the high-dose or low-dose 
group, depending on whether they had received more or less than 2.8 pg kg-i m in1. 
Additionally those patients who had received a bolus of 50 pg kg-iwere included in the high- 
dose group (Callaham et al., 1991). The study was therefore somewhat flawed, as it was not 
comparing 2 distinct doses rather it was looking at a continuous scale with an arbitrary dividing 
line. The only significant difference between the 2 trials in terms of complications was a greater 
depression of serum calcium in the high-dose adrenaline group. No significant difference was 
seen in survival to hospital discharge, although 30% of patients in the standard-dose group 
survived compared to 18% of the high-dose treated patients. Although no conclusions can be 
drawn in the absence of statistical significance, the trial was probably underpowered to detect 
a survival difference and the results suggest better survival in the low-dose-treated group.
The same group of investigators went on to carry out a randomised clinical trial of high-dose 
adrenaline and standard dose adrenaline in pre-hospital cardiac arrest. The study enrolled 816 
patients. Noradrenaline was also examined as a vasopressor in this trial, and the results of this 
part of the study are discussed elsewhere. In addition to restoration of spontaneous circulation,
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additional outcome measures were included. These were survival to hospital admission, 
survival to hospital discharge, and their Cerebral Performance Category score (a measure of 
mental function and capacity) measured whilst the patients were in hospital. High-dose 
adrenaline increased the probability of achieving restoration of spontaneous circulation. In the 
high-dose group, circulation was restored in 13% of patients compared to 8% for standard-dose 
adrenaline. However, no statistically significant increase to hospital discharge was noted, 
although this trial was probably underpowered to detect any such change (Callaham et al., 
1992).
At around the same time, another group carried out a randomised trial of standard- and high- 
dose adrenaline, specifically during asystole and electromechanical dissociation. The trial 
included 68 adult patients and was blinded. Survival to hospital discharge was the primary 
endpoint. There was a trend towards a higher rate of discharge in the high-dose adrenaline 
group although this did not reach statistical significance. Blood pressure was higher at one and 
five minutes post resuscitation and the rate of initial restoration of circulation was better in 
high-dose-treated groups (57% v. 15%) and there was no difference in the incidence of adverse 
effects between groups (Lindner et al., 1991a).
Paradis1 group have long been interested in resuscitation. In one early study they examined the 
effects of coronary perfusion pressure on the restoration of spontaneous circulation. The trial 
was relatively small, recruiting 100 patients. In addition to the main focus of the study, the 
investigators also analysed some data relating to patients in the study who had been treated
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with high-dose rather than standard-dose adrenaline. No difference was seen in terms of 
achievement of restoration of spontaneous circulation and no patients in either group survived 
to hospital discharge. Results from the trial gave some indication that high coronary perfusion 
pressures were correlated with good rates of restoration of spontaneous circulation, confirming 
the data seen elsewhere in animal models. It was tentatively suggested that a coronary 
perfusion pressure of 15mmHg might be a cut-off point, below which restoration of 
spontaneous circulation was unlikely or impossible (Paradis et al., 1990). The group therefore 
went on to carry out a small clinical trial (32 patients) designed to address specifically the 
question of how high- and low-dose adrenaline affected coronary perfusion pressure during 
cardiopulmonary resuscitation. They discovered that high-dose adrenaline was more effective 
than standard dose at raising the coronary perfusion pressure above their previously defined 
critical level; and hence, they suggested that high-dose adrenaline may be more effective at 
achieving restoration of spontaneous circulation than the standard dose (Paradis et al., 1991).
The Multicenter High-Dose Epinephrine Study Group performed a large trial comparing 
standard- and high-dose adrenaline in cardiac arrest outside the hospital. 1280 patients were 
randomised to receive either 0.02 mg.kg 1 or 0.2 mg.kg1 given intravenously. The study 
included patients with any presenting rhythm and examined multiple endpoints including 
restoration of spontaneous circulation, survival to hospital admission, survival to hospital 
discharge, and neurological outcome. No difference could be found between the two groups 
with respect to any of these outcomes. The authors attributed this failure to the delay in 
reaching the patient and the extensive ischaemic damage that had already occurred (Brown et 
al., 1992).
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At one hospital, the radical alteration of resuscitation protocols allowed a comparison to be 
made. Initially no adrenaline was used in resuscitation; however, the revised guidelines 
directed physicians to use high dose adrenaline (lOmg). A retrospective analysis was then 
carried out, investigating the success of resuscitation before and after the protocol was 
changed. Immediate survival was 43% in patients who did not receive adrenaline but only 22 % 
in high-dose-treated patients. This difference was statistically significant (Marwick et al., 1988). 
The weakness of the study was that, as a retrospective analysis, it could not be randomised; 
however, the study focused on patients presenting with ventricular fibrillation after failure to 
respond to initial defibrillation, and was thus more focussed than other studies which recruited 
patients with numerous presenting rhythms and causes of cardiac arrest. Of 210 patients, 77 
received high-dose adrenaline and the rest received no drug. Multiple logistic regression 
analysis showed adrenaline to be an independent predictor of poor outcome but no significant 
difference was seen in survival to hospital discharge. The authors suggested that this might be 
due to the very small number of patients who survived to be discharged. One study attempted 
to determine whether high-dose adrenaline could exert any beneficial effects after the failure 
of standard therapy (Sherman et al., 1997). Although small (140 patients), this study had the 
advantage of being blinded and randomised. No benefit of high-dose adrenaline was seen in 
terms of any of the outcome measures. It should be remembered that the ischaemic damage to 
the heart and other organs are likely to be very high after initial treatments have been tried and 
have failed. It would be surprising if any intervention could be of benefit at this stage.
The European Epinephrine Study Group conducted a large multicentre randomised trial (3327 
patients), comparing the use of high-dose (5 mg) and standard-dose (1 mg) adrenaline in
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cardiac arrest outside the hospital (Gueugniaud et al., 1998). The investigators found a small 
increase in the likelihood of restoring circulation when high-dose adrenaline was used (40.4% 
vs. 36.4 %). Analysis of subgroups revealed that high dose adrenaline improved the chances of 
restoring circulation in patients with asystole but not when ventricular fibrillation was the 
presenting rhythm. No difference was seen between the groups in terms of survival to hospital 
discharge or in terms of neurological outcome. One group carried out a randomised, blinded 
trial, comparing standard (1 mg) and high (10 mg) doses of adrenaline in asystole. The 
investigators did not find any difference in survival between the groups in terms of survival 
although the study was extremely small, recruiting only 40 patients and was thus vastly 
underpowered to detect any such changes (Lipman et al., 1993).
A retrospective study of 178 patients in ventricular fibrillation showed that high cumulative 
doses of adrenaline given during resuscitation were correlated with poor neurological outcome 
as assessed by the cerebral performance score (Behringer et al., 1998).
In conclusion, it seems that high-dose adrenaline is more efficient at achieving a restoration of 
spontaneous circulation than the standard dose, but no trial has shown an increase in survival 
to hospital discharge or any improvement in long-term neurological function in survivors. On 
this basis, the use of high-dose adrenaline may be unwarranted; the benefit to the patient of 
achieving restoration of spontaneous circulation but dying soon after certainly seems 
negligible. One interpretation of this data is that the increased benefit from the additional
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vasopressor effect of high-dose adrenaline is counterbalanced by increased cardiac adverse 
effects.
4.1.2.2 O ther adrenerg ic  agents  
Noradrenaline has been compared to adrenaline in one randomised clinical trial of out-of­
hospital resuscitation. No significant difference was seen between standard-dose adrenaline 
and noradrenaline (11 mg). However, there was a trend towards a better initial achievement of 
restoration of spontaneous circulation but worse neurological recovery in patients treated with 
noradrenaline (Callaham etal., 1992).
One randomised study including 102 patients set out to compare adrenaline with the ai- 
adrenoceptor selective agonist, methoxamine, in resuscitation from ventricular fibrillation 
(Olson et al., 1989). The study was carefully designed and equipressor doses of each drug were 
given. Methoxamine was less effective at achieving restoration of spontaneous circulation than 
was adrenaline. However this study was very interesting, since the dose of adrenaline given was 
0.5 mg. This is half the clinically recommended dose. However, 19.6% of patients in the 
adrenaline group were discharged alive from hospital, a reasonably high figure by the standards 
of resuscitation trials. This result should be followed up with a larger comparison of standard- 
and low-dose adrenaline and ideally a placebo group to discover, firstly, whether or not 
adrenaline is beneficial in resuscitation, and, if this is the case, to enable the optimal dose of 
adrenaline to be found.
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4.1.2 .3  Non-adrenergic vasopressors 
After initial successes in animal models and the observation that vasopressin can increase 
coronary perfusion pressure during human cardiopulmonary resuscitation (Morris et al., 1997), 
several studies of resuscitation using vasopressin in humans have been carried out despite the 
fact that this drug is known to be a coronary vasoconstrictor (Martinez et al., 2003). A small, 
early study (8 patients), suggested that vasopressin may be more effective than adrenaline at 
achieving restoration of spontaneous circulation from cardiac arrest (Lindner et al., 1996b). 
These researchers went on to echo their findings in a larger study (40 patients; (Lindner et al., 
1997)) which recruited patients in ventricular fibrillation and showed a benefit of vasopressin 
over adrenaline in initially restoring circulation. Stiell carried out a randomised, triple blind, 
controlled trial, comparing adrenaline (1 mg), and vasopressin (40 U) in cardiac arrests which 
occurred in the hospital. Two hundred patients were recruited into the study, which found no 
difference between the patient groups in terms of 1-hr survival or survival to hospital discharge. 
The authors concluded that vasopressin should not be recommended for cardiopulmonary 
resuscitation (Stiell et al., 2001). In the biggest comparison of vasopressin and adrenaline 
carried out so far, 1219 patients who had suffered cardiac arrest outside the hospital were 
randomised to receive either adrenaline (1 mg) or vasopressin (40 U). One of the endpoints 
used was survival to hospital admission. Although no overall difference was seen between the 
groups, the large number of patients recruited into the study enabled analysis of subgroups to 
be carried out. It was found that when the presenting rhythm was asystole, patients treated 
with vasopressin were more likely to survive to hospital discharge than adrenaline-treated 
patients (Wenzel et al., 2004).
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4.1.2.4  Vasopressor com binations
One study including 298 patients found that administering adrenaline together with 
vasopressin resulted in a greater rate of success than when adrenaline was used alone. The 
authors suggested that the synergistic vasopressor effects of the 2 drugs allowed smaller than 
usual doses of each to be given, thus reducing adverse effects. In fact, in this trial the same 
total dose of adrenaline (3.8 mg) was given to both groups of patients (Guyette et al., 2004).
4.1.2 .5  Conclusions fro m  clin ical tr ia ls
There are no studies that show adrenaline to be better than placebo in terms of survival. Higher 
than standard adrenaline doses do not lead to better results and may in fact lead to worse 
outcomes.
4.1.3 Possible reasons for the ineffectiveness of adrenaline 
Adrenaline is a non-selective a and adrenoceptor agonist, released by the adrenal medulla in 
response to stress. The cardiovascular effects of adrenaline are complex, due to the fact that 
several subtypes of adrenoceptors are present in the heart and in the vasculature and 
physiological responses are usually the result of a combination of effects.
In ventricular myocardium and the sino-atrial node, adrenaline acts predominantly on pr  
adrenoceptors to mediate positive chronotropic and inotropic effects. This leads to an increase 
in oxygen demand in the myocardium. In the ischaemic heart, activation of 0-adrenoceptors
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can therefore lead to a worsening of ischaemia. During ventricular fibrillation, adrenaline also 
increases the energy demands of the myocardium (Monroe et al., 1960; Monroe et al., 1961).
The stimulation of ai-adrenoceptors may also be undesirable in resuscitation because they are 
also found in the heart, where they mediate a positive inotropic effect, leading to an increased 
oxygen demand in the myocardium. This has been demonstrated both in the rat (Broadley et 
al., 1999; Williamson & Broadley, 1989) and in human subjects (Landzberg et al., 1991). 
Although it should be noted, that when a non-selective adrenoceptor agonist such as 
adrenaline is given, the predominant effect on inotropy is likely to be through 3-adrenoceptors. 
Despite the apparent contraindications to a i stimulation, some investigators have studied the 
possibility of using methoxamine, an ai-adrenoceptor agonist in the resuscitation setting. Two 
studies compared the use of this agent with adrenaline. In a canine model of resuscitation, 
methoxamine was found to be superior to adrenaline (Roberts et al., 1990), however in a 
clinical study in man adrenaline was superior (Olson et al., 1989).
The cardiodynamics of adrenaline are complicated because it can cause vasoconstriction (a- 
adrenoceptors) and vasodilatation (3-adrenoceptors). However high-doses of adrenaline can 
result in coronary vasoconstriction (Karch, 1989). This presents a major limitation to the use of 
adrenaline in resuscitation.
Adrenaline can be oxidised In vivo by ceruloplasmin, a plasma a-globulin, by 
polymorphonucleocytes and by cytochrome oxidase (Behonick et al., 2001). Oxidation products 
of adrenaline, of which adrenochrome is the main example (Green & Richter, 1937) have been
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demonstrated to inhibit catechol-o-methyl transferase, an enzyme responsible for the 
inactivation of catecholamines (Abbs et al., 1967). This has the potential to further increase the 
concentrations of active catecholamines.
The oxidation products of catecholamines have been known for some time to cause damage to 
myocardial tissue (Dhalla et al., 1978; Yates & Dhalla, 1975) although it is not known if they are 
more or less harmful than adrenaline itself (Behonick et al., 2001; Bindoli et al., 1992). It has 
been demonstrated that oxidation of catecholamines is partially responsible for the increased 
levels of reactive oxygen species observed during ischaemia. High levels of oxygen radicals are 
partly responsible for post-ischaemic contractile dysfunction because they cause peroxidation 
of membrane phospholipids, disrupting the structure of the membrane and increasing its 
permeability. This leads to cell death by necrotic mechanisms (Lazzarino et al., 1994; Moens et 
al., 2005).
The aim of this study was therefore to investigate the effects of exogenous adrenaline on 
stunning (Chapter 4, Part 1) and infarct size (Chapter 4, Part 2) in order to explore the 
possibility that the poor outcome of cardiopulmonary resuscitation when adrenaline is used is 
due to cardiac actions of adrenaline. Additionally the effects of endogenous catecholamines 
were examined by the use of selective and non-selective antagonists in the stunning model 
(Chapter 4 Part 1). Experiments investigating the effects of adrenoceptor antagonists on infarct 
size are described later in the thesis (Chapter 5 ).
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Chapter 4 Part 1: How does exposure to adrenaline and
adrenoceptor antagonists at reperfusion affect stunning in isolated 
rat atria and ventricles ?
4.2 Hypotheses
•  Exogenously applied adrenaline will have a detrimental effect upon contractile recovery 
when applied at reperfusion.
•  3-adrenoceptor antagonists applied at reperfusion will improve contractile recovery 
after ischaemia by preventing the pharmacological actions of endogenous 
catecholamines.
4.3 Methods
Male Sprague Dawley rats were purchased from B and K universal, (Grimston UK) and weighed 
300-450g at the time of killing. Isolated left atrial and right ventricular preparations were 
prepared as described above (Section 2.4). Initial diastolic tension was lg  for atrial tissues and 
1.5g for ventricular tissues. Tissues were allowed to stabilise for 20 minutes before induction of 
simulated ischaemia. Reoxygenation and return to standard KHB occurred after 30 minutes. 
Preparations were left to recover for one hour during which time the KHB was replaced every 
fifteen minutes. Preparations were exposed to a range of P-adrenoceptor ligands with different 
actions and selectivities (Table 4-1). The drugs were administered 10 minutes prior to
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reperfusion. At reperfusion, the drugs were replaced in the organ bath and remained there for 
fifteen minutes.
Table 4-1 A summary of the pharmacological actions of the agents used in this study and the concentrations at which they 
were used
Drug Concentration Pharmacological action
Adrenaline 10 pM Non-selective adrenoceptor agonist
Timolol lp M Non-selective 3-adrenoceptor antagonist
CGP-20712A lOnM Selective 3i-adrenoceptor antagonist
ICI-118,551 lOnM Selective 32-adrenoceptor antagonist
Timolol was used as a non-selective adrenoceptor antagonist in these experiments and 
hereafter in place of propranolol. This was because of the suggestion by a colleague that the 
'membrane stabilising' effects of propranolol might confound the results. The study of a list of 
the pharmacological properties of numerous 3-adrenoceptor antagonists (Broadley, 1996) 
revealed that timolol i) is a non-selective 3-adrenoceptor antagonist ii) does not display 
membrane stabilising effects iii) does not display partial agonist effects (intrinsic 
sympathomimetic activity). This agent was thus chosen as the non-selective agent to be used in 
this study and in future experiments.
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Figure 4-1 Experimental protocols used in this series of experiments
4.3.1 Experimental protocols 
Controls received no treatment other than the ischaemic insult. The effects of administering 
each of the adrenoceptor ligands at reperfusion were investigated (Table 4-1). Adrenaline was 
administered to mimic the treatment of cardiac arrest, and selective and non-selective 
adrenoceptor antagonists were used to investigate the effects of endogenous catecholamines. 
After 20 minutes of simulated ischaemia, a dose of drug was added. The same dose was 
replaced at the time of reperfusion. The drug was removed from the organ bath by the washing 
of the tissue at the standard 15 minute intervals according to the protocol described above.
J
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Ischaemia
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135
4.3.2 Adrenaline at reperfusion
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The non-selective adrenoceptor agonist, adrenaline (lOpM) was added to the bath for the final 
10 minutes of ischaemia and the first 15 minutes of reperfusion
4.3.3 Adrenoceptor antagonists at reperfusion
At the same time point described above, the non-selective (3-adrenoceptor antagonist timolol, 
lp M ; the selective (32-adrenoceptor antagonist ICI-118551, lOnM and the selective 
adrenoceptor antagonist CGP-20712A, lOnM were added to the bath
4.3.4 Adrenaline at reperfusion in the presence of timolol
The effects of administering adrenaline in the presence of the non-selective adrenoceptor 
antagonist timolol were examined. Timolol was administered to the tissues at the same time as 
the adrenaline (10 minutes prior to reperfusion) and was washed out at the same time.
4.3.5 Analysis of data
Prism version 4.02 for windows (GraphPad Software, Inc) was used for production of graphs 
and statistical analyses. Tension was monitored continuously, enabling calculation of diastolic 
(baseline) and developed tension. Cardiac function was assessed at fifteen and sixty minutes 
post reoxygenation. Developed tension at these time points was calculated as a percentage of 
developed tension at the end of the stabilization period for each preparation. Groups of data 
were compared by one-way ANOVA followed by Student-Newman-Keuls post hoc test.
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4.4 Results
4.4.1 Baseline functional data  
The baseline developed tension for each experimental group in this study is shown (Table 4-2). 
There were no statistically significant differences between groups.
Table 4 -2 .Baseline developed tension for th e  exp erim en ta l groups used in this study.
Atria Ventricle
n developed tension n developed tension
Control 5 0.43±0.07 6 0.84±0.17
Adrenaline 5 0.34 ±0.08 4 0.62±0.13
Timolol 6 0.42±0.04 6 0.76±0.14
Adrenaline + timolol 6 0.46±0.08 5 0.78±0.13
ICI-118,551 3 0.44±0.08 4 0.91±0.11
CGP 5 0.55±0.04 4 1.05±0.06
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4.4.2 C ontractile  p ro file  o f contro l tissues 
The contractile profile of a control atrial and ventricular preparations were consistent with data 
seen previously (Chapter 3 in this thesis).
Measurements of contracture are not reported here, as in the previous chapter, as this study 
involved only interventions at reperfusion which therefore cannot alter ischaemic contracture. 
Developed tension increased throughout the recovery period although did not reach pre- 
ischaemic levels. In ventricular control studies, after 30 minutes of ischaemia, the mean 
developed tension was 5.7 ± 1.3 % (n=6). Reperfusion caused mean developed tension to rise to 
a plateau with a maximum of 86.2 ± 6.9 % after 60 minutes (Figure 4-3 B). In atrial control 
studies, after 30 minutes of ischaemia, the mean developed tension was 9.9 ± 1.11 % (n=5). 
Reperfusion caused mean developed tension to rise constantly with a maximum of 47.8 ± 4.5 
%after 60 minutes of reperfusion (Figure 4-3 A).
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Figure 4-2 Developed tension after 15 minutes reoxygenation in A) atria and B) ventricular strips. Developed tension is 
expressed as a percentage of the developed tension achieved at the end of the stabilisation period. *  indicates p<0.05.
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Figure 4-3 Developed tension after 60 minutes reoxygenation in A) atria and B) ventricular strips. Developed tension is 
expressed as a percentage of the developed tension achieved at the  end of the stabilisation period. * indicates p<0.05.
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4.4.3  Effects of adrenaline administration at reperfusion
Adrenaline caused a positive inotropic effect during early reperfusion in both atria and 
ventricles. This was still apparent as a non-statistically-significant trend in ventricles, 15 minutes 
after reoxygenation (developed tension was 95.3 1 9.0 % of baseline) but not atria (developed 
tension was 21.2 ± 2.9 % of baseline) (Figure 4-2 B). CorOPared to controls, adrenaline did not 
significantly alter the recovery of stunning achieved at 60 minutes after reoxygenation in either 
tissue (Figure 4-3).
4 .4 .4  Effects of timolol administered at reperfusion
Timolol did not significantly affect the recovery of stunning at either time-point in atria or 
ventricles. However, there was a trend towards better recovery than controls in both time- 
points in atria. At 15 minutes after reoxygenation, timolol treated atria had recovered to 42.5 ±
9.1 % of baseline (Figure 4-2 A), and by 60 minutes, developed tension had reached 60.5 ± 9.0 
% of baseline (Figure 4-3 A).
ANOVA did reveal a significant difference between timolol treated atria and tissues treated 
with both adrenaline and timolol at 15 minutes after reoxygenation. The latter group had 
recovered significantly (p<0.05) less well. Developed tension in tissues treated with both 
adrenaline and timolol was 15.7 ± 4.5 % of baseline (Figure 4-2 A).
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At 60 minutes after reperfusion, a significant (p<0.05) difference was observed between the 
developed tension in atria treated with timolol (60.5 ± 9.0 % of baseline) and tissues treated 
with adrenaline (29.3 ± 3.9% of baseline) (Figure 4-3 A).
4 .4 .5  Effects o f ad ren a lin e  a d m in is te red  a t reperfusion in the presence o f 
tim olo l
Administration of adrenaline in the presence of timolol at reoxygenation had no effect upon 
stunning in either tissue at either 15 or 60 minutes after reoxygenation when compared to 
controls (Figure 4-2, Figure 4-3).
4 .4 .6  Effects o f p i-ad ren o cep to r antagonist ad m in is tered  a t reperfusion  
Administration of the f3i-adrenoceptor antagonist, CGP-20712A, at reoxygenation had no effect 
upon stunning in either tissue at either 15 or 60 minutes after reoxygenation when compared 
to controls. Additionally, the CGP-20712A treated tissues were not significantly different from 
any other experimental group (Figure 4-2, Figure 4-3).
4 .4 .7  Effects o f p2-ad ren o cep to r antagonist adm in is tered  a t reperfusion  
Administration of the (32-adrenoceptor antagonist, ICI-118,551, at reoxygenation had no effect 
upon stunning in either tissue at either 15 or 60 minutes after reoxygenation when compared 
to controls. Additionally, the ICI-118,551 treated tissues were not significantly different from 
any other experimental group (Figure 4-2, Figure 4-3).
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4.5 Discussion
Whilst none of the experimental groups in this study demonstrated a statistically significant 
change in recovery of contractile recovery when compared to control groups, there were some 
interesting differences between groups which may give some indication as to the effect of (3- 
adrenoceptor activation on stunning.
The most important finding from these experiments was that endogenous and exogenous 
adrenaline may mediate a detrimental effect at reperfusion as demonstrated by the fact that 
atria treated with timolol recovered to a greater extent than those treated with adrenaline at 
60 minutes after reoxygenation. However, this improvement was not seen with either the 
selective (3i antagonist, CGP-20712A or the selective (^-antagonist ICI-118,551. It is thus not 
possible to determine which (3-adrenoceptor subtype is responsible for this effect. It is possible 
that activation of both subtypes is necessary for the effect, or that the concentrations of these 
agents used were insufficient to overcome the effects mediated by endogenous 
catecholamines. Higher concentrations could not be used, however or selectivity of the drugs 
would have been lost.
Any effect of antagonist given at this time-point is quite remarkable because there was 
probably insufficient time for the antagonist to reach equilibrium at its receptor. However this 
timing was chosen to ensure that we were studying effects of p-adrenoceptors at reperfusion 
and not during ischaemia. Additionally, in some preliminary experiments whereby timolol was 
present in the KHB throughout the entire experiment, the baseline developed tensions were
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unsurprisingly significantly lower than in controls. It was not known how this effect may affect 
the recovery of tissues after ischaemia and so this approach was avoided.
These results also demonstrated a detrimental effect of adrenaline administration upon atrial 
stunning at 15 minutes after reoxygenation. Tissues treated with adrenaline alone had 
recovered less well than those treated with adrenaline and timolol.
Because the myocardium in this model was subjected neither to circulating catecholamines nor 
sympathetic nerve stimulation, the effects of endogenous catecholamines are likely to have 
been underestimated. This is a very important limitation in this model. In atria at 60 minutes 
after reperfusion, there was a trend towards improved recovery of timolol treated tissues when 
compared to controls. It is interesting to speculate whether this trend would have reached 
statistical significance, had the endogenous catecholamine concentrations been larger.
Although high, the concentration of adrenaline used in these experiments is clinically relevant. 
Clinical studies in which plasma concentrations of catecholamines were measured after 
successful resuscitation in patients with out-of-hospital cardiac arrest found concentrations as 
high as 2.17|iM  (Prengel et a!., 1992) . In the experiments reported here, a slightly higher 
concentration (lOpM) was used in order to account for the fact that the adrenaline had to 
diffuse from the KHB into the tissue.
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The strength and weaknesses of this model have been previously discussed (Chapter 3). 
However it should be noted that as ^-adrenoceptor ligands were administered at reperfusion in 
this study, the fact that this model excludes any coronary or peripheral vascular effects of drugs 
applied to the preparation is even more relevant.
No intervention had any effect on stunning in ventricles at 60 minutes after reoxygenation. 
However recovery was very good in controls and all experimental groups had a recovery 
averaging above 80 %. It is probably very difficult to show any improvement above this level. 
The level of recovery seen in these experiments was higher than was observed in similar 
experiments carried out in the previous chapter (18 months previously). Cardiff University had 
changed its supplier of rats during this time period, although this is unlikely to account for the 
change. The difference may however be due to the equilibration time prior to experimentation. 
In the early experiments described in the previous chapter, preparations were allowed to 
equilibrate for 60 minutes before use, however it was noted that in most cases, a stable level of 
contraction had been achieved after 20 minutes. Conscious of the fact that such preparations 
deteriorate with time and that cell death occurs continuously as demonstrated in Chapter 3, 
the decision was made to reduce the equilibration time for these later experiments.
Because no intervention significantly altered post-ischemic recovery when compared to 
controls, the possibility remains that this model does not allow for protective interventions at 
reperfusion. In a similar model to that used in this study, it was demonstrated that the 
administration at reperfusion of IB-MECA, a selective agonist of the adenosine A3 receptor,
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improved functional recovery in guinea-pig paced papillary muscles and left atria (Gardner et 
al., 2004). However, this study was carried out in a different species (guinea-pig) and the tissues 
were challenged only with hypoxia in normal Krebs, whereas in this study an attempt was made 
to simulate ischaemia by additionally using glucose-free KHB.
It is also possible that a higher number of experimental replicates would be required to turn 
trends into statistically significant differences. However the number of replicates used in this 
study was comparable to that used in Chapter 3 where differences were seen. Thus it was 
decided to devote further time and resources to the studies described in later chapters.
It is important to understand the effects of adrenoceptor activation upon myocardial stunning 
because of the high concentrations of catecholamines which the heart is exposed to during 
ischaemia and reperfusion. During myocardial ischaemia the non ischaemic region of 
myocardium will be exposed to high levels of catecholamines released from the adrenal 
medulla in response to pain and stress. Although the ischaemic region is not exposed to 
circulating catecholamines until reperfusion, the local concentrations are nonetheless high due 
to local release of catecholamines from sympathetic nerve endings. Noradrenaline is released 
during ischaemia as a result of the reverse function of the uptakei transporter (Schoemig et al., 
1991). Circulating adrenaline is taken up into sympathetic nerve endings and can be released 
along with noradrenaline in response to nerve stimulation (Esler et al., 1991a; Esler et al., 
1991b; Esler et al., 1995; Johansson et al., 1997; Lameris et al., 2000; Lameris et al., 2002; 
Majewski et al., 1981; Peronnet et al., 1993). Additionally, adrenaline can be synthesised and
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stored in the heart and released from intrinsic cardiac adrenergic cells in response to ischaemia 
(Kuroko et al., 2007). Indeed, increased myocardial interstitial concentrations of adrenaline, 
noradrenaline and dopamine are all seen after ligation of the left anterior descending coronary 
artery in pigs. Adrenaline concentrations do not rise in non-ischaemic regions suggesting a 
myocardial rather than a circulating adrenaline source (Lameris et al., 2000).
4.5.1 Clinical relevance  
These results do not demonstrate any significant detrimental effect of adrenaline upon post- 
ischaemic stunning. However there is some limited evidence that activation of 3-adrenoceptor 
at reperfusion might worsen stunning. However based on these results, the poor clinical 
outcome of patients who have been treated with adrenaline during cardiac arrest cannot be 
attributed to an effect of adrenaline on stunning.
4.6 Conclusion
•  Stunning was not significantly affected by application of exogenous adrenaline at 
reoxygenation.
•  Endogenous catecholamines do not play an important role in causing stunning because 
stunning was neither affected by selective nor non-selective adrenoceptor antagonists.
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Chapter 4 Part 2: What effect does exogenous adrenaline have 
upon infarct size after regional ischaemia in the rat Langendorff 
heart?
4.7 Hypotheses
•  Adrenaline, administered at reperfusion, will lead to an increased infarct size compared 
to control hearts.
•  Adrenaline, administered at reperfusion, will lead to worsened post-ischaemic 
contractile recovery.
4.8 Methods
Rats were obtained from B&K international and weighed 250-350g at the time of killing. 
Langendorff heart preparations were set up as previously described (Chapter 2). After 20 
minutes stabilisation, hearts were exposed to 35 minutes regional ischaemia achieved by 
ligation of the left main coronary artery after which the hearts were reperfused for two hours 
before undergoing staining to determine infarct size. Control hearts were otherwise untreated. 
Treatment groups were exposed to a range of concentrations of adrenaline (In M , lOOnM, 
lOpM) for the final 10 minutes of ischaemia and the first ten minutes of reperfusion (Figure 
4-4).
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Figure 4-4 Experimental Protocols used in this study- Time is shown along the abscissa. Yellow areas denote normal 
perfusion and red areas indicate ischaemia.
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4.9 Results
4.9.1 Baseline data
Table 4-3 Baseline cardiodynamics. There were no statistically significant differences between the groups.
Treatment n Baseline RPP 
(mmHg.min'VlOOO)
Baseline CF 
(m l.m in1)
AAR(KTotal)
Control 6 32.7±5 13.611.6 24.213.5
Adrenaline 1 nM 6 23.2±2 14.411.3 31.413.4
Adrenaline 100 nM 4 27.0±2 12.814.3 31.913.6
Adrenaline 10 pm 5 23.8+4 11.410.9 27.414.7
There were no statistically significant differences between experimental groups in terms of 
baseline coronary flow or rate-pressure product. Evans blue staining revealed no significant 
difference in the percentage of the heart made ischaemic by the coronary ligation (Table 4-3).
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4.9.2 Infarct size
None of the concentrations of adrenaline had any statistically significant effect on infarct size 
when added to the tissues at reperfusion (Figure 4-5).
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Figure 4-5: Infarct sizes in control hearts and hearts exposed to adrenaline at reperfusion.
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4.9.3 Functional data 
None of the treatment groups had any significant effect on the timecourse of coronary flow 
throughout the experiment (Figure 4-6).
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Figure 4-6 The timecourse of coronary flow (expressed as a percentage of the baseline value) throughout the experiment in 
each of the experimental groups. Error bars have been removed from all groups except for controls to improve clarity.
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None of the treatment groups had any significant effect on the timecourse of rate pressure 
product (Figure 4-7) or left ventricular developed pressure (Figure 4-8) throughout the 
experiment.
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Figure 4-7 The timecourse of rate pressure product (expressed as a percentage of the baseline value) throughout the 
experiment. Error bars have been removed from all groups except for controls to improve clarity.
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Figure 4-8 The timecourse of left ventricular developed pressure (expressed as a percentage of the baseline value) 
throughout the experiment. Error bars have been removed from all groups except for controls to improve clarity.
The administration of adrenaline at reperfusion caused a concentration-dependent increase in 
diastolic tension immediately after reperfusion (Figure 4-9). In all tissues, the highest diastolic 
tension occurred 10 minutes after reperfusion (45 minutes after the onset of ischaemia). This 
difference reached statistical significance at the highest concentration (10 pm) of adrenaline 
(Figure 4-10). At this concentration of adrenaline, the diastolic tension increased to 28.9±7.8 
mmHg above baseline, compared to 3.0±4.1 in controls.
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Figure 4-9 The change in diastolic tension throughout the experiment from baseline values.
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Figure 4-10 The maximum diastolic tension after reperfusion in each of the experimental groups. In each group, the largest 
diastolic tension occurred at 10 minutes post reperfusion. Units are mmHg change from baseline values.
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4.10 Discussion
It has been demonstrated that, at the concentrations used in this study, adrenaline does not 
affect infarct size. Furthermore, recovery of rate pressure product and coronary flow were 
unaffected by adrenaline. This was contrary to expectations. The very poor survival rate after 
cardiac arrest with adrenaline treatment led to the hypothesis that cardiac effects of adrenaline 
were responsible for outweighing the benefit elicited by peripheral vasoconstriction. These 
results do not support this hypothesis.
Adrenaline did not significantly affect the recovery of rate-pressure-product. There was an 
expected dose-dependent trend towards increasing rate pressure product in early reperfusion, 
due to the positive chronotropic and inotropic effects of adrenaline. However, due to the high 
degree of variability inherent in these measurements, this trend did not reach statistical 
significance.
It is interesting that adrenaline administered at reperfusion worsened post-ischaemic 
contracture (hypercontracture). It has been suggested that the development of reperfusion 
contracture and post-ischaemic necrosis are causally related (Pantos et al., 2006). Reperfusion 
contracture is responsible for contraction band necrosis (Fujiwara et al., 1989) and in severe 
cases the stone heart' phenomenon (Pantos et al., 2006). However, the increased contracture 
in adrenaline-treated hearts did not result in increased cell death in this model over two hours 
of reperfusion, neither was it associated with a worsening of contractile recovery.
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This study used a regional no-flow model of ischaemia to replicate the cardiac conditions during 
cardiac arrest. However, when cardiac arrest is accompanied by cardiopulmonary resuscitation, 
it could be argued that a global low-flow model of ischaemia would better replicate the 
pathophysiological conditions. The regional ischaemia model was however chosen for this 
study for a number of reasons: i) Cardiac arrest most commonly occurs secondary to 
myocardial ischaemia (Engdahl et al., 2003; Fischer et al., 1997; Grubb et al., 1995; Kuisma & 
Alaspaa, 1997; Weston et al., 1997) and thus there are probably regions of low-flow and 
regions of zero-flow in the arrested heart undergoing cardiopulmonary resuscitation, ii) When 
myocardial ischaemia is the cause of cardiac arrest, resuscitation guidelines allow thrombolysis 
as part of the resuscitation therapy (International Liaison Committee on Resuscitation, 2005), 
thus reperfusion after regional no-flow ischaemia occurs, iii) Infarct size (the most important 
factor in determining survival) cannot be reliably visualised after global ischaemia. Other 
investigators have however used low-flow models of ischaemia to monitor myocardial function 
and at the same time have collected coronary perfusate and measured cardiac enzyme release 
as a surrogate marker of cell death. It would be interesting to test the effects of adrenaline at 
reperfusion in that model and compare the results with those presented here, iv) Later 
chapters investigate the effects of endogenous adrenaline upon infarct size in regional 
ischaemia and reperfusion, by the use of 3-adrenoceptor antagonists. Use of the same model in 
each set of experiments aids comparisons.
The failure to demonstrate a change in infarct size by any of the treatment groups is not a 
feature of the model used. The same experimental techniques were utilised in Chapters 5 and 6 
where both beneficial and detrimental effects on infarct size are provoked by treatments.
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One possibility which has not been investigated in this study is that adrenaline mediates 
detrimental cardiac effects in the resuscitation setting by increasing the frequency of lethal 
reperfusion arrhythmias. High concentrations of adrenaline are known to be highly 
arrhythmogenic (Tisdale et al., 1995). However, perhaps the most likely explanation for the 
ineffectiveness of adrenaline is that resuscitation after several minutes cardiac arrest in 
patients who are likely to have underlying pathologies and are in most cases elderly is very 
difficult. Thus it is almost impossible to show improved recovery with any treatment. However, 
if the rationale for the use of adrenaline in cardiac arrest is that it causes peripheral 
vasoconstriction, it should be compared in well-controlled clinical trials with more selective 
vasopressor agents.
4 .10.1  Clinical im plications  
Adrenaline did not have any effect on the development of infarct size at any of the 
concentrations used. The poor clinical outcome of patients in cardiac arrest treated with 
adrenaline is probably not due to an effect of adrenaline on infarct size. This field needs a great 
deal more experimental and clinical studies to determine why adrenaline is ineffective at 
resuscitation, and whether any alternative compound is more effective.
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4.11 Conclusions
Adrenaline, applied at reperfusion, increases the magnitude of reperfusion contracture 
in a dose-dependent manner.
Adrenaline, at the concentrations used in this study, has no effect on infarct size when 
applied at reperfusion.
The effects of adrenaline when administered in the clinic during resuscitation are 
probably a result of the overall haemodynamic actions of this drug
Chapter 5
Chapter 5 Is the activation of p-adrenoceptors necessary for 
postconditioning after regional ischaemia in the rat 
Langendorff heart?
5.1 Introduction
Ischaemic preconditioning and postconditioning act through similar mechanisms to activate 
RISK pathways and to prevent MPTP opening at reperfusion (Hausenloy et al., 2007b). See 
Section 1.3 for further details. Ischaemia can cause the release of the catecholamines 
noradrenaline (Schoemig et al., 1991) and adrenaline (Kuroko et al., 2007) in the myocardium 
from sympathetic nerve endings and intrinsic cardiac adrenergic cells . These can activate 0- 
adrenoceptors on the cardiomyocytes and therefore ischaemic catecholamine release has been 
proposed as a mechanism by which ischaemic preconditioning exerts protection. The data 
regarding this hypothesis are conflicting (See Section 1.5) however in Chapter 3, it was 
demonstrated that activation of 3-adrenoceptors is required for the reduction in stunning 
caused by ischaemic preconditioning in isolated paced atria and ventricles. Others have shown 
that preconditioning-induced reduction of infarct size can be mimicked by application of 3- 
adrenoceptor agonists, (Lange et al., 2006; Lochner et al., 1999; Marais et al., 2001; Moolman 
et al., 2006b; Moolman et al., 2006c; Nasa et al., 1997; Robinet et al., 2005; Tong et al., 2005; 
Yabe et al., 1998; Yates et al., 2003) suggesting that 3-adrenoceptor agonists can activate RISK 
pathways. Recently, some direct evidence that 3-adrenoceptor can activate PI3K (Yano et al., 
2007). and Erk 1/2 (Ciccarelli et al., 2007; Galandrin et al., 2006; Tutor et al., 2007) has been 
presented (See Section 1.5).
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Because 3-adrenoceptor activation can initiate signalling via kinases involved in RISK pathways, 
agonists of these receptors have the potential to mimic postconditioning when applied in the 
early minutes of reperfusion. It has been proposed that postconditioning acts by mechanically 
delaying the washout of adenosine from the ischaemic region, allowing it to activate protective 
signalling pathways. It is possible that the same could be true of catecholamines which also 
accumulate in ischaemic regions and are presumably washed out soon after reperfusion.
To date, there have been no reported investigations into the possibility that ischaemic 
postconditioning exerts its protective effects by this mechanism. If this is the case, it would be 
expected that the protection of postconditioning could be attenuated by a 3-adrenoceptor 
antagonist. It may also be possible to measure released catecholamines in coronary perfusate 
collected from isolated hearts during the postconditioning phase.
Studies have demonstrated that 3i-adrenoceptor antagonists applied at reperfusion lead to 
infarct size reduction (Feuerstein et al., 1998; Gao et al., 2000), suggesting a detrimental role 
for activation of these receptors by endogenous catecholamines at reperfusion. It is therefore 
unlikely that 3i-adrenoceptors are involved in the protection of postconditioning. However, 
signalling downstream of 32-adrenoceptors and 33-adrenoceptors has the potential to activate 
RISK pathways (See Section 1.5.3) and therefore to mimic postconditioning
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5.2 Hypotheses
•  Protection afforded by postconditioning will be abrogated by a non-selective 0- 
adrenoceptor antagonist.
•  Postconditioning is mediated by the endogenously released catecholamines 
noradrenaline and adrenaline.
•  Protection afforded by postconditioning will be blocked by $2 or p3 adrenoceptor 
antagonists
•  Antagonists of pi adrenoceptors at reperfusion will confer cardioprotection.
5.3 Methods
5.3.1 Langendorff protocols 
Male Sprague-Dawley Rats 280-360g were obtained from B&K international (Grimston, UK). 
Langendorff perfused hearts were prepared as described previously (Chapter 2). Hearts which 
fulfilled inclusion criteria were randomised to one of ten experimental groups. Control hearts 
were exposed to 35 minutes ischaemia and 120 minutes reperfusion. At the end of the 35 
minute ischaemic episode, postconditioned tissues were reperfused for 30 seconds, after which 
the coronary artery was re-occluded for 30 seconds. This cycle of reperfusion /  re-occlusion was 
repeated twice more (Figure 5-1). Hearts were also exposed to postconditioning in the
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presence of selective and non-selective adrenoceptor antagonists (Table 5-1) and to each of 
these antagonists alone (without postconditioning). All drugs were applied for the final ten 
minutes of ischaemia and the first ten minutes of reperfusion. Studies of cardioprotection have 
consistently cited early reperfusion as the crucial target of protection (Piper et al., 2004). Thus, 
it was decided to apply the drug for the first 10 minutes of reperfusion. Although the lag 
volume in this system was kept to a minimum (*5 ml) it was decided to switch to drug perfusion 
ten minutes before reperfusion to ensure that the first KHB to reach the reperfused tissue 
contained the required concentration of drug. Had the tissue been exposed to the tissue for 
longer than 10 minutes during ischaemia, problems such as receptor desensitisation may have 
been more likely. Additionally it would have been more difficult to determine whether 
protective drugs exerted their actions during ischaemia or at reperfusion.
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Figure S-l Experimental Protocols used in this study. Dark regions indicate ischaemia and light regions, normal perfusion.
Table S-l Pharmacological agents and their concentrations used in this study.
Drug Concentration Pharmacological action
Timolol lOpM Non-selective 3-adrenoceptor antagonist
CGP-20712A lOnM Selective 3i antagonist
ICI-118,551 lOnM Selective 32 antagonist
SR-59230A lOOnM Selective 33 antagonist
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Table 5-2 Justifications for the concentrations of drugs used in this study taken from the literature and from preliminary 
experiments in naive tissues, the results of which are reported as follows NE, no effect; - small negative inotropic effect; -- 
moderate negative inotropic effect; — large negative inotropic effect.
Drug Cone.
used
Literature reference Inotropic
effect
Timolol 10 pM A slightly lower concentration (5pM) abolished p- 
adrenoceptor-mediated preconditioning in isolated 
perfused rat hearts (Nasa et al., 1997).
CGP-20712A 10 nM Near-maximal reduction of adenylyl cyclase 
activation by isoprenaline in a rat- heart cell 
membrane model (Arnold et al., 1993).
ICI-118,551 10 nM This concentration blocks residual inotropic effects 
of isoprenaline in sheep ventricular muscle after 
Pi-adrenoceptor blockade (Borea et al., 1992).
SR-59230A 100 nM This dose causes a rightward shift of the 
chronotropic effects of the selective p3- 
adrenoceptor agonist ZD 7114 in rat atria (Sterin- 
Borda et al., 2006)
NE
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5.3.2 Separation and detection of catecholamines in coronary perfusate 
Coronary perfusate was collected at the end of the stabilisation period, at the end of ischaemia 
and at 3 minutes after reperfusion and was stored and analysed according to the method 
described in Section 2.7.
Sample Coronary Perfusate
Ischaemia /  Reperfusign Control
20"
Postconditioning
20"
Formoterol
20"
Formoterol
Figure 5-2 Protocol for sampling of coronary perfusate
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5.3.3 P resentation  o f data and statistics  
This chapter describes a single study in which the order of the experiments was randomised. 
Statistical analysis was carried out by comparing all ten groups using a single one-way ANOVA, 
however in order to improve the clarity of the results section, the results are presented as a 
series of graphs comparing each intervention to the same control and postconditioning group.
5.4 Results
5.4.1 Baseline card iodynam ics for in fa rc t size study  
The baseline cardiodynamics for hearts used in this study are shown below (Table 5-3). There 
were no statistically significant differences between any of the treatment groups.
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Table 5-3 Baseline cardiodynamics and Area at risk as a percentage of total area for hearts used in these studies. RPP, Rate 
pressure product; CF, Coronary flow; AAR, Area at risk.
Treatment n Baseline RPP 
(mmHg.min'VlOOO)
Baseline CF 
(m l.m in1)
AAR (%Total 
area)
Control 11 21.6 ± 2 14.0 ± 0.7 35.0 ± 3.3
Postconditioning 6 21.6 ± 3 19.8 ± 1.7 49.8 ± 3.3
Timolol 6 18.8 ± 4 16.9 ± 1.7 42.0 ±10.1
Timolol + Postconditioning 5 20.2 ± 3 18.1 ± 2 47.1 ± 6.2
CGP-20712A 5 24.6 ± 4 16.0 ± 0.9 36.6 ± 8.8
CGP20712A+Postconditioning 3 26.4 ± 3 15.5 ± 3.2 26.3 ±0.7
ICI-118,551 5 20.5 ± 3 11.4 ±6 .3 48.9 ± 5.3
ICI-118,551+Postconditioning 7 26.4 ± 3 12.0 ± 1.6 46.6 ± 2.1
SR-59230A 5 25.8 ± 4 12.7 ±1 .3 31.8 ± 5.8
SR-59230A+Postconditioning 4 22.5 ± 5 10.2 ± 0.5 34.6 ± 8.0
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5.4.2 Infarct size reduction by postconditioning and functional 
parameters -  Effects of timolol.
Infarct size, expressed as a percentage of the area at risk, in postconditioned hearts (13.07 ± 
3.0 %) was significantly (p<0.01) smaller than in control hearts (41.1 ± 5.1), representing a 68 % 
relative reduction (Figure 5-3). In tissues treated with the non-selective 3-adrenoceptor 
antagonist, timolol alone, infarct size was not different to controls (45.1 ± 3.9 %). When timolol 
was combined with postconditioning, the infarct size (73.7 ± 7.2) was significantly larger than 
postconditioned (p<0.001) and control (p<0.01) hearts. These effects occurred without 
significantly affecting the timecourse of coronary flow (Figure 5-4) throughout the experiment, 
or the recovery of contractile function as assessed by rate pressure product (Figure 5-5) or left 
ventricular developed pressure (Figure 5-6).
i
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★ *
Figure 5-3 The effect of the non-selective 0-adrenoceptor antagonist, timolol on infarct size reduction by postconditioning. 
*p<0.05 * *  p<0.01 * * *  p<0.001.
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Figure 5-4 The timecourse of coronary flow for each experimental group in experiments to determine the effect of the non- 
selective 3-adrenoceptor antagonist, timolol on infarct size reduction by postconditioning. There were no significant 
differences between groups. Error bars have been removed from all groups except for controls in order to improve clarity.
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Figure 5-5 The timecourse of rate-pressure product for each experimental group in experiments to determine the effect of 
the non-selective p-adrenoceptor antagonist, timolol on infarct size reduction by postconditioning. There were no significant 
differences between groups. Error bars have been removed from all groups except for controls in order to improve clarity.
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Figure 5-6 The timecourse of left ventricular developed pressure for each experimental group in experiments to determine 
the effect of the non-selective 0-adrenoceptor antagonist, timolol on infarct size reduction by postconditioning. There were 
no significant differences between groups. Error bars have been removed from all groups except for controls in order to 
improve clarity.
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5.4.3 Infarct size and functional parameters -  CGP-20712A  
When hearts were treated with the selective pi-adrenoceptor antagonist CGP-20712A at 
reperfusion, the infarct size (12.6 ± 3.3) was significantly (P<0.05) smaller than control hearts 
and a 69 % relative reduction in infarct size (Figure 5-7). When postconditioning and CGP- 
20712A were combined, there was a trend towards a smaller infarct size than control hearts, 
although this did not reach statistical significance. These effects occurred without significantly 
affecting the timecourse of coronary flow (Figure 5-8) throughout the experiment, or the 
recovery of contractile function as assessed by rate pressure product (Figure 5-9) or left 
ventricular developed pressure (Figure 5-10). However there did appear to be a trend towards 
improved function in CGP-20712A treated hearts and indeed ANOVA of the final time-point of 
the LVDP graph (60 minutes after reperfusion) demonstrated a significant difference between 
controls and CGP-20712A treated hearts.
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Figure 5-7 The effect of the selective 0r adrenoceptor antagonist, CGP-20712A on infarct size reduction by postconditioning. 
* p<0.05 • •  p<0.01.
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Figure 5-8 The timecourse of coronary flow for each experimental group in experiments to determine the effect of the 
selective Pj-adrenoceptor antagonist, CGP-20712A on infarct size reduction by postconditioning. There were no significant 
differences between groups. Error bars have been removed from all groups except for controls to improve clarity.
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Figure 5-9 The timecourse of rate-pressure-product for each experimental group in experiments to determine the effect of 
the selective 3!-adrenoceptor antagonist, CGP-20712A on infarct size reduction by postconditioning. There were no 
significant differences between groups. Error bars have been removed from all groups except for controls to improve clarity.
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Figure 5-10 The timecourse of left ventricular developed pressure for each experimental group in experiments to determine 
the effect of the selective (Jj-adrenoceptor antagonist, CGP-20712A on infarct size reduction by postconditioning. There were 
no significant differences between groups. Error bars have been removed from all groups except for controls to improve 
clarity.
179
Chapter 5
5.4 .4  In fa rc t size and functional param eters -  IC I-118 ,551  
When hearts were treated with the selective p2-adrenoceptor antagonist ICI-118,551 at 
reperfusion, the infarct size (79.7 ± 5.3) was significantly (P<0.01) larger than control hearts, a 
94 % relative increase in infarct size (Figure 5-11). When postconditioning and ICI-118,551 were 
combined, the infarct size was (76.8 ± 6.7), significantly larger than both control (p<0.01) and 
postconditioned (p<0.01) hearts. These effects occurred without significantly affecting the 
timecourse of coronary flow (Figure 5-12) throughout the experiment, or the recovery of 
contractile function as assessed by rate pressure product (Figure 5-13) or left ventricular 
developed pressure (Figure 5-14).
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* * *
Figure 5-11 The effect of the selective 02-adrenoceptor antagonist, ICI-118,551 on infarct size reduction by postconditioning.
* *  p<0.01, * * *  p<0.001.
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Figure 5-12 The timecourse of coronary flow for each experimental group in experiments to determine the effect of the 
selective p2-adrenoceptor antagonist, ICI-118,551 on infarct size reduction by postconditioning. There were no significant 
differences between groups. Error bars have been removed from all groups except for controls to improve clarity.
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Figure 5-13 The timecourse of rate-pressure product for each experimental group in experiments to determine the effect of 
the selective P2-adrenoceptor antagonist, ICI-118,551 on infarct size reduction by postconditioning. There were no significant 
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the selective 02-adrenoceptor antagonist, ICI-118,551 on infarct size reduction by postconditioning. There were no significant 
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5.4.5 In fa rc t size and functional param eters  -  SR-59230A  
When hearts were treated with the selective (53-adrenoceptor antagonist SR-59230A at 
reperfusion, the infarct size (66.3 ± 12.9) was significantly (P<0.05) larger than control hearts, a 
61 % relative increase in infarct size (Figure 5-15). When postconditioning and SR-59230A were 
combined, the infarct size was (61.6 ± 12.9), significantly larger than postconditioned (p<0.001) 
hearts, but not significantly different from controls. These effects occurred without significantly 
affecting the timecourse of coronary flow (Figure 5-16) throughout the experiment, or the 
recovery of contractile function as assessed by rate pressure product (Figure 5-17) or left 
ventricular developed pressure (Figure 5-18).
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Figure 5-15 The effect of the selective 03-adrenoceptor antagonist SR-59230A 223 on infarct size reduction by 
postconditioning. * p<0.05,** p<0.01, * * *  p<0.001.
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selective f)r adrenoceptor antagonist, SR-59230A on infarct size reduction by postconditioning. There were no significant 
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Figure 5-17 The timecourse of rate-pressure-product for each experimental group in experiments to determine the effect of 
the selective Pj-adrenoceptor antagonist, SR-59230A on infarct size reduction by postconditioning. There were no significant 
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5.4 .6  Baseline cardiodynamics for catecholamine release study 
Baseline cardiodynamics for both treatment groups are shown below (Table 5-4). There were 
no significant differences between the groups. Parameters were compared using an unpaired t- 
test.
Table 5-4 Baseline cardiodynamics for catecholamine release study
Treatment n Baseline RPP 
(mmHg.mln'VlOOO)
Baseline CF 
(m l.m in1)
Control 4 22.9 ± 3 12.3 ± 1.3
Postconditioning 4 19.0 ± 3 11.3 ±0 .8
5.4.7 Catecholamine release at reperfusion 
Adrenaline and noradrenaline were successfully separated using HPLC and detected using 
electrochemical detection. A sample trace is shown below (Figure 5-19) Retention times were 
154 seconds for noradrenaline and 190 seconds for adrenaline. End stabilisation values of both 
catecholamines were approximately In M . Using a signal/noise ratio of 3, 0.1 nM of adrenaline 
or noradrenaline could be detected using this method.
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Figure 5-19. A trace from a HPLC experiment demonstrating peak resolution between adrenaline and noradrenaline. The 
shoulders probably represent a breakdown product of catecholamines. Further work would be required for formal 
identification. Equal concentrations (10 nM) of adrenaline and noradrenaline standards were injected into the column 
simultaneously.
Neither noradrenaline nor adrenaline concentrations were significantly altered by ischaemia or 
reperfusion (Figure 5-20).
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Figure 5-20 Concentration of adrenaline (A) and noradrenaline (B) in coronary perfusate at the end of ischaemia and after 3 
minutes reperfusion in control and postconditioned tissues expressed as a percentage of end-stabilisation values which were 
approximately In M  for both catecholamines.
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5.5 Discussion
This study presents the first evidence that 3-adrenoceptor activation is required for 
postconditioning. The non-selective 3-adrenoceptor antagonist, timolol prevented infarct size 
reduction by postconditioning. When timolol was administered to tissues which endured 
ischaemia and reperfusion without postconditioning, infarct size was comparable with 
untreated controls. This suggests that timolol had no effect on reperfusion injury when applied 
alone at reperfusion, however studies designed to identify the receptor subtype responsible for 
the protective effect of postconditioning, suggest that when a non-selective antagonists such as 
timolol is applied, the outcome is a combination of its effects on different 3 -adrenoceptor 
subtypes. These multi-factorial effects may go some way towards explaining the surprising 
result whereby timolol and postconditioning combined gave a larger infarct size than seen in 
controls which would otherwise be difficult to explain.
In common with other investigators (Feuerstein et a i,  1998; Gao et a i,  2000) it was found that 
administration of a selective 3i-adrenoceptor antagonist (in this case, CGP-20712A) at 
reperfusion led to a significant reduction in infarct size. The infarct size reduction was of a 
similar magnitude to that achieved by postconditioning. When postconditioning and CGP- 
20712A were combined, the result was neither significantly different from control nor from 
postconditioned tissues. This is probably due to the fact that a number of experiments in this 
group were excluded for technical reasons, leaving a small number of replicates. However, 
these results suggest that activation of 3 i-adrenoceptors by endogenous catecholamines at 
reperfusion has a detrimental effect on survival which can be abrogated by use of a selective 
antagonist. This presents a therapeutic strategy in the reduction of reperfusion injury. It was
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interesting to note the trend towards improved recovery of coronary flow and rate-pressure­
product in tissues treated with CGP-20712A. Although no significant difference was seen when 
the recovery curves were compared using repeated-measures ANOVA, a t-test comparing the 
LVDP at 60 minutes after reperfusion showed a significantly improved function at this time- 
point, in addition to the reduction of infarct size. Although the validity of performing such a 
statistical test may be questioned, it is nonetheless interesting because the idea of 
administering a negatively inotropic agent to a post-ischemic heart may be questioned by 
conventional wisdom, even if it results in a reduction of infarct size, because of its potential to 
depress cardiac function at a critical time when cardiac output may be compromised. However, 
these results demonstrate that cardiac function is not compromised by this agent, and suggest 
that it may even be improved.
Conversely, an increase in infarct size above control was observed in both postconditioned and 
non-postconditioned tissues treated with the selective 32-adrenoceptor antagonist, ICI-118,551. 
This is interesting in light of a study which demonstrated that ICI-118,551 caused cell death by 
apoptosis in cultured myocytes (Communal et a i,  1999). The detrimental effects of a 32- 
adrenoceptor antagonist at reperfusion suggest that endogenous catecholamines are acting 
upon these receptors and conferring innate protection. The identity of the catecholamine is not 
immediately clear however. Noradrenaline is released from sympathetic nerve endings during 
ischaemia as a result of the reverse function of the uptakei transporter (Schoemig & Richard, 
1991). However noradrenaline preferentially activates 3i-adrenoceptors, whereas adrenaline 
preferentially activates 32-adrenoceptor (Lands et al., 1967). Thus adrenaline is more likely to
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mediate this effect. Indeed, adrenaline was detected in the coronary effluent from hearts in 
this study indicating its release within the heart.
The concentrations of adrenaline and noradrenaline at the end of stabilisation were similar, 
and were not altered by ischaemia. This may be interpreted as a failure to demonstrate 
ischaemia-induced catecholamine release. However, given that these experiments were carried 
out in isolated tissues in which the reserves of adrenaline and noradrenaline are limited and 
constantly depleting, the fact that the concentration at the end of ischaemia is the same as at 
the beginning despite this depletion is remarkable and might be indicative of the release of 
catecholamines. This question could be answered with the use of non-ischaemic time control 
tissues which were unfortunately not employed in this study. Catecholamine levels at 
reperfusion were not different in control and postconditioned hearts. Therefore these results 
do not support the hypothesis. However, it remains possible that the difference in 
catecholamine levels is too small to be detected by the assay employed, or that the washout of 
the catecholamines had already occurred by the perfusate samples were taken at the end of 
postconditioning.
The hypothesis that postconditioning prevents the immediate washout of endogenous 
mediators at reperfusion allowing activation of RISK pathways, is an attractive one. The 
hypothesis was first proposed for adenosine (Kin et a!., 2005; Philipp et a!., 2006). However any 
autacoid which can activate RISK pathways at reperfusion should be able to mimic 
postconditioning. The importance of different mediators may vary between experimental
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models. In this study, an important role for 3-adrenoceptors in postconditioning has been 
demonstrated.
ICI-118,551 is the only available selective 32-adrenoceptor antagonist, thus it could be argued 
that an off-target toxic effect is responsible for the infarct-potentiating effect. This cannot be 
ruled out, however emerging evidence in other models of cellular injury has demonstrated 
potentiation of damage in 32-adrenoceptor knockout strains. Patterson (2004) conducted 
studies in which isoprenaline was infused into 3 i-adrenoceptor and 32-adrenoceptor knockout 
mice; there was greater mortality and increased myocyte apoptosis in the 32-adrenoceptor 
knockout mice. Thus it had been suggested that 3i-adrenoceptor signalling is pro-apoptotic and 
32-adrenoceptor signalling is anti-apoptotic (Xiao et al.t 2004). How this relates to cell death at 
reperfusion which is probably predominantly necrotic, is not yet known.
Postconditioning was unable to reverse the increase in infarct size caused by ICI-118,551. 
Indeed, there was not even a trend towards smaller infarct sizes in hearts exposed to 
postconditioning and ICI-118,551. This suggests that either 32-adrenoceptor activation is 
necessary for postconditioning to be protective, or that antagonism of 32-adrenoceptors, in the 
absence of concomitant 3 i-adrenoceptor antagonism at reperfusion is so devastating to the cell 
that cell death is inevitable and postconditioning cannot confer any protection.
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Thus, the absence of an effect of timolol alone on reperfusion may in fact reflect functional 
antagonism between a protective 3 i-adrenoceptor antagonist and a detrimental 32- 
adrenoceptor antagonist at reperfusion.
It was also interesting that the experiments utilizing the 33-adrenoceptor antagonist, SR- 
59230A, gave very similar results to the 32-adrenoceptor antagonist. It caused an increase in 
infarct size above that seen in controls and this damage could not be reversed by 
postconditioning. It is known that 33-adrenoceptors couple to Gj and are in th a t respect similar 
to 32-adrenoceptor. Little is known about the function of 33-adrenoceptors in the heart, 
however, they are present in far smaller density than 32-adrenoceptors. In light of this, it would 
seem surprising that a 33-adrenoceptor antagonist could have such a marked effect on infarct 
size. This result could be due to non-selective interactions of SR-59230A which was the first 
commercially available 33-adrenoceptor antagonist (Nisoli et al., 1996), however some studies 
have suggested that SR-59230A is not selective for 33-adrenoceptors, causing antagonism of 
other 3-adrenoceptor subtypes (Candelore et al., 1999) and a-adrenoceptors (Leblais et al., 
2004). It also appears that there are considerable differences between hum an and rodent 33- 
adrenoceptors (Alexander et al., 2008). Thus, it is difficult to determine from these results alone 
whether this represents a true 33-adrenoceptor-mediated effect or w hether the effect was 
mediated via 32-adrenoceptor antagonism. The use of 33-adrenoceptor knockout strains could 
help to clarify this result in the future.
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If these results were indicative of the situation in humans in vivo they would be of extreme 
relevance in the clinic, where 0-adrenoceptor antagonists are administered for the treatment 
of angina, hypertension and heart failure (Mehta, 2006). It would appear that antagonists 
which act upon the p2-adrenoceptor or 03-adrenoceptor are detrimental at reperfusion and 
consequently Pi-adrenoceptor antagonists are likely to be more protective than non-selective 
antagonists, at least acutely at reperfusion. Mechanical postconditioning induced by repeated 
inflations and deflations of an angioplasty balloon have been shown to reduce creatine kinase 
release (a marker of infarct size) from human hearts undergoing revascularisation therapy after 
myocardial infarction (Staat et al., 2005). Recently, long term clinical benefits have also been 
reported (Thibault et al., 2008). Postconditioning is therefore moving from an experimental 
observation to a clinical therapy. Thus it is important to investigate whether commonly used 
drugs have the potential to prevent protection induced by postconditioning (or worse, to cause 
increased infarct size in non-postconditioned tissues).
Pharmacological mimetics of postconditioning are being actively sought (Vinten-Johansen et al., 
2005a; Vinten-Johansen et al., 2005b). This study demonstrated that 02-adrenoceptor 
antagonists had detrimental effects when administered at reperfusion. This leaves open the 
possibility that agonists at these receptors may have the opposite effect and could be used to 
induce postconditioning. Alternatively, 02-adrenoceptors may be maximally stimulated by 
endogenous agonists in which case no effect of additional exogenous agonists would be 
expected. Even if this is the case, it would appear that administration of a fr-adrenoceptor 
antagonist reduces infarct size
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The relevance of these results to the clinical situation is limited by the ex vivo nature of the 
preparation. This model lacks sympathetic stimulation and circulating catecholamines, so the 
concentrations of the catecholamines in the myocardium may have been far removed from 
physiological normal levels.
Because of the well documented vascular effects of (3-adrenoceptor ligands, a-adrenoceptors 
mediating vasoconstriction and (3-adrenoceptors mediating vasodilatation (Ahlquist, 1948), it is 
important to exclude the possibility that adrenoceptor-mediated variations in blood flow are 
responsible for any protective or detrimental effects seen at reperfusion. In this study, there 
was no significant difference between experimental groups in the timecourse of coronary flow 
throughout ischaemia and reperfusion. However, this method was unable to demonstrate any 
alterations in regional blood-flow. This is worthy of further investigation. It is not clear whether 
activation of (3-adrenoceptors at reperfusion would cause a homogenous vasodilatation 
throughout the heart, or whether vasodilatation would occur preferentially in tissue which had 
not previously been ischaemic causing coronary 'steal'(Reivich et al., 1961) and directing blood- 
flow away from damaged regions. A final possibility is that blood would be diverted towards the 
area at risk. Thus, an important topic for future investigation would be the measurements of 
regional coronary flow during ischaemia and reperfusion. This could be achieved using 
fluorescently labelled microspheres (Chien et al., 1995).
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5.5.1 Clinical im plications  
This study has confirmed the results seen elsewhere that 3i-adrenoceptor antagonists at 
reperfusion lead to a reduction in infarct size and thus clinical benefit may be gained by the use 
of antagonists selective against 3i-adrenoceptors at reperfusion. Many patients with 
cardiovascular disease are prescribed 3-adrenoceptor antagonists, including a number of non- 
selective agents such as carvedilol and propranolol. The results from this study suggest that 
these agents have the potential to abrogate the protective effects of postconditioning. Because 
postconditioning has been demonstrated in man in vivo (Staat et al., 2005) and has been 
proposed as a therapeutic strategy, a thorough understanding of any factors likely to blunt its 
protection is essential. Antagonists of 32-adrenoceptors and 33-adrenoceptors may also blunt 
protective effects mediated by endogenous catecholamines in the absence of postconditioning. 
This has important implications for the use of non-selective antagonists.
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5.6 Conclusions
•  The postconditioning protocol used in this series of experiments significantly reduces 
infarct size.
•  The protection afforded by postconditioning is abrogated by a non-selective p- 
adrenoceptor antagonist.
•  The protection afforded by ischaemic postconditioning is abrogated by antagonism of 
adrenoceptors.
•  No detectable differences in the concentrations of adrenaline and noradrenaline in the 
coronary perfusate of control and postconditioned tissues were observed.
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Chapter 6 -  Can p-adrenoceptor agonists mimic
postconditioning in the ra t Langendorff heart ?
6.1 introduction
In Chapter 5, it was demonstrated that the protection afforded by ischaemic postconditioning 
was lost in the presence of a non-selective 3-adrenoceptor antagonist (timolol), suggesting that 
3-adrenoceptor activation is necessary for postconditioning to exert its effect. Furthermore it 
was demonstrated that the protection is probably mediated via the 32-adrenoceptor or the 33- 
adrenoceptor, because selective antagonists for these receptors (ICI-118,551 and SR-59230A 
respectively), when applied at reperfusion, led to larger infarct sizes than seen in controls, 
implying a protective effect of endogenous catecholamines on these receptors.
Further evidence of the infarct-sparing effects of 32-adrenoceptor and 33-adrenoceptor 
activation could be provided by applying selective agonists of these receptors at reperfusion 
and examining whether the protective effects of postconditioning are mimicked. This chapter 
will thus examine the effects of the administration of selective and non-selective 3- 
adrenoceptor agonists at reperfusion.
It was also demonstrated in Chapter 5 that the selective 3r adrenoceptor antagonist, CGP- 
20712A was protective when applied at reperfusion, suggesting that activation of 31- 
adrenoceptors and subsequent activation of the pathway involving adenylyl cyclase, cAMP, and
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protein kinase A at reperfusion is detrimental. This set of experiments will also endeavour to 
demonstrate that this is the case. Noradrenaline will be used to stimulate the 0i-adrenoceptor, 
it should be selective at the concentrations used. However, in order to overcome any problems 
of receptor selectivity and to eliminate any secondary signalling pathways emanating from the 
0 i-adrenoceptor, forskolin, a direct activator of adenylyl cyclase will be additionally employed.
If 0i-adrenoceptor activation at reperfusion is detrimental and 02-adrenoceptor or 03- 
adrenoceptor activation is beneficial, it is unclear how non-selective agents will act when 
applied at reperfusion. One study, conducted in anesthetised dogs exposed to regional 
ischaemia, showed that isoprenaline, provided inotropic support but does not alter infarct size 
(LaBruno et al., 1998). Therefore, the effects of the non-selective agent isoprenaline applied at 
reperfusion will be examined in this rat isolated heart model. The effects of administration of 
the non-selective a /0  agonist, adrenaline, were described previously in Chapter 4. Adrenaline 
had no effect on infarct size at any of the concentrations employed.
If these agonists exert salutary effects by activation of RISK pathways, it should be possible to 
detect activation of these kinases using Western blotting techniques after treatment with the 
agonist. This will be an additional aim of this chapter.
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6.2 Hypotheses
•  Activation of 0i-adrenoceptors at reperfusion will increase infarct size in rat Langendorff 
heart preparations exposed to regional ischaemia and reperfusion.
•  Direct activation of adenylyl cyclase using forskolin will increase infarct size, in 
Langendorff perfused rat hearts.
•  The infarct-sparing effect of postconditioning will be mimicked by p2 and 03 
adrenoceptor agonists in Langendorff perfused rat hearts.
•  Protective effects are mediated via phosphorylation of the RISK pathway kinase Akt.
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6.3 Methods
6.3.1 Infarct size study 
Male Sprague-Dawley rats 250-350g were obtained from B&K international (Grimston, UK). 
Langendorff perfused rat hearts were set up as described previously (Chapter 2). After 20 
minutes stabilisation, hearts were exposed to 35 minutes regional ischaemia and 2 hours 
reperfusion.
Control
20' Stabilisation 35' Ischaemia 120' Reperfusion
Drug Treatment
Drug 
4  »
i i i i i 11 1 i
-20 35
Time (minutes) since onset of ischemia
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Figure 6-1 Experimental protocols used in this study. Time is shown along the abscissa. Yellow areas denote normal 
perfusion and red areas indicate ischaemia. Table 6-1 gives details of drugs and concentrations used
A range of selective and non-selective 3-adrenoceptor agonists, and the adenylyl cyclase 
activator, forskolin (Table 6-1) were administered for the final 10 minutes of ischaemia and the 
first ten minutes of reperfusion (Figure 6-1).
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Table 6-1 Pharmacological agents and their concentrations used in this study. All agents were administered for the final 10 
minutes of ischaemia and the first ten minutes of reperfusion (Figure 6-1)
Drug Concentration Pharmacological action
Isoprenaline 0.1 pM Non-selective 3-adrenoceptor agonist
Noradrenaline 0.1 pM Selective 3i agonist
Salbutamol lp M Selective fc agonist (short acting)
Formoterol 10 nM Selective agonist (long acting)
BRL-37344 300 nM Selective 3b agonist
Forskolin 250 nM Adenylyl cyclase activator
ICI-118,551 lOnM Selective 32 antagonist
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Table 6-2 Justifications for the concentrations of drugs used in this study taken from the literature and from preliminary 
experiments in naTve tissues, the results of which are reported as follows NE, no effect; + small positive inotropic effect; ++ 
moderate positive inotropic effect; +++ large positive inotropic effect
Drug Concentration Literature reference Inotropic effect
Isoprenaline 100 nM Similar concentrations have been shown to 
elicit preconditioning against stunning in 
guinea-pig isolated atria (Yates et al., 2003).
+++
Noradrenaline 100 nM This concentration elicited preconditioning 
against post-ischaemic contractile 
dysfunction in isolated perfused rat hearts 
(Asimakis et al., 1994).
+++
Forskolin 250 nM This concentration causes sub-maximal 
cardiostimulant effects in isolated perfused 
rat hearts (England & Shahid, 1987).
+++
Salbutamol lp M A slightly lower dose causes large changes in 
coronary flow and left ventricular developed 
pressure in isolated rat heart (Vleeming et al., 
1993)
++
Formoterol 10 nM Submaximal chronotropic effect on guinea pig 
atria (Freyss Beguin et al., 1983)
++
BRL-37344 300 nM Submaximal negative inotropic concentration in 
perfused rat heart (Barbier et al., 2007)
NE
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6.3.2 Western blotting 
In a further series of experiments, left apex tissue was harvested for western blotting for 
phosphorylated and total Akt. Samples were taken at the end of ischaemia and three minutes 
after reperfusion in control tissues and in tissues that had been subjected to ischaemic 
postconditioning and formoterol treatment at reperfusion (Figure 6-2).
t Harvest tissue fo r Akt Blots
Ischaemia
20/
Ischaemia /  Reperfusion
2 O'
Postconditioning
20'
Formoterol
2CT
3'
t
Formoterol
Figure 6-2 Protocol for tissue sampling in Western blotting study. n=4 for all groups except formoterol treatment (n=3).
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6.4 Results
6.4.1 Baseline cardiodynamics -  infarct size study 
The baseline cardiodynamics for hearts used in this study are shown below (Table 6-3). There 
were no statistically significant differences between any of the treatment groups.
Table 6-3 Baseline cardiodynamics and Area at risk as a percentage of total area for hearts used in these studies
Treatment n Baseline RPP
(mmHg.minVlOOO)
Baseline CF 
(ml.min’1)
AAR
(%Total area)
Control 19 26.3 ± 3 14.18 ± 0.8 30.9 ± 3.4
Isoprenaline 8 20.4 ± 2 14.5 ± 1.2 22.0 ±2.8
Noradrenaline 7 27.5 ± 2 15.9 ± 1.7 23.6 ± 2.5
Salbutamol 7 17.4 ± 2 10.5 ± 0.8 28.7 ± 4.8
Formoterol 6 25.6 ±3 17.5 ± 1.2 28.7 ± 4.9
Formoterol + ICI 5 28.3 ± 2 15.7 ± 2.3 25.6 ±3
BRL-37344 6 20.9 ± 5 12.4 ± 0.4 27.3 ± 4.5
Forskolin 6 30.8 ± 2 15.7 ±2.1 27.4 ±3.9
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6.4.2 Infarct size
In control tissues, the infarct was 38.8 ± 3.4 % of the area at risk. This was not significantly 
affected by administration of the non-selective 3-adrenoceptor antagonist, isoprenaline at 
reperfusion which produced an infarct size of 30.8 ± 8.9. Noradrenaline which predominantly 
activates 3i-adrenoceptors also had no significant effect, the infarct size was 24.8 ± 5.4 (Figure 
6-3).
The short-acting 32-adrenoceptor agonist, salbutamol, did not have any effect on infarct size. 
The infarct size was 30.6 ± 6 .6 . However formoterol, a long-acting 32-adrenoceptor agonist, 
significantly (p<0.05) reduced infarct size to 15.0 ± 3.1 %, representing a 61 % relative reduction 
in infarct size. No protection by formoterol was seen in the presence of the 32-adrenoceptor 
antagonist, ICI-118,111, indeed, the infarct size was 57.3 ± 9.8, significantly (p< 0.05) greater 
than controls (Figure 6-3).
The 33-adrenoceptor agonist, BRL-37344, reduced infarct size to 17.2 ± 4.4 % of the area at risk 
when administered at reperfusion, a statistically significant (p<0.05) 56 % relative reduction in 
infarct size compared to controls (Figure 6-3).
The adenylyl cyclase activator, forskolin, led to an increase in infarct size which was significantly 
(p<0.05) greater than controls encompassing 59.0 ± 2.6 % of the area at risk and representing a 
52 % relative increase in infarct size (Figure 6-3).
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Figure 6-3 Infarct Size expressed as a percentage of the area at risk (%AAR) for the experimental groups in this study * indicates p<0.05.
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6.4.3 Functional parameters 
Regional ischaemia was confirmed by a drop in coronary flow of at least 30% in all preparations. 
Rate pressure product also fell rapidly during ischaemia. Recovery of both parameters was seen 
at reperfusion. No significant differences were seen between experimental groups in the 
timecourse of coronary flow (Figure 6-4), rate pressure product (Figure 6-5) or left ventricular 
developed pressure (Figure 6-6 ) throughout the experiment.
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Figure 6-4 Timecourse of coronary flow throughout the experiment. There were no significant differences between the 
groups. Error bars have been removed from  all groups except controls to improve clarity.
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Figure 6-5 Timecourse of rate pressure product throughout the experiment. There were no significant differences between 
the groups. Error bars have been removed from all groups except controls to improve clarity.
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Figure 6-6 Timecourse of LVDP throughout the experiment. There were no significant differences between the groups. Error 
bars have been removed from all groups except controls to improve clarity.
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6.4.4 Baseline cardiodynamics -  hearts used for Western blots 
There were no significant differences between the experimental groups in terms of the baseline 
parameters (Table 6-4).
Table 6-4 Baseline cardiodynamics for hearts used in the Western blotting study
Treatment n Baseline RPP
(mmHg.min'VlOOO)
Baseline CF 
(m l.m in1)
Stabilisation 4 21.9 ±2 12.3 ± 0.7
Ischaemia 4 21.6 ± 5 12.0 ± 1.7
Reperfusion 4 22.9 ±3 12.3 ± 1.3
Ischaemic Postconditioning 4 19.0 ±3 11.3 ±0.8
Formoterol Postconditioning 3 18.9 ± 8 14.0 ±2.0
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6.4.5 Akt phosphorylation 
There were no significant differences between the experimental groups in terms of the extent 
of Akt phosphorylation at three minutes after reperfusion (Figure 6-7).
Ischaemia Reperfusion Postcon. Formoterol
Total Akt
1.50-
Figure 6-7 Ratios of phosphorylated/total Akt and Western blots for hearts at the end of ischaemia (n=4), at early 
reperfusion in control (n=4), postconditioned (n=4) and formoterol (n=3) treated hearts. The western blots from which the 
data were calculated are shown above the bars. Only one band was visible per blot, this was seen between 50 and 75 Kilo 
Daltons and is thus characteristic of Akt. Each lane on the gel corresponds to one heart.
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6.5 Discussion
The most important novel finding from this study is that postconditioning can be mimicked by 
application of formoterol, a 32-adrenoceptor agonist at reperfusion. Similarly, the 33- 
adrenoceptor agonist, BRL-37344 reduced infarct size when given just prior to reperfusion. It 
was decided to concentrate further investigation on the protective effect of the 32- 
adrenoceptor. This was because of the potential selectivity problems of 33-adrenoceptor 
ligands and the wide species variations in this receptor (discussed in Chapter 5). Additionally, 
the widespread availability of 32-adrenoceptor agonists in the clinic, where they are used to 
treat asthma, made the 32-adrenoceptor an attractive target. However, because both a 33- 
adrenoceptor agonist and an antagonist have been demonstrated to affect infarct development 
in this model, there is a strong possibility that they play an important role in postconditioning. 
This certainly warrants further investigation.
The protective effect of formoterol was not seen in the presence of the selective 32- 
adrenoceptor antagonist ICI-118,551. This suggests a receptor-dependent mechanism. 
However, as was demonstrated in Chapter 5, ICI-118,551 alone increases infarct size above 
controls. Indeed in this study, the combination of ICI-118,551 and formoterol resulted in an 
infarct size larger than control. This makes it difficult to draw a firm conclusion about the 
receptor-dependence of the result. It could be argued that the non-selective 3-adrenoceptor 
antagonist, timolol should have been used, as this alone does not appear to have any effect on 
infarct size (Chapter 5). However, because a 3i-adrenoceptor antagonist decreases infarct size 
at reperfusion, and 32-adrenoceptor and 33-adrenoceptor antagonists increase infarct size, the
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effects of a non-selective agent are likely to be a complicated summation of a number of effects. 
For this reason, the use of ICI-118,551 was preferable. Ultimately, 32-adrenoceptor knockout 
strains should be used to investigate these effects, although, such experiments would be 
complicated by the fact that the animal would be lacking the 32-adrenoceptor throughout 
ischaemia and reperfusion.
The mechanism of this protection has only begun to be elaborated by this study. This 
protection is unlikely to be mediated by a classic 3-adrenoceptor signalling pathway via G*, 
adenylyl cyclase, cAMP and protein kinase A, because neither isoprenaline (a non selective 3- 
adrenoceptor agonist) nor forskolin (a direct activator of adenylyl cyclase) mimicked this 
protective effect. Indeed forskolin exerted a pro-infarct effect in this model. Furthermore, 
noradrenaline which predominately activates 3 i~adrenoceptors and thereby signals 
downstream via protein kinase A, also failed to protect at reperfusion. This detrimental effect 
of PKA activation at reperfusion may be due entirely to a worsening of ischaemia caused by the 
positive inotropy and chronotropy elicited by this signalling pathway, however, it is interesting 
to note that studies have demonstrated pro-apoptotic actions of 3 i-adrenoceptor signalling 
(Xiao et al., 2004)
In an attempt to investigate the effects by which this protection is mediated, samples of apex 
tissue were taken from hearts which had been treated with formoterol at reperfusion. Western 
blot analysis did not demonstrate activation of Akt after three minutes of reperfusion, in hearts 
treated with formoterol at reperfusion. However, Akt phosphorylation was not increased by
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postconditioning, in which it is known to play an important role (Schwartz et a/., 2006; 
Sivaraman et al., 2007; Tsang et al., 2004; Zhu et al., 2006). Thus this part of the study lacked a 
positive control. It is likely therefore that the fact that Akt phosphorylation was not observed in 
this study was due to a feature of the methodology employed. In particular, the time at which 
samples were taken is likely to be important. It has been demonstrated that when the 
adipocytokine, apelin-13 is applied to the heart at reperfusion, Akt phosphorylation increases 
with time, although the activity of Akt does not follow the same timecourse (Smith et al., 2007). 
There is not yet any consensus as to the time of maximal Akt phosphorylation after ischaemic 
postconditioning. Furthermore, when the heart was dissected, it was impossible to be certain 
whether the sample of tissue taken was from the centre of the risk zone, the edge of the risk 
zone or from tissue which was normally perfused throughout the experiment. This is likely to 
have consequences for the levels of tissue phosphorylation. If further time and resources were 
available, it would be interesting to sample heart tissues at a number of time-points after 
reperfusion and also in non-ischaemic tissues exposed to formoterol. It would also be 
interesting to sample also for phosphorylation of another important RISK pathway mediator Erk 
1/2 which may also be activated by 0-adrenoceptors (Galandrin et al., 2006; Tutor et al., 2007) 
and is therefore a potential mediator of protection at reperfusion.
This study is the first to demonstrate pharmacological postconditioning by a 02-adrenoceptor
agonist. However, a recent study employing a model of hypoxia and reoxygenation in cultured
human umbilical vein endothelial cells demonstrated that addition of formoterol to the
medium, throughout hypoxia and reoxygenation led to reduced cell death. The effect was
blocked by ICI-118,551 and by a nitric oxide synthase inhibitor (Pottecher et al., 2006). This is
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interesting because of the central role of nitric oxide in RISK pathways. However, because th e  
time of administration of formoterol was different to that used in our protocol, it cannot be  
concluded whether or not the mechanism is the same as in our study. In human umbilical vein  
endothelial cells, reduction of reactive oxygen species by formoterol administration was an  
important part of the mechanism (Pottecher et al., 2006).
It was interesting that an alternative 32-adrenoceptor agonist, salbutamol did not elicit 
protection. This may be a simple question of selectivity. Salbutamol is less selective, potent and  
has a lower affinity for the 32-adrenoceptor than formoterol (Linden et al., 1996). Any 0 i -  
adrenoceptor activity in this setting might abrogate protective signalling via 32-adrenoceptors. 
Thus, it may be that the concentration of salbutamol used in this study was too high. 
Formoterol is highly selective for 32-adrenoceptors (Anderson, 1993). Another, major difference 
between these two molecules is that salbutamol is a 'short acting' 3-adrenoceptor and  
formoterol is a 'long acting' agent. The difference between these is not merely pharmacokinetic, 
it is thought that long-acting 32-adrenoceptor agonists may bind to  an additional site on the 0 2- 
adrenoceptor (Anderson, 1993). Whether this has the potential to alter signalling is not certain. 
Finally, studies have demonstrated that drugs which act as agonists for classic 3-adrenoceptor 
signalling do not necessarily act as activators of secondary signalling pathways such as Erk 1 /2 ,  
which are likely to lead to cardioprotection. In fact they may possess properties of a neutral 
antagonist or an inverse agonist. However, only a very small number of 3-adrenoceptor 
agonists have been investigated for their effects on Erk 1/2 signalling and it is not yet clear 
whether the additional binding site is responsible for this effect. Based on the results described 
here, this appears to be the case, as formoterol, a long acting agent which binds to both sites 
was protective whereas salbutamol, which binds to a single site, did not. Thus, this w ork
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highlights the need for a systematic study of a range of [J2-adrenoceptor antagonists to screen 
them for cardioprotective properties.
It has been demonstrated in rat internal anal sphincter muscle that p2-adrenoceptor agonists 
can lead to increased activity of protein kinase G, through a Gi mediated mechanisms 
(Galandrin et al., 2006; Li et al., 2004). If the same were true in the heart, this mechanism could 
explain the powerful cardioprotection elicited via f$2-adrenoceptor at reperfusion. Protein 
kinase G is one of the final stages in the RISK pathways, required to prevent cell death at 
reperfusion.
6.5.1 Clinical im plications  
If these findings could be replicated in man and in-vivo, they would be of considerable clinical 
interest. A wide range of p2 agonists including formoterol, are already available in the clinic for 
the treatment of asthma. These drugs could potentially be administered immediately prior to 
reperfusion for their infarct-sparing effects. However, there are many reasons why the same 
mechanisms may not be important in vivo where maximal p2-adrenoceptor stimulation may 
already occur. These effects may also be altered by peripheral vasodilator (hypotensive) actions 
of p2-adrenoceptor agonists which would be undesirable in conditions of poor cardiac output.
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6.6 Conclusions
•  Direct activation of adenylyl cyclase at reperfusion is detrimental and leads to increased 
infarct development.
•  Cardioprotection can be elicited by 02 and P3 adrenoceptor agonists applied at 
reperfusion.
•  Cardioprotection elicited by the 32-adrenoceptor agonist formoterol is not seen in the 
presence of the p2-adrenoceptor antagonist, ICI-118,551.
•  Increased levels of phosphorylated Akt are not detectable after ischaemic or 
pharmacological postconditioning at 3 minutes after reperfusion.
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Chapter 7 - General discussion
7.1 Summary of novel findings
•  Ischaemic preconditioning can protect against stunning in isolated rat atria and 
ventricles. This protection is dependent on 3-adrenoceptor activation.
•  3-adrenoceptor preconditioning can protect against stunning in isolated rat atria.
•  Endogenous and exogenous adrenaline may worsen stunning when applied at 
reperfusion.
•  Adrenaline does not affect infarct size when applied at reperfusion but increases 
reperfusion contracture in the Langendorff heart preparation.
•  The non-selective 3-adrenoceptor antagonist, timolol, has no overall effect on infarct 
size when given at reperfusion after regional ischaemia but blocks the protection 
elicited by postconditioning in the Langendorff heart preparation.
•  Infarct size is greatly increased by antagonists of the 32- and 33-adrenoceptor given at 
reperfusion. This damage cannot be overcome by postconditioning.
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•  Infarct size is increased by activation of adenylyl cyclase at reperfusion.
•  Antagonists of the pi-adrenoceptor receptor reduce infarct size when applied at 
reperfusion.
•  Agonists of the p2- and 33-adrenoceptor reduce infarct size when applied at reperfusion
7 .2  R elevance o f findings 
Catecholamines and adrenoceptors have long been known to have important roles during 
ischaemia and reperfusion. The inspiration for this investigation resulted from a desire to re­
evaluate these roles in the light of the recent discovery of ischaemic postconditioning. 
Experiments designed to test the hypotheses that postconditioning could be mimicked by 3- 
adrenoceptor activation and that the mechanism of ischaemic postconditioning involved 3- 
adrenoceptor activation formed the most important part of this investigation, both in terms of 
scientific novelty and because of the potential clinical implications of these hypotheses.
Activation of 3-adrenoceptors had already been demonstrated to mimic preconditioning 
against infarct size. However, experiments designed to demonstrate whether ischaemic 
preconditioning was dependent on 3-adrenoceptor activation had provided conflicting results 
suggesting that the result obtained was largely dependent on the experimental model 
employed. Rather than wade into this already complicated and controversial field with little 
possibility of providing a conclusive answer, it was decided to investigate a lesser studied
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possibility, that 3-adrenoceptor activation could cause preconditioning against stunning. It was 
discovered that in the isolated cardiac tissues used, that this was the case and that ischaemic 
preconditioning also relied upon 3 -adrenoceptor activation to ameliorate stunning.
Another aspect of interest was the fact that adrenaline is administered to patients in cardiac 
arrest as part of international resuscitation protocols. This is essentially a mimic and an 
extension of the central and local catecholamine release which occurs in the body during this 
condition. Adrenaline is administered fo r its vascular rather than its cardiac effects in this 
setting and there is little or no evidence for its effectiveness. It was hypothesised that the 
reason for the ineffectiveness of adrenaline was that it elicited detrimental cardiac effects. The 
most im portant of these is that that adrenaline increases the energy requirements of both the 
fibrillating and the beating heart and thus worsens ischaemia. It was hypothesised that adverse 
cardiac effects might offset the benefit achieved by peripheral vasoconstriction and that this 
could explain the very poor survival of patients undergoing this treatment.
Despite indications that adrenaline may worsen stunning and reperfusion contracture, it did 
not have any effect on infarct size at any of the concentrations employed. This was initially a 
surprise but later experiments dem onstrated the remarkable infarct-sparing effects of 32- 
adrenoceptor activation at reperfusion. Adrenaline has greater efficacy at 32-3drenoceptors 
than 3 i-adrenoceptor and therefore, this 32*adrenoceptor sctivation may be sufficient to offset 
the damage which would be expected from  giving this inotropic agent at reperfusion.
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It was demonstrated that in the Langendorff preparation of the rat heart, activation of 3- 
adrenoceptors is required for postconditioning and that postconditioning can be mimicked by 
agonists of 32-adrenoceptor and 33-adrenoceptors. These are the most important results 
described in this thesis because of their clinical relevance. However these experiments revealed 
an interesting profile of the effects of 3 -adrenoceptor agonists and antagonists given at 
reperfusion (Figure 7-1).
The 3i*adrenoceptor antagonist, CGP-20712A was protective at reperfusion. Noradrenaline, a 
3 i-adrenoceptor agonist had no significant effect, interestingly though, there was a trend 
towards smaller infarct sizes in tissues treated with noradrenaline. This is in contrast with the 
results seen when tissues were treated with forskolin, a direct activator of adenylyl cyclase, 
which led to a larger area of infarction. Forskolin and 3 i_adrenoceptor agonists would be 
expected to act in a similar manner. This result may be because of a non-selective action of 
noradrenaline on the 32-3drenoceptor.
Neither a non-selective 3 -3drenoceptor agonist (isoprenaline) nor a non-selective antagonist 
(timolol) had any effect on infarct size. This probably reflects the opposing actions of these 
receptors on the different subsets of 3 -3drenoceptors.
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Figure 7-1 Sum m ary of da ta  regarding effects of adm in istering  p-adrenoceptor ligands and th e  direct adenylyl cyclase 
a c tiva tor, forskolin at reperfusion. D ata are p resented  as re la tive  reductions or increases in infarct size com pared to  controls, 
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7.3 How does p-adrenoceptor activation confer cardioprotection? 
Apart from a short Western blotting study which was inconclusive, this study has been focussed 
upon p-adrenoceptor subtypes and has not probed the signalling pathways and mechanisms 
leading to protection. Many other research groups are currently investigating the mechanisms 
of cardioprotection and hence from the literature some probable downstream targets of p- 
adrenoceptor signalling can be identified. Activation of RISK pathways at reperfusion and 
prevention of MPTP opening has been shown to be a common mechanism in ischaemic and 
pharmacological preconditioning and postconditioning. Thus, although it was not possible to 
detect enhanced levels of Akt at reperfusion, it remains likely that p2-adrenoceptor activation 
exerts cardioprotection by activating RISK pathways at reperfusion. There are potentially two  
mechanisms by which p-adrenoceptors may cause preconditioning, either by inducing demand 
ischaemia by positive inotropic and chronotropic effects (a predominantly pi-adrenoceptor 
mediated effect) or by receptor-mediated activation of RISK pathways (a p2-adrenoceptor or p3- 
adrenoceptor effect). Different mechanisms may mediate preconditioning against stunning and 
cell death.
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7 .4  L im ita t io n s  o f  th is  s tu d y  
The isolated atrial and ventricular tissue preparations provide a convenient model of post 
ischaemic stunning, however they are limited by the fact that diffusion cannot supply the whole 
tissue with oxygen and nutrients and so cell death occurs. The Langendorff buffer perfused 
heart used in these experiments is a rapid, reliable and reproducible model for studying the 
effects of pharmacological interventions upon infarct size after regional ischaemia and 
reperfusion. These models are by necessity reductionist and differ from the physiological 
condition in a number of respects which have been discussed extensively elsewhere (Doring et 
al., 1987 ; Skrzypiec-Spring et al., 2007; Sutherland et al., 2000). In particular, high glucose 
concentrations are required to compensate for the absence of fatty acids, which under 
physiological conditions are the major energy source of the heart. Oxygen delivery to the 
tissues is also suboptimal in the absence of erythrocytes and buffers such as that used in these 
experiments can only provide sufficient oxygen to the heart when coronary flow is higher than 
the physiological norm (Sutherland et al., 2000). However, perhaps more important in this 
study is the fact that these preparations were not subjected to circulating catecholamines or 
sympathetic neuronal transmission. Thus any effects of endogenous catecholamines acting in 
these preparations would be those stored of synthesised in the heart, and depletion would be 
expected as the experiment progressed. Furthermore, catecholamines modulate vascular 
reactivity, thereby affecting peripheral resistance in vivo. Thus further study in an in vivo model 
is required.
The duration of ischaemia to which the tissues in these experiments were exposed (30-35 
minutes) is short compared to the likely duration of ischaemia experienced by patients
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suffering acute myocardial infarction. However species differ in the time over which infarct 
development takes place, even allowing for different degrees of collateral anastamoses (Philipp 
et al., 2(305). Recent evidence suggests that postconditioning in rats is ineffective after 45 
minutes ischaemia (Tang et al., 2006), whereas in humans protection is still possible after 
several hours of ischaemia (Thibault et al., 2007a; Thibault et al., 2007b; Thibault et al., 2008). 
Thus, whilst this model is a well-validated experimental tool, it is important to remember that it 
is far removed from physiological reality in man
7 .5  C lin ic a l a p p l ic a b i l i ty  o f  re s u lts  
The demonstration of infarct-potentiating effects of adrenoceptor and ^-adrenoceptor 
antagonists when given at reperfusion suggests that activation of these receptors by 
endogenous catecholamines exerts a protective effect. If the same is true in man In-vivo there 
would be important clinical consequences. Whilst 3-adrenoceptor antagonists undoubtedly 
save many lives when prescribed for heart failure and hypertension, it is possible that non- 
selective agents may have detrimental effects acutely at reperfusion after myocardial 
ischaemia. Patients prescribed 3-adrenoceptor antagonists are likely to be at high risk of 
myocardial ischaemia
When considering experimental results such as these, it is interesting to consider how the 
results relate to clinical observations. In this study, a detrimental effect of 32-adrenoceptor 
antagonism has been demonstrated. There is no clinical use for a 32-adrenoceptor antagonist 
(this is probably why there is only one selective compound available for experimental use),
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however some clinically used agents such as carvedilol are antagonists of 32-adrenoceptors in 
addition to 3i~adrenoceptors. Results from experimental models demonstrated a superiority of 
carvedilol over metoprolol (a 3 i~adrenoceptor selective antagonist) at reducing infarct size 
when given just before reperfusion in the rabbit (Feuerstein et al., 1998). However, carvedilol 
has complicated effects because it is additionally a powerful antioxidant and has other atypical 
pharmacology (Carreira et al., 2006) and thus its effects cannot be attributed solely to  its 
actions on (3-adrenoceptors. Interestingly, the experimental benefit of carvedilol over 
metoprolol did not translate to a clinical benefit (Toelg et al., 2006) thus there is scope for a 
study of the effects of 32-adrenoceptor blockade at reperfusion in different species..
The results presented in this thesis confirm the results of other groups which have shown  
benefits of 3 i-adrenoceptor adrenoceptor antagonists at reperfusion and they suggest that 
exogenously applied 32-adrenoceptor agonists may be protective when given at reperfusion. If 
this is the case in vivo it would offer a potential new therapeutic strategy in the tre a tm e n t of 
myocardial ischaemia -  a treatment which would be particularly useful because it co u ld  be 
administered at the time of the clinical reperfusion intervention.
7.6 Future Work
The experiments using isolated atria and ventricles have proven successful in dem onstrating  
that 3 -adrenoceptor preconditioning can protect against stunning in the rat heart and th a t  in 
this model ischaemic preconditioning is dependent on 3-adrenoceptor activation. H o w e v e r ,  the 
mechanisms of protecting against stunning and cell death are not necessarily the sam e, and
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thus it would be useful to carry out a series of similar experiments investigating the roles of 3 - 
adrenoceptors in preconditioning against cell death in this model. This could be achieved by 
increasing the duration of ischaemia. The experiments investigating the effects of 3- 
adrenoceptor ligands at reperfusion could also be repeated in this model.
The study of the effects of (5-adrenoceptor activation at reperfusion in the Langendorff 
preparation leaves open a number of questions which can be divided into two categories. I) A 
mechanistic study of how (5-adrenoceptors elicit cardioprotection. II) A study to determine 
whether 32-adrenoceptor activation is cardioprotective in vivo.
The first objective could be achieved in a number of ways. Pharmacological inhibitors exist for 
most components of RISK pathways and these could be use to determine which kinases were 
involved in eliciting (5-adrenoceptor mediated cardioprotection. These could be used to 
determine which kinases are essential for 3-adrenoceptor postconditioning. Hearts could also 
be sampled for Western blot analysis of relevant kinases such as Erk 1/2 and PI3K. Additionally, 
it would be of great interest to know how each of the available 3 -adrenoceptor ligands affects 
Erk 1/2 activation. This would involve very many experiments and might be more readily 
achieved using isolated cardiomyocytes than isolated hearts. Cells in culture could be exposed 
to 3-adrenoceptor ligands and then lysed and Western blotting could be carried out to measure 
out in order to measure total and phosphorylated proteins of interest.
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The in vivo study would determine whether ^-adrenoceptor agonists at reperfusion would 
provide a realistic clinical target. Coronary ligation techniques in anesthetised animals are well 
established and infarct size can be measured post-mortem with similar techniques to those 
described in this thesis.
Medical research progresses through laboratory experiments of increasing complexity before 
promising drugs and techniques are tested in the clinic. This work has demonstrated important 
roles of ^-adrenoceptors (both protective and detrimental) at reperfusion after ischaemia in a 
very basic model. The most important work arising from this study will be aimed at moving 
these findings along the tortuous pathway from bench to bedside, initially by investigating 
whether the same mechanisms are important in more complex experimental models in vivo.
"Now this is not the end. It is not even the beginning o f the end. But it is, perhaps, the end of the
beginning"
Winston Leonard Spencer Churchill 
Speech at the Mansion House, London, 10th November 1942
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